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SUMMARY
The aim of this work was to describe the pharmacological profile of the Ascaris
muscle GABA receptor, and to compare its properties to those of GABA receptors in
vertebrates. The interest of such study is to show the existence of pharmacological
differences between Ascaris and vertebrate GABA receptors, which may be exploited in
antiparasitic drug research. A short review will be presented first on the anatomy,
physiology and pharmacology of the neuro-muscular system of Ascaris, and on the
pharmacological characteristics of GABA receptors in vertebrates and invertebrates. It
will be followed by a simplified presentation of the receptor theory and the subsequent
development of drug-receptor interaction theories.
The effects of GABA and various GABA-agonists on the membrane input
conductance of Ascaris muscle cells were studied using a current-clamp technique.
Dose-response curves were obtained and described by a modified Hill equation for each
agonist tested. The relative potencies of GABA-agonists in Ascaris are compared to
those obtained at vertebrate GABA-A receptors. Despite some differences: inactivity of
sulphonic acid derivatives and the loss of relative potency of rigid analogues of GABA,
such as muscimol, THIP and isoguvacine, the agonist profile of Ascaris muscle
GABA receptor appears correlated with the agonist profile of vertebrate GABA-A
receptors.
In contrast, the antagonist profile of Ascaris GABA receptors differs greatly from
the antagonist profile of the vertebrate GABA-A receptor. The two classical GABA-A
antagonists, picrotoxin and bicuculline, were found very weak or inactive at
antagonizing GABA responses in Ascaris. The steroid derivative, RU5135, a very
potent competitive antagonist in vertebrate (IC50=5nM, rat cuneate nucleus, Simmonds
and Turner, 1985), was found to hold back some activity in Ascaris , but in a non
competitive manner and with an IC50 of 117jlM.
The effects of the arylaminopyridazine GABA derivatives SR95103 and SR95531
on GABA responses were investigated on GABA-induced conductance changes using a
current-clamp technique. Arylaminopyridazine GABA derivatives are specific and
competitive antagonists at the vertebrate GABA-A receptor, SR95531 being the most
potent analogue. In Ascaris SR95103 was found more potent than SR95531 at
antagonizing GABA responses. This potency order contrasts with that at vertebrate
GABA-A receptors. The antagonism of SR95103 was associated with a parallel shift to
the right in the GABA dose-response relationship. A modified Schild plot was used to
describe the action of SR95103, the data is consistent with a competitive mechanism
XVI
involving two molecules of GABA but one molecule of antagonist interacting with the
receptor. The estimated Kg for SR95103 is 64±13(iM (mean±SE, n=14) and the
pA2=4.
The actions of SR95103 were further examined on GABA-activated single-channel
currents using an outside-out patch-clamp technique. The presence of SR95103 (30-
100|iM) did not alter the GABA-activated channel main conductance, but reduced the
open-probability of the channels. No effect on the mean burst duration, corrected mean
open-time and the distribution of burst-durations, was observed with 30(iM SR95103.
However, when a higher concentration was used, lOOjiM, mean open-time and mean
burst duration were reduced, and the proportion of short bursts (mainly represented by
single openings) was increased. The mode of action of SR95103 is discussed, and it is
suggested that most of the antagonism is competitive and produced by a single molecule
of SR95103 combining with the receptor-channel complex, as suggested by the
current-clamp data. However, an additional non-competitive component, possibly a
channel block, is detected at high concentrations. This non-competitive component
accounts only for a small proportion of the antagonism, since no reduction in the
maximal response was detected by the current-clamp technique, even when high
antagonist concentrations were used (ImM).
Other arylaminopyridazine derivatives were tested on GABA response in Ascaris
using a current-clamp technique. The order of potency of these compounds on Ascaris
muscle GABA receptor, was found different from the order of potency at the vertebrate
GABA-A receptor. One analogue, SR95132, virtually inactive in vertebrate
preparations was found equipotent to SR95103 in Ascaris. When tested on GABA
dose-response curves, SR95132 (KB=65pM) and other potent analogues, displaced
GABA dose-response curves to the right without decrease in the maximal response.
The modified Schild plots for these compounds, were also consistent with a
competitive mechanism involving two molecules of GABA and only one molecule of
antagonist interacting with the receptor. Structure-activity relationships for this series of
compounds are examined in Ascaris and compared to the vertebrates. Substitution on
the pyridazine ring in 4-position, while detrimental for the antagonist potency at the
vertebrate GABA-A receptor, appears to be a prerequisite for antagonistic activity on
Ascaris muscle GABA receptor. Newly synthesized arylaminopyridazine derivatives
confirmed that the presence of a substituent in the 4-position is very important for the
antagonistic activity at the Ascaris GABA receptor. The ethyl-4-substituted derivative,
NCS247-90 with Kb=55(iM, was found to be more potent than SR95103 and
SR95132. Benzyl- (NCS251-90) and the isopropyl-(NCS252-90) 4-substituted
derivatives also appeared to be potent antagonists. Besides the role of the 4-position,
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the length of the side chain and the acidic function were also investigated. A longer
side-chain (5C), as in NCS194-83, decreaseithe potency but does not produce a
complete loss of potency. Replacement of the carboxylic acid group by a sulphonic acid
group produceja total inactivation of the compound, as seen with NCS249-90 and
NCS250-90. This is in agreement with the lack of potency of sulphonic acid derivatives
as agonists. These results are discussed in terms of the accessory binding sites theory
of Ariens, and suggest the existence of different accessory sites responsible for the
binding of antagonists on Ascaris GABA receptor.
In conclusion, the Ascaris muscle GABA receptor differs from vertebrate GABA-A
receptors in terms of antagonist properties, whereas its agonist properties are very
similar to those of vertebrate GABA-A receptors. Among GABA antagonists, the
exploration of the arylaminopyridazine GABA derivatives family may lead to the
discovery of a new generation of anthelminthics. Already, one analogue, SR95132,
shows an antagonistic activity in Ascaris but not in vertebrates.
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GENERAL INTRODUCTION
Ascaris suum is a large intestinal nematode parasite of the pig. Nematode infestation
is the most common cause of parasitism in the world, in both humans and animals.
Ascaris suum is so similar to its close relative, Ascaris lumbricoides, parasite of
humans, that they have been previously classified as a same species: Ascaris
lumbricoides (Soulsby, 1965). Ascaris lumbricoides is the most abundant and prolific
of all helminths in humans, it is said to infest more than one billion people (Lancet
editorial, 1989). There is no equivalent parasite in apes and monkeys, suggesting that
man has acquired Ascaris, not phylogenetically, but from close contact with pigs.
Although, Ascaris suum can sometimes infect humans, and Ascaris lumbricoides, pigs,
the cross transmission is normally very rare. Because of its resemblance to the human
parasite, Ascaris suum is a good experimental model and has been used in pathological
studies (Crompton, Nesheim and Pawlowsky, 1989), and pharmacological studies
(Toscano-Rico, 1926; Baldwin and Moyle, 1949; Norton and De Beer, 1957; Del
Castillo, De Mello and Morales, 1964c; Ash and Tucker, 1965; Martin, 1982, 1985;
Harrow and Gration, 1985; Holden-Dye, Hewitt, Wann et al., 1988; Holden-Dye,
Walker, Nielsen et al., 1989).
Ascaris lumbricoides was described by the ancient Romans as an earth-worm,
Lumbricus teres, able to live in man (Lancet, 1989). To combat Ascaris infection, the
ancient Greeks used santonica, an extract of the Levant wormseed, Artemica maritima
(Bowman and Rand, 1980). Santonin, in conjunction with kairtic acid which
potentiates its action (Bowman and Rand, 1980), has been for a long time the main
treatment for ascariasis. The chenopod oil, extracted from Chenopodium ambrosioides,
was also used widely as a "vermifuge". Chenopodium ambrosioides, is mentioned also
in the Sahagun's Florentine codex, written by Aztec botanists and physicians, in the
XYI century (Kliks, 1990).
Besides these classical treatments, the major advance in the development of
anthelminthic therapeutics was made by Boismare, a French pharmacist, who observed
that people treated for gout with piperazine, eliminated worms as well. The discovery
of Boismare led to a more elaborate investigation of anthelmintic properties of
piperazine by Fayard in his medical Thesis (1949) (quoted by Goodman and Gilman,
1985).
The mode of action of piperazine was then, the object of numerous studies.
Piperazine was first shown to induce a reversible paralysis of Ascaris suum in vitro
(Standen, 1955) and Norton and DeBeer (1957) suggested that it acted as an
acetylcholine antagonist. Later, Del Castillo, De Mello and Morales (1964b, 1964c),
measuring the changes in membrane potential of Ascaris suum muscle cells, proposed
that piperazine acted like the endogenous inhibitory transmitter, y-aminobutyric acid
(GABA). Using voltage-clamp and patch-clamp techniques, Martin (1982, 1985)
confirmed that piperazine acts at the Ascaris suum muscle GABA receptor and activates
the same CI channels. Other classical anthelminthics such as pyrantel, morantel and
levamisole have been studied in Ascaris suum and were shown to act at the
acetylcholine receptor (Harrow and Gration, 1985). Recently ivermectin (TVOMEC®)
has also been studied using Ascaris suum as an experimental model (Kass, Wang,
Walrond et al., 1980; Kass, Larsen, Wang et al., 1982; Holden-Dye et al„ 1988;
Martin and Pennington, 1989), and shown to act as a GABA antagonist at micromolar
concentrations (Holden-Dye et al., 1988; Martin and Pennington, 1989). The GABA
receptor in helminths emerges thus as a possible target for anthelminthic drugs. When
this present study started, little was known on the GABA receptor in Ascaris suum. In
this thesis on the pharmacology of the Ascaris GABA receptor, a review of Ascaris
suum neuromuscular anatomy, physiology and pharmacology, of GABA receptors in
vertebrates and invertebrates and of the basis of drug-receptor interactions theories, will
be presented in Section 1. The experimental work was carried out on the Ascaris suum
muscle preparation, using current-, voltage- and patch-clamp techniques. General
methods are described in Section 2, but each specific technique will be described in
more details in the appropriate sections. The agonist profile of the GABA receptor is
presented and compared to the vertebrate GABA-A receptor in Section 3. Sections 4
describes the action of classical GABA-A antagonists, at the Ascaris GABA receptor
using current-clamp; Section 5 describes the action of the two arylaminopyridazine
GABA derivatives, SR95531 and SR95103. The antagonist effects of SR95103 are
investigated at the single-channel current level in Section 6. Finally, Section 7 examines
the structure-activity relationships of a series of pyridazine derivatives and compares
their antagonist properties seen in Ascaris with those seen in vertebrate studies. The
work presented in the last section was realized in collaboration with Professor
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C.G.Wermuth, Dr M.Schmitt and J.M.Sitamze from the "Laboratoire de Neurochimie
du CNRS", Strasbourg, France.
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SECTION I: LITERATURE REVIEW
A. ASCARIS SUUM
I A SCARIS MUSCLE CELLS
For reviews, see Cappe de Baillon (1911) and DeBell (1965). The anatomy of
Ascaris suum was studied as early as 1866 (Schneider, quoted by DeBell, 1965).
Schneider was the first to describe the muscle cell as composed of two histologically
separate regions: striated and vesicular. The striated region is the contractile part of the
cell, and the vesicular region is the non contractile part. At that time, few people could
conceive of the existence of a non contractile part in a muscular fibre. Schneider was
therefore the first to claim that the transverse strands, described by others as circular
muscles (Cloquet, 1824, quoted by Cappe de Baillon, 1911, and DeBell, 1965) or
nerves (Meissner, 1853, quoted by Cappe de Baillon, 1911, and DeBell, 1965), were
in fact part of the muscle cell itself:
"..Jn the nematodes, the nerves do not branch out to the muscles,
instead branches of the muscle reach the nerves..."
After Schneider, numerous scientists found an interest in the anatomy of Ascaris
muscle and its nervous system, leading to various theories and harsh discussions
concerning the organization of the muscle cell and the neuromuscular junction (Apathy,
1893, 1894; Bilek, 1909, 1910; Biitschli, 1874, 1892; Deineka, 1908; Glane, 1910;
Goldschmidt, 1908, 1909, 1910; Hesse, 1892; Rohde, 1885; quoted by Cappe de
Baillon, (1911) and DeBell, (1965|. The anatomical terms of arm ("bras"), belly
("panse") and spindle ("fuseau") were first introduced by Cappe de Baillon (1911),
who gave a good account of the histology of Ascaris muscle cells. However the
anatomy of the neuromuscular junction was not described before the use of the electron
microscope (Rosenbluth, 1963, 1965b).
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1. Morphological studies of the muscle cells
1.1. Belly or bag region
The belly is a large round bag shaped part of the somatic muscle cell, which lies in
the pseudocoelomic space. The cytoplasm contains the nucleus and is almost entirely
filled with particulate glycogen (Rosenbluth, 1963, 1965b). Harris and Crofton (1957)
suggested that the muscle cells bellies played the role of an endoskeleton. See Figures 1
and 2.
1.2. Arm and syncytium
The arm is a thin process leaving the base of the belly of the muscle cell in the
direction of the nerve cord, where it makes synaptic contacts (see Figures 1 and 2).
Several arms can leave the same cell (Cappe de Baillon,1911). The arms were
originally believed to form a syncytium surrounding the nerve cord (Del Castillo, De
Mello and Morales, 1963a). This was also suggested by Cappe de Baillon (1911),
"...27 nous parait absolument impossible de nier qu'il existe une
liaison tris intime pour ne pas dire de continuite entre lesfibrilles de
soutien qui sortent des bras et celles quiforment manchon autour
des fibres nerveuses et des autres formations de la ligne mediane..".
But in fact, the processes are separated from each other with numerous tight junctions
present in the distal part near the synaptic region, increasing the electrical coupling of
the muscle cells (Rosenbluth, 1965b). Recent scanning electron microscopy studies
show that the muscle arms approach the nerve cord in bundles separated by wide gaps
and that the arms extend longitudinally, overlapping with those from other arms to form
the so called "syncytium" (Del Castillo, Riviera, Solorzano et al., 1989). Synapses are
formed between the "syncytium" and the nerve cord.
1.3. Spindle
The spindle is the contractile part of the muscle cell forming a long tube lying
against the hypodermis (see Figures 1 and 2). The apparent lack of cross-striations
gave rise to the suggestion that the Ascaris muscle cells were a smooth muscle cell type
(Rosenbluth, 1973). Rosenbluth (1965a) has reconstructed the fibrillar structure of the
Ascaris muscle cells using electron microscopy, and shown that the H, A and I bands
are present as in the striated skeletal muscle; the Z band is replaced by a less organized
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Figure 1: Diagram of a muscle cell from the body wall of Ascaris suum (from
Rosenbluth, 1973)
The cell consists of three parts: the belly (b) which contains the nucleus and glycogen
stocks; the spindle (s) or contractile part; the arm (a) which stretches to the nerve cord
(n) to make neuromuscular junctions, (h) is the hypodermis and (c) the cuticule.
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Figure 2: Ascaris muscle cells: scanning electron micrograph
To obtain free muscle cells, Ascaris muscle was treated with collagenase and kept at
until free muscle cells appeared in the medium.
(a) arm; (b) belly; (s) spindle; (v) vesicles
Note the presence of two arms leaving the base of the belly, one is damaged and
appears torn.
 
structure of dense bodies. However the striation does not form a 902 angle as in the
skeletal muscle, but only a 6- angle (Figure 3). This explains why the striations had
previously remained unnoticed, although Apathy (1894, quoted by Cappe de Baillon
(1911)), detected some striation:
"...les bandes ne sont pas toutes paralliles, mais sont groupies en
bande paralliles entre elles. Ces groupements se confrontent iris
obliquement dans une grande variiti de plans..." .
Rosenbluth (1973) classified the Ascaris muscle as a new type, the "Obliquely striated
muscle". It turned out later that the obliquely striated muscle is widely distributed
among soft bodied invertebrates but is not known to occur in any vertebrate
(Rosenbluth, 1965a; and see Rosenbluth, 1973 for review).
Conclusion: this particular arrangement allows sliding of the thin filaments with
respect to the thick ones and shearing of the thick filaments. The shearing phenomenon
confers great extensibility and the sliding phenomenon preserves the velocity in length
change. Obliquely striated muscle has therefore the extensibility of smooth muscle and
the velocity of contraction of skeletal muscle.
2. Biochemistry of contraction
2.1. Actin and myosin
It is commonly reported that Ca mediated actin fixation is the principal mechanism
of contraction in the skeletal muscle, whereas the Ca-dependent myosin
phosphorylation is the principal mechanism in the vertebrate smooth muscle
(Rosenbluth, 1973). In Ascaris muscle, the two mechanisms are present. The fast
twitch is apparendy regulated by a Ca-mediated actin fixation and muscle relaxation
involves the myosin phosphorylation mechanism (Martin and Donahue, 1987). The
fibrillar composition of obliquely striated muscle is very close to vertebrate skeletal
muscle: troponin and tropomyosin are present in a similar stoichiometry and the myosin
light chain is present in three isoforms, similar to those present in the rabbit skeletal
muscle (Donahue, Michnoff and Masaracchia, 1985). It appears therefore that the
mechanisms underlying muscle contraction in Ascaris are very similar to those involved,
in the skeletal muscle.
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Figure 3: Diagram of the striation of a muscle fibre from Ascaris suum (from
Rosenbluth, 1973)
Rosenbluth (1965a) has reconstructed the fibrillar structure of the Ascaris muscle cells
using electronic microscopy (E.M.).
XY is the transversal plan (transverse section of the body)
XZ is the lateral plan (tangential section of the body)
YZ is the horizontal plan (longitudinal section of the body)
A. Part of the spindle region of a muscle cell
B. The tangential section XZ shows the oblique striation
The H, A and I bands are present as in the striated skeletal muscle. The Z band is
replaced by a less organized structure of dense bodies. However the striation does not
form a 902 angle as in the skeletal muscle.
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2.2. Energy metabolism
Histological observations (Rosenbluth, 1963) suggest that, glycogen plays an
important role in the supply of energy for muscle contraction. Glycogenolysis provides
the principal source of substrates for ATP synthesis during non feeding intervals
(Donahue, Yacoub, Kaeine et al., 1981c, Donahue, Yacoub and Harris, 1982). Two
pathways are present as in the skeletal muscle: a cAMP dependent mechanism,
analogous to the mammalian pathway, where serotonin is believed to be the primary
messenger which induces the rise in cAMP (Donahue, Yacoub, Michnoff et al., 1981a;
Donahue, Yacoub, Kaiene, 1981b; Donahue et al., 1981c); a cAMP independent
pathway, less characterized but which appears to be Ca-dependent and activated by
acetylcholine (Donahue et al., 1981c, 1985).
Conclusion: histologically the Ascaris somatic muscle is different from the
vertebrate skeletal and vertebrate smooth muscle, and has been classified as a special
type: "Obliquely striated muscle" (Rosenbluth 1965a; see Rosenbluth, 1973, for
review). Biochemically however, the mechanisms and enzymes involved are very
similar to those in the vertebrate skeletal muscle (Donahue et al., 1981b, 1981c, 1985).
3. Electrical activity of the muscle cells
3.1. Resting membrane potential
The main characteristic of the resting membrane potential of Ascaris muscle cells is
its insensitivity to changes in ionic composition of the extracellular solution (Del
Castillo, De Mello and Morales, 1964a). The muscle bags are normally bathed with
perienteric fluid (mM: Na 129; K 24; Ca 6; Mg 5; CI 53; organic anions 120, mainly
volatile fatty acid), (Hobson, Stephenson and Beadle, 1952). Most electrophysiological
studies have been performed using artificial perienteric fluids where organic anions
were never considered. However they may play an important role. Several mechanisms
have been proposed to explain how the cell maintains its resting potential, but none of
them is fully satisfactory.
a. The Na shunt conductance
Del Castillo et al. (1964a) were the first to study the influence of ion substitution on
the resting membrane potential. The membrane potential was little affected by changes
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in the K concentration, but was affected by changes in external CI concentration. Their
conclusion was that a CI battery with a low internal resistance seemed to be largely
responsible for the maintenance of the membrane potential. The role of a K battery was
limited by a high internal resistance. Both CI and K batteries were shunted by a high Na
conductance. In the vertebrate smooth muscle the membrane potential is due to a CI
battery as well, and is shunted by a high Na conductance. The ionic permeability
sequence in vertebrate smooth muscle is: Cl>S04>Br>NC>3>I; and in Ascaris muscle:
N03>I>Br>Cl>S04, NO3 is the most permeant anion.
b. Compensatory changes in membrane conductance
Brading and Caldwell (1964) first suggested that compensatory changes in
membrane permeability counteracted changes in ion concentration. But after using
labelled ion flux experiments, Caldwell and Ellory (1968) refuted this hypothesis.
c. Operation of an electrogenic pump
Assuming that the constant field theory is applicable to Ascaris muscle, Brading and
Caldwell (1971) studied the effect of ion replacement using the Goldman-Hodgkin-
Katz equation (Hille, 1984a):
F _ RT . PK[K]o+PNa[Na]0+Pci[Cl](k+x
F * 10§n PK[K]i+PNa[Na]i+Pci[Cl]frfy
Their results suggested that there was a major factor determining the Ascaris muscle
membrane potential other than the contribution of the identified K, Na and CI ions.
Brading and Caldwell (1971) proposed the existence of a carboxylic acid transport
system associated with Na transport. However, when they looked at the effect of
several transmitters, they concluded that GABA did not affect Pel or Pk. but inhibited
the putative carboxylic acid transport system and consequently decreased the Na
secretion. GABA does not act this way, but activates a CI conductance in Ascaris
muscle (Martin, 1980), suggesting either that the mechanism proposed by Brading and
Caldwell (1971) is unlikely to occur, or that their experimental conditions were not
satisfactory, making their results difficult to interpret.
Conclusion: a satisfactory explanation for the resting membrane potential in Ascaris
muscle remains to be found, although it seems possible that an active transport of
organic anions is involved.
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3.2. Spontaneous electrical activity of the muscle cells
Jarman (1959) was the first to report the spontaneous depolarizing potentials in
Ascaris muscle. Later, DeBell, Del Castillo and Sanchez (1963), showed that these
depolarizations were myogenic, arising from what they described as a syncytial region
of the muscle cells. DeBell et al. (1963) reported two functional classes of
depolarization: spikes of variable amplitude and of duration 5-50ms, and slow waves
up to 20mV amplitude and lOO-lOOOms duration. Weisblat, Byerly and Russel (1976)
reported a third class: long lasting modulations of 5mV amplitude and 3-20s duration
which corresponded to rhythmic contractions of the whole animal. The pattern of each
type of electrical activity is considered in more details in the next paragraphs.
a. Spike potentials
Spike potentials are graded in their amplitude (Jarman, 1959) and originate from the
syncytial region near the nerve cord (DeBell et al., 1963). Ion replacement studies have
shown that they are mediated by Ca (Weisblat et al., 1976). Variations in K
concentration and application of TEA do not affect the spike potentials, suggesting that
K is not involved in terminating the spike potentials in Ascaris muscle.
b. Slow waves
Ion replacement experiments showed that slow waves can be carried by Na or Ca
(Weisblat et al., 1976). TEA, externally applied had no effect upon the amplitude or
the duration of individual slow waves (Weisblat et al., 1976), suggesting that a K
conductance is not involved. The mechanism of generation and termination of slow
waves is not known.
c. Modulation and square waves
Modulation is sometimes seen in spontaneously active preparations and coincides
generally with the contraction of the whole animal. Modulation is a rhythmic
depolarization (lasting 3-20s), inducing a burst of electrical activity such as slow waves
and spike potentials. Experimentally, TEA, and Ca replacement by Sfor Ba, induced
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long lasting depolarizations similar to the modulation waves, called square waves by
Weisblat et al. (1976).
Low-Ca and high-Mg solutions also induced square waves, but the replacement of
Na by TRIS inhibits the generation of square waves. These facts suggest that Na but
not Mg can carry currents generating the square waves. Weisblat et al. (1976)
suggested that square waves corresponded to the modulation activity seen under normal
conditions in spontaneously active preparation, and could be carried by Ca, Na, Ba and
St as for the slow waves. The rapid rise and fall of square waves seems to indicate that
voltage-dependent Ca channels are involved. Weisblat et al. (1976) proposed a
mechanism in which the internal accumulation of Ca itself regulates the Ca
conductance. The accumulated Ca would need to be pumped out before the next square
wave.
Conclusion: three different types of spontaneous electrical activity have been
demonstrated in Ascaris muscle. Although their ionic mechanisms remain imperfecdy
understood, Ca appeared to play an important role. These three activities are myogenic
and are probably involved in coordinating contraction.
Conclusion on Ascaris muscle cells:
The histology of the muscle cell of Ascaris suum differs greatly from the skeletal and
smooth muscle cell types of vertebrates. Firstly the cell itself is specialized in three
parts: spindle (contractile), belly (energy and metabolism), arm (connection with the
nervous system). Secondly, the contractile part is obliquely striated and forms a new
type of muscle cell besides the classical skeletal and smooth muscle cells. Obliquely
striated muscle cells combine the elasticity of a smooth muscle and the velocity of a
skeletal muscle. The mechanisms and enzymes involved in the contraction are very
similar to those present in skeletal muscle, but in terms of spontaneous electrical
activity, the Ascaris muscle resembles the vertebrate smooth muscle type.
II ASCARIS NERVOUS SYSTEM
The nervous system of Ascaris was studied as early as 1892 (Hesse). Goldschmidt
(1908,1909, quoted by DeBell, 1965) reconstructed the anatomy of the neurones in the
head and the tail, showing that they are completely reproducible from animal to animal
and that only a small number of neurones are present (250). These two features have
made the nematode Ascaris attractive for the analysis of nervous system function.
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1. Morphological studies
Near the head, a series of ganglia is associated with a nerve ring from which the ventral
and dorsal nerve cords originate. In the posterior region, there is a second set of
ganglia. However the motorneurone cell bodies, located in the ventral nerve cord, are
not arranged in ganglia, but are scattered (Goldschmidt, 1908, 1909, quoted by DeBell,
1965). Two pairs of lateral nerve cords are also present, a dorsal lateral cord running
along the anterior and posterior parts of the body, a ventral lateral cord situated only in
the posterior part of the worm. In the anterior part of the parasite, the dorsal lateral
nerve cord is accompanied by two sublateral nerve cords: dorsal and ventral (Figure 4).
Stretton, Fishpool, Southgate et al. (1978) have studied the structure of the
motorneurones in the ventral nerve cord. Based on anatomical features, they have been
divided in seven classes: V-l, V-2, DEI, DE2, DE3, DI, VI. They are named after their
targets and their effects. D cells innervate the dorsal musculature; V cells innervate the
ventral musculature; E cells are excitatory and I cells are inhibitory. V-l and V-2
appeared to be excitatory, although there is no direct physiological evidence yet. Each
motorneurone is composed of a cell body and a process in the ventral nerve cord. Five
types also have a dorsal process in the dorsal nerve cord, linked to the ventral process
by a single transverse fibre called a commissure (Hesse, 1892). The commissures are
arranged in a highly reproducible pattern along the body of the worm, forming five
segments each containing eleven motorneurones (Figure 5). The segments are linked by
six non segmental interneurones (Stretton et al., 1978). Dorsal excitatory neurones,
besides making neuromuscular junctions, excite ventral inhibitory neurones. Dorsal
excitatory neurones receive their input from interneurones in the ventral nerve cord. V-l
and V-2 ventral excitatory motorneurones also receive their input from interneurones
but excite dorsal inhibitory motorneurones (Walrond, Kass, Stretton et al., 1985).
Besides the well documented ventro-dorsal commissures, Johnson and Stretton
(1987), described latero-ventral commissures. They are processes of neurones whose
cell bodies are located in the lateral nerve cords or in the tail. In the male, there is a large
number of lateral to ventral commissures associated with sensory papillae in the tail.
There are also latero-ventral commissures associated with the nerve ring in the head
(Johnston and Stretton, 1987).
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Figure 4: Diagram of the major and minor nerve cords in Ascaris suum (from Johnson
and Stretton, 1987)
The largest section is made in the anterior part of the parasite; the smallest section is
made in the posterior part. (D) dorsal nerve cord; (Y) ventral nerve cord; (DL) dorsal
lateral nerve cord; (VL) ventral lateral cord; (DsubL) dorsal sublateral nerve cord;
(VsubL) ventral sublateral nerve cord; (c) cuticule; (h) hypodermis; (LL) lateral lines.
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Figure 5: Schematic diagram of the organization of the dorsal and ventral nerve cord in
Ascaris suum: one typical repetitive segment







Each neurone is classified according the shape of its cell body:
dorsal excitatory motorneurones: DEI, DE2, DE3
ventral excitatory motorneurones: V-l, V-2
dorsal inhibitory motorneurones: DI
ventral inhibitory motomeurone: VI




Electrical stimulation of the nervous system evokes either excitatory or inhibitory
potentials in muscle cells (DeBell et al., 1963; Del Castillo, De Mello and Morales,
1967; Weisblat et al., 1976). Walrond et al. (1985) have developed a technique
allowing the stimulation of an identified neurone and the recording of the muscle
response in the innervated area. Davis and Stretton (1989a) have recorded
intracellularly from the commissure of identified motorneurones. These studies have
allowed a model for the role of the nervous system in locomotion to be developed
(Walrond and Stretton, 1985a, 1985b).
2.1. Graded responses
a. Graded neuromuscular response
Electrical stimulation of the ventral nerve cord produced graded muscle cell
responses, no all or none threshold response was recorded (Walrond et al., 1985).
Similarly, direct intracellular recordings from commissural neurones have shown that
the neurones do not propagate action potentials, but show graded responses (Davis and
Stretton, 1989b).
b. Passive membrane properties
Since the muscular response is graded with the neuronal stimulus, signalling
appears to rely on passive properties of neuronal membranes. This was confirmed by
the unusual membrane properties of Ascaris motorneurones: high membrane resistance
(61-251 kQcm2) and large space constant (4-10mm); that make them well designed for
conducting passive voltages over long distances (Davis and Stretton, 1989a). Cells
with such membrane properties and long processes, have been described among
sensory cells conveying graded responses (Prasztor and Bush, 1982).
c. Graded active responses
Although motorneurones can function with passive signalling, small voltage
activated currents are recorded in the commissure. These currents underlie small active
responses obtained at the offset of the depolarizing or hyperpolarizing stimulus. These
offset responses are graded with the stimulus intensity (Davis and Stretton, 1989b). In
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inhibitory motorneurones, strong depolarization induces oscillations of the membrane
potential. Such oscillations can sometimes be found spontaneously and may be related
to the presence of these voltage activated channels (Davis and Stretton, 1989b).
2.2. Tonic release of neurotransmitter
The presence of voltage-activated channels at the normal resting membrane
potential, may suggest a tonic release of neurotransmitter from the commissure (Davis
and Stretton, 1989b). A tonic release of acetylcholine had been shown earlier by Del
Castillo et al. (1963a) since curare, an acetylcholine antagonist, hyperpolarized and
neostigmine, an inhibitor of acetylcholinesterase, depolarized the muscle cells.
2.3. Complex neuromuscular responses
Besides the unusual signalling properties of the Ascaris motorneurones, several
important types of neuromuscular responses have been described. Complex
intracellular potentials are often obtained after stimulation of a single motorneurone. For
example, the stimulation of an excitatory motorneurone often produced a depolarization
followed by a small hyperpolarization (Stretton et al., 1978). These complex responses
may result from neurone-neurone interaction in the dorsal nerve cord or membrane
properties of muscle cells.
2.4. Reciprocal inhibition
Dorsal excitatory motorneurones interact synaptically with ventral inhibitory
neurones. A neuronally evoked dorsal contraction is complemented by a neuronally
evoked ventral inhibition. A similar circuit seems to exist within the ventral nerve cord,
involving V-l, V-2 and DI (Walrond and Stretton, 1985b).
2.5. Excitatory and inhibitory muscle activity evoked by stimulation of
single dorsal excitatory motorneurones.
Stimulation of a dorsal excitatory motorneurone leads to depolarization in the
corresponding musculature and to an hyperpolarization in the surrounding dorsal
region. This hyperpolarization seems to be due to synaptic activation of DI by the DE
neurones (Walrond and Stretton., 1985b). Stimulation of a dorsal excitatory
motorneurone leads to muscle contraction in the corresponding innervated dorsal area,
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and to relaxation of the corresponding ventral muscle. The surrounding dorsal
musculature is also inhibited, giving an omega shape (Q) to the body. The mechanism
of wave propagation remains to be determined, but the interneurones may play an
important role (Walrond and Stretton, 1985b).
HI NEUROMUSCULAR PHARMACOLOGY
Toscano-Rico (1926) was the first to develop a technique for testing effects of
drugs on Ascaris; he used a portion of worm linked to a kymograph, and observed the
contracting effect of nicotine. The technique was improved in order to bring the drugs
in direct contact with the musculature and to short-circuit the protective effect of the
cuticule (Baldwin and Moyle, 1947, 1949). The two main effects reported were:
contraction and relaxation.
1. Cholinergic neuromuscular pharmacology
1.1. Excitatory effects of acetylcholine
Acetylcholine at micromolar concentrations, produces muscle contraction (Baldwin
and Moyle, 1949; Del Castillo et al., 1963a; Natoff, 1969; Rozhkova, Malyutina and
Shishov, 1980), muscle cell depolarization and increase in cation conductance (Martin,
1982; Harrow and Gration, 1985; Colqhoun, Holden-Dye and Walker, 1990).
Stimulation of the ventral nerve cord often produces muscle contraction (Walrond and
Stretton, 1985a) suggesting that the neurotransmitter for muscle contraction is
acetylcholine. Choline acetyl transferase activity was found in the commissure, and cell
bodies of identified excitatory motorneurones (Johnson and Stretton, 1987) and was in
agreement with acetylcholine being an excitatory transmitter in Ascaris. At first,
acetylcholine receptors were thought to be exclusively located in the nervous system
and at neuromuscular junctions (Norton and DeBeer, 1957). However, Brading and
Caldwell (1971) recorded acetylcholine responses from the bag region of muscle cells
after section of the arms: they suggested that receptors were also present
extrasynaptically on the bellies. This was confirmed later by ionophoresis experiments
(Martin, 1982).
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1.2. Pharmacology of the Ascaris muscle acetylcholine receptor
Contraction is also produced by nicotine at low concentrations (Toscano-Rico,
1926; Baldwin and Moyle, 1949; Natoff, 1969). Acetylcholine induced contractions are
blocked by tubocurarine but not by atropine (Baldwin and Moyle, 1949; Natoff 1969;
Rozhkova et al., 1980). Natoff (1969), Rozhkova et al. (1980) and Colquhoun et al.
(1990), tried to further classify this receptor into ganglionic or muscular nicotinic types.
The selective and potent ganglionic agonist, dimethylphenylpiperazinium (DMPP), has
been shown to be the most potent agonist on Ascaris acetylcholine receptor (Natoff,
1969; Colqhoun et al., 1990). Moreover, mecamylamine, a relatively specific
ganglionic antagonist is the most potent cholinergic antagonist in Ascaris (Natoff,
1969) after N-methylaconitine (Colquhoun et al., 1990). However there is some doubt
about the potency of nicotine; Baldwin and Moyle (1949) and Natoff (1969), reported
nicotine to be more potent than acetylcholine, whereas Rozhkova et al. (1980) and
Colqhoun et al. (1990) found it was less potent. The low potency of the ganglionic
blocker hexamethonium casts doubt on the proposed ganglionic nicotinic type for the
Ascaris acetylcholine receptor (Rozhkova et al., 1980; Colquhoun et al,. 1990). The
two anthelmintics; morantel and pyrantel have been shown to be potent agonists on
Ascaris muscle acetylcholine receptor, and were nearly as potent as DMPP (Harrow
and Gration, 1985). Levamisole has also been shown to act as an acetylcholine agonist
but with a much lower potency (Harrow and Gration, 1985). The Tables 1 and 2
summarize^ the pharmacological characteristics of this receptor.
1.3. Acetylcholine-gated channels in Ascaris muscle
The acetylcholine-activated single currents in Ascaris muscle have been shown to
have two conductances. The larger being 30-50pS, and the smaller being 15-25pS
(Pennington and Martin, 1990). The channel kinetics for the larger conductance are
described by two exponentials for the open durations, and three exponentials for the
closed durations (Pennington and Martin, 1990). Similar results are found in vertebrate
preparations.
Conclusion: acetylcholine appears to be the excitatory neurotransmitter in Ascaris,
synaptic and extrasynaptic acetylcholine receptors are present on the muscle cells.
Pharmacological studies show that the Ascaris acetylcholine receptor is closely related
to a vertebrate ganglionic type, but has some specific characteristics which may be
exploited therapeutically.
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Table 1: Summary of the properties of various agonists on Ascaris cholinoreceptor
Baldwin and Natoff Rozhkova Harrow and Colquhoun
Moyle 1969 et al., 1980 Gration et al., 1990
1957 (1) (2) (3) 1985 (4) (5)




Nicotine 1 2-38 3.5 0.3
Carbachol 5-55 4.1 0.5
Suberyldicholine 4.7











(1) ribbon like stripe of dorsal musculature, lowest concentration inducing
contraction (|lM)
(2) strip of dorsal musculature, range of concentrations inducing contraction (|lM)
(3) strip of dorsal musculature, contraction EC50 (p.M)
(4) muscle flap preparation, measure of the change in membrane input conductance
EC50 (|iM)
(5) muscle flap preparation, measure of the change in membrane input conductance,
relative potency
Table 2: Summary of the properties of various antagonists on Ascaris
cholinoreceptor
Baldwin and Natoff Rozhkova Colquhoun
Moyle 1949 1969 1980 et al., 1990
0) (2) (3) (4)
N-methylaconitine 0.23
Bungarotoxin 1.4
Mecamylamine 6.6 (0.25) 0.33
Strychnine 100 1.29
d-tubocurarine 100 5.63-2.34 6.3 (0.5) 3.1
TEA 5.2 (6)
Hexamethonium 4.4 (40) 43
Pancuronium 3.2
Atropine 4,1 (80) 4.1 (80) 6.7
(1) ribbon like stripe of dorsal musculature, lowest concentration inducing
contraction (fiM)
(2) strip of dorsal musculature, pA2 (calculated IC50 |iM)
(3) strip of dorsal musculature, pA2 (calculated IC50 (iM)
(4) muscle flap preparation, IC50 (|iM)
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2. GABA-ergic neuromuscular pharmacology
2.1. Inhibitory effects of GABA
GABA applied at micromolar concentrations produces muscle relaxation, cell
membrane hyperpolarization (Del Castillo et al., 1964b) and an increase in membrane
conductance (Martin, 1980; Holden-Dye et al., 1988). GABA has been suggested to be
the inhibitory transmitter in Ascaris, and GABA immunoreactivity was found in the
commissures and cell bodies of identified inhibitory motorneurones (Johnson and
Stretton, 1987). As for acetylcholine, it was originally claimed that GABA receptors
were exclusively present at the neuromuscular junction (Norton and DeBeer, 1957),
although later they were found on the extrasynaptic muscle bag region (Brading and
Caldwell, 1971; Martin, 1980).
2.2. Pharmacology of the Ascaris muscle GABA receptor
The anthelmintic piperazine has been shown to induce a reversible paralysis of
Ascaris suum in vitro (Standen, 1955), and was suggested to act as an acetylcholine
antagonist (Norton and De Beer, 1957). However, using a denervated preparation, Del
Castillo et al. (1963a, 1964b), Del Castillo, Morales and Sanchez (1963a), showed that
spontaneous contractions of the muscle were of myogenic origin. Acetylcholine
increased the rhythm of contraction while tubocurarine antagonized acetylcholine
induced contractions but not the spontaneous ones (Del Castillo et al., 1964c). They
then proposed that piperazine acted like the endogenous inhibitory transmitter, since
piperazine paralysis could be mimicked by stimulation of the nerve cord. Finally, Del
Castillo et al. (1964c) showed that GABA has similar effects to piperazine, but was 100
times more potent. Ash and Tucker (1966), investigated the pharmacology of the
GABA receptor using measurements of the length of the dorsal musculature, and
confirmed the paralysing actions of GABA (0.5)ig/ml) and piperazine (50|ig/ml).
Although the GABA receptor appeared to be a suitable target for anthelmintic drugs, its
pharmacological profile was not investigated seriously until recently (Wann, 1987;
Hewitt, 1988; Holden-Dye et al., 1988,1989). The purpose of this work presented here
is to study the pharmacological profile of Ascaris muscle GABA receptor. A detailed
description of the pharmacology is given in the Section 3 for the agonists and in the
Sections 4, 5, 6 and 7, for the antagonists.
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2.3. GABA-gated channel
GABA activates a CI conductance in Ascaris muscle, as at the vertebrate GABA-A
receptor (Del Castillo et al., 1964b; Martin, 1982, 1985; Holden-Dye et al., 1988). The
characteristics of the Ascaris GABA-activated channel are similar to that of the
vertebrate GABA-A-activated channels (Martin, 1985). In outside-out patches, GABA
produces channels with a main-state conductance of 22.0pS, and two rare
subconductances of 30% and 70% of the full level (Martin, 1985). In the presence of
GABA 3|lM, the effective mean open time is 30.5ms; the channel open times kinetic is
described by two exponentials: 2.1 and 46.0ms; the closed times kinetic is described by
three exponentials: 1.6,40.0 and 1320ms (Martin, 1985). At concentration greater than
5pM, GABA-activated channels show desensitization (Martin, 1985).
3. Serotonin: muscular effects
3.1. Serotonin is an endogenous modulator
There is evidence for serotonin (5-hydrotryptamine; 5-HT) receptors in Ascaris
muscle based on radiolabeled ligand binding techniques (Chaudhuri and Donahue,
1989). Serotonin can be absorbed from the host or synthesized by the parasite
(Chaudhuri, Martin and Donahue, 1988).
3.2. Serotonin regulates the glycogen metabolism
Serotonin does not induce contraction or relaxation, but appears to regulate
glycogen metabolism in Ascaris muscle (Donahue et al., 1981a). Glycogen metabolism
regulation relies mainly on the activity of two enzymes: glycogen synthetase,
responsible for the synthesis of glycogen from glucose-6-phosphate; and glycogen
phosphorylase, responsible for the breakdown of glycogen into glucose-6-phosphate.
These enzymes can exist in several states of activation depending on their level of
phosphorylation. Serotonin induces inactivation of glycogen synthetase but activates
the glycogen phosphorylase and produce a three fold increase in cAMP (Donahue et al.,
1981b).
Hence it appears that the glycogen metabolism can be regulated by two mechanisms
which are either cAMP dependent or cAMP independent. The excitatory
neuromuscular-transmitter acetylcholine, besides producing muscle contraction,
23
activates the glycogen synthetase, and prevents inactivation of glycogen phosphorylase;
there is no increase in cAMP. GABA induces hyperpolarization and relaxation which
require energy; GABA prevents inactivation of glycogen synthetase and the conversion
of glycogen phosphorylase to an inactivated form, there is no increase in cAMP
(Donahue et al., 1981b). Serotonin has been identified as the primary messenger
which promotes the increase in cAMP. Serotonin in Ascaris muscle appears to play a
role similar to adrenaline in skeletal muscle. Adrenaline and noradrenaline have no
effect on muscle contraction or glycogen metabolism in Ascaris (Donahue et al.,
1981a).
3.3. Pharmacology of the serotonin receptor
Binding studies have shown that the Ascaris serotonin binding site has greater
affinity for the vertebrate 5-HT2 agonists and antagonists than for the vertebrate 5-HT1
agonists and antagonists. Specific binding is found in the muscle and in the intestine
(Chaudhuri and Donahue, 1989).
4. FMRF-amide: neuro-muscular effects
FMRF-amide is a tetrapeptide which was first isolated from the cardiorespiratory
system of a mollusc (Price and Greenberg, 1977). FMRF-amide-like peptides (FLPs),
have since been isolated in a great variety of species (Cowden, Stretton and Davis,
1989). FLPs have a wide variety of actions mediated by different types of receptor:
activation of sodium, potassium and chloride currents, suppression of calcium currents
and depression of voltage-dependent potassium and calcium currents (Cowden et al.,
1989).
4.1. FMRF-amide immunoreactivity in Ascaris
FLP immunoreactivity appears widespread in Ascaris; it is found in the anterior
region of the parasite, concentrated near the pharyngeal nerves, as well as in the four
major nerve cords along the length of the body (Davenport, Lee and Isaac, 1988).
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4.2. Physiological activity of a purified FLP: AF1
FLPs extracted from Ascaris heads are heterogeneous; whether or not they belong
to an intragenic family is not known. One purified and sequenced form, called AF1, is
an heptapeptide (A for Ascaris, F for FMRFamide, 1 for the first purified form), and
has been shown to be biologically active in Ascaris (Cowden et al., 1989). AF1
reduces the input resistance in inhibitory motorneurones (recorded from the
commissures), but has no effect on excitatory motorneurones. The decrease in input
resistance produces changes in the membrane space constant that may impair inhibitory
transmission (Cowden et al., 1989). One putative target for AF1 is the slow voltage-
sensitive conductance activated by strong depolarization: AF1 could activate this
conductance.
It has been proposed that AF1 suppresses the inhibitory circuit leading to paralysis
of the body, and this during the feeding period. However there is no direct evidence
yet for the role of FLPs in Ascaris, and it seems likely that the variety of FLPs and




The first report of y-aminobutyric acid (GABA) as a neuro-inhibitory substance was
made by Florey (1954). He described the inhibitory activity of a substance extracted
from the mammalian nervous system, Factor I, on the crayfish stretch receptor. Later,
Factor I was shown to be mostly GABA (Bazemore, Elliot and Florey, 1957). The
recognition of GABA as an inhibitory transmitter in the vertebrate nervous system came
with the demonstration of its wide distribution in association with the related enzymes
required for its synthesis and degradation, and the discovery of its physiological role
(Curtis and Johnston, 1974; Krnjevfc, 1974). GABA has an inhibitory action at the
cellular level, but it may produce disinhibition and leads to a general excitatory effect at
a more integrated level. GABA-ergic neurotransmission is involved in the control of
more specific physiological mechanisms (see for a review Matsumoto, 1989; Sieghart,
1989) such as: hormone secretion of prolactin and growth hormone, control of
cardiovascular function, mechanisms underlying pain, anxiety and feeding and
aggressive behaviour. This list is certainly not exhaustive, but gives an idea of the
important role played by GABA neuro-transmission in the vertebrate systems. GABA
receptors subtypes were discovered using new techniques such as radiolabelled-ligand
binding and molecular cloning. Two GABA receptor types are commonly recognized,
A and B (Bowery and Hudson, 1979), which have different physiological roles (see
Matsumoto, 1989 for a review). There is also indirect evidence for a third type, non-A,
non-B, tentatively named a GABA-C receptor by Johnston (1986), on which baclofen
and bicuculline are inactive (Ault and Nadler, 1983). Different pharmacological
subtypes have also been described, within GABA-A and GABA-B types. Whether or
not these subtypes have different physiological functions is not known. In this chapter,
a short review of the GABA receptors in vertebrates is presented; it concentrates mostly
on the GABA-A type, since the Ascaris GABA receptor is more closely related to this
type than to the B type.
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1. GABA-A receptor complex
1.1. Association of the GABA receptor with a CI channel and regulatory
sites
Rather than "GABA-A receptor", the term of "GABA-A receptor-channel complex"
is more appropriate. Despite early evidence for the coupling between the GABA
receptor and a CI channel (Bowery and Brown, 1974), the use of the term "GABA
receptor-channel complex" really emerged with the discovery of the association of
benzodiazepine receptors and GABA receptors (Tallman, Thomas and Gallager, 1978).
Now several others regulatory binding sites have been identified: the picrotoxin binding
site; the benzodiazepine binding site; and the steroid binding site.
These sites were shown to interfere with the binding of GABA and to interact with
each other. The description of these interactions and of their physiological relevance is
discussed below.
a. Benzodiazepine binding sites
Benzodiazepines were first shown to potentiate presynaptic inhibition in the spinal
cord (Pole, Mohler and Haefely, 1974), in cultured mammalian neurones (MacDonald
and Barker, 1978), and pre- and post-synaptic inhibition in cat cuneate nucleus (Pole
and Haefely, 1976). The interaction between GABA-A and benzodiazepine receptors
was confirmed using binding techniques (radiolabelled-ligand binding techniques),
where GABA was shown to enhance benzodiazepine binding (Tallman et al., 1978;
Karobath and Sperk, 1979). This enhancement is antagonized by GABA-A competitive
antagonists, such as bicuculline (Tdlman et al., 1978), suggesting an action mediated
by the GABA receptor itself. However, GABA does not increase the binding of
benzodiazepine antagonists, such as R015-1788, and even decreases the binding of
benzodiazepine inverse agonists, such as methyl-P-carboline-3-carboxylate (Braestrup
and Nielsen, 1981; Ehlert, Roeske, Braestrup et al., 1981).
The benzodiazepine site interferes reciprocally with [3H]GABA binding; agonists at
the benzodiazepine receptor increase the affinity of the GABA receptor (Guidotti,
Toffano and Costa 1978). It was proposed that benzodiazepines act by competing or
removing an inhibitory protein at the GABA receptor: GABA modulin (Guidotti et al.,
1978; Guidotti, Konkel, Ebstein et al., 1982). An increase in GABA binding affinity is
also obtained by pretreatment of the membranes with triton X-100 or by freezing-
thawing cycles (Enna and Snyder, 1977). These treatments were thought to denature an
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inhibitory protein which might be similar to the one regulated by the benzodiazepines.
More recently the patch-clamp technique has shown that benzodiazepines increase the
probability of channel opening without affecting the mean open time; but at high
concentrations agonists like diazepam appear to accelerate desensitization of GABA
receptors (bovine chromaffin cells, Mathers, 1987). An attractive model for the
interaction benzodiazepine-GABA receptors has been proposed by Mathers (1987):
GABA-activated channels opening is regulated by a putative protein preventing
repetitive opening and subsequent desensitization. In the presence of benzodiazepines,
this regulatory protein is inhibited and the channel open probability is increased until a
desensitization threshold is reached.
b. Picrotoxin binding site
The recording of GABA activated single channel currents in patch-clamp studies
(Bormann, Sakman and Seifert, 1983) and the measurement of changes in the flux of
36C1 in brain slices (Wong, Leeb-lundberg, Teichberg et al., 1984) or brain microsacs
(Harris and Allan, 1985), has confirmed the widespread assumption that GABA-A
receptors are directly coupled to CI channels. The well known non competitive GABA-
A antagonist, picrotoxin, its close derivative picrotoxinin and the "cage convulsant"
TBPS, are believed to bind a site located on the channel itself (Squires, Casida,
Richardson et al., 1983; Supavilai and Karobath, 1984). These compounds also
interfere with non GABA-gated CI channels in invertebrates, again suggesting that their
site of action is on the channel itself (Eldefbawi and Eldefrawi, 1987).
Barbiturates are believed to act on the same site as well. Depressant barbiturates
such as pentobarbitone potentiate GABA by increasing the receptor affinity (Ticku and
Olsen, 1978). At high concentrations they have a direct GABA mimetic effect (Leeb-
Lundberg, Snowman and Olsen, 1980; see Johnston and Willow, 1982 for review). In
patch-clamp studies, barbiturates promote a burst-like pattern of channel openings
(Mathers, 1987) by increasing the burst duration (Twyman, Rogers and MacDonald,
1989), and may well be responsible for desensitization at higher concentrations
(Mathers, 1987). Whether the barbiturate-GABA interaction is relevant is not known
since the concentrations of barbiturates required to potentiate GABA responses are not
compatible with therapeutic concentrations. The channel binding site is certainly of
great pharmacological importance; the recent discovery of the action of some naturally
occurring steroids brings a new interesting development to this field. Because of its
importance, the action of steroids on the GABA-A receptor-channel complex will be
treated in a separate paragraph.
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c. Benzodiazepine and picrotoxin binding sites interactions
Barbiturates can increase, indirectly, benzodiazepine binding by increasing the
GABA-receptor affinity; but in the presence of an excess of GABA, barbiturates still
increase benzodiazepine binding (Leeb-Lundberg et al., 1980). A similar type of
interaction is described with the anxiolytics etazolate and cartazolate: they are also
supposed to bind to the CI channel, and they increase benzodiazepine binding, but in
contrast to barbiturates they do not interfere with GABA binding (Beer, Klepner, Lippa
et al., 1978; William and Risley, 1979; Supavilai and Karobath, 1979). The
antiparasitic drug, avermectin B1 has been shown to have similar properties as well
(Williams and Yarbrough, 1979). In view of the difficulties in interpreting binding
studies, only rational physiological experiments are likely lead to a better understanding
of the interactions between the different regulatory sites at the GABA-A receptor-
channel complex.
d. Steroid binding site
Recently, the GABA receptor complex has been shown to be modulated by steroids
in a stereospecific manner (Simmonds, Turner and Harrison, 1984; Majewska,
Harrison, Schwartz et al., 1986). Naturally occurring steroid hormone metabolites are
effective at very low concentrations (Majewska, Bisserbe and Eskay, 1985; Majewska
et al., 1986; Turner, 1986; Callahan, Cottrell, Hather et al., 1986; Barker, Harrison,
Lange et al., 1986; Morrow, Suzdack and Paul, 1987; Ong, Kerr and Johnston, 1987;
see Gee, 1988 for a review) and so is the steroid anaesthetic alphaxalone (Harrison and
Simmonds, 1984; Barker et al., 1986; Cottrell, Lambert and Peters, 1987). The
receptor involved is not the classical cytoplasmic steroid receptor since the
stereospecificity is different, and steroids displace [35S]TBPS from its binding site.
The steroid binding site seems identical to the previously described TBPS, picrotoxin,
barbiturate binding site. However, the stimulatory effects of secobarbital and
pregnenolone on the GABA receptor can be blocked selectively and the stimulation of
[3H]muscimol binding by secobarbital and pregnenolone is additive (Kirkness and
Turner, 1988). These two facts are in favour of a separate site of action, but here as
well, it would be interesting to know if this difference can be demonstrated under more
physiological conditions. Steroids are an interesting area of research and may be
considered as natural modulators at the CI channel level.
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Figure 6: Schematic diagram of the GABA-A
receptor-channel complex (from Braestrup et al.,
1986).
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Conclusion: all these pharmacological and biochemical approaches have revealed
different sites on the GABA-A receptor, which can be pharmacologically manipulated.
Figure 6 is a schematic representation of these different sites of the GABA-A receptor
(from Braestrup and Nielsen, 1986).
1.2. Pharmacology of the GABA-A receptor
The main aspects of the pharmacology of the vertebrate GABA-A receptors are
summarized in Table 3, and compared with the GABA-B receptor. The rigid analogues
of GABA, muscimol, isoguvacine and THIP are usually potent and rather specific
agonists at GABA-A receptors. Bicuculline and picrotoxin are potent, specific
antagonists at GABA-A receptors. Bicuculline is a competitive antagonist, whereas
picrotoxin acts non-competitively at the channel level. However, there are some
variations in the relative potencies of agonists and antagonists within the population of
the GABA-A receptors, indicating of the heterogeneity of the GABA-A receptors
(Krogsgaard-Larsen, 1988).
1.3. Heterogeneity of GABA-A receptors
a. Pharmacological evidence
If GABA-A receptors are defined as bicuculline sensitive and baclofen insensitive
receptors (Bowery, Hill and Hudson, 1983), different subtypes can be described. Their
classification is made on the basis of either their localization (central or peripheral,
synaptic or extrasynaptic), affinity (high, medium or low affinity) or putative function
(uptake sites or autoreceptors) (see Krogsgaard-Larsen, 1988, for a review).
- High, medium and low affinity sites
Two GABA-A binding sites: high and low affinity (Guidotti, Gale, Suria et al.,
1979) have been described. The relative density of the high affinity site varies within
the brain; a high density is found in the striatum and the substantia nigra. After lesion of
the striato-nigral GABA-ergic system, there is an augmentation in the number of high
affinity sites but not in the number of low affinity sites. A similar increase in the
proportion of high affinity GABA sites is seen in brains from humans suffering from
Huntington's Chorea. This was interpreted as up-regulation of the high affinity
receptor, suggesting that the high affinity site was physiologically relevant in the
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Table 3
Summary of the main differences between GABA-A and GABA-B receptor types (from
Bowery et al., 1983).
GABA-A GABA-B
muscimol potent agonist weak agonist















G protein not linked second messenger ?
benzodiazepines potentiate no effect
barbiturates potentiate no effect
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striato-nigral system (Guidotti et al., 1979). There are as well some pharmacological
differences between these two binding sites: dihydromuscimol, muscimol and
thiomuscimol are more potent on the low affinity site, and are the most potent activators
of benzodiazepine binding. In contrast THIP is a potent [3H]GABA displacer on the
high affinity site, but is weak at enhancing benzodiazepine binding. The extreme case is
the sulphonic derivative P4S, which is a potent agonist on the high affinity site but
which has a deacti$ng effect on benzodiazepine binding (Krogsgaard-Larsen, 1988).
These differences lead to the hypothesis of two separate GABA receptors, only one
being associated with the benzodiazepine binding sites. Pharmacological similarities
between the low affinity binding site and the benzodiazepine binding stimulation, and
the fact that micromolar concentrations of GABA are required to get physiological
responses, suggest that the low affinity binding site is the physiological GABA-A
receptor.
Falch and Krogsgaard-Larsen (1982), using THIP as a ligand, described a third,
medium affinity, binding site in the CNS. They proposed that this medium affinity site
was physiologically relevant since its pharmacological profile was similar to the
pharmacological properties observed in electrophysiological studies in the CNS.
Conclusion: the distinction between high, medium and low affinity binding sites is
based on binding studies and may not reflect the real actions of GABA and GABA
agonists observed under more physiological conditions. The difference in affinity
detected may correspond to different states of the same receptor, these states may have
different pharmacological properties (see Mathers, 1987).
- Synaptic and extrasynaptic GABA-A receptor subtypes
With hippocampal neurones, GABA applied ionophoretically on the soma induced
hyperpolarization, but GABA applied on the dendrites induces depolarization (Alger
and Nicoll, 1982). The different response is explained by differences in the CI potential
between the two regions. However the two responses present a different
pharmacological sensitivity: the depolarizing response is 10-100 times more sensitive to
picrotoxin and bicuculline than the hyperpolarizing response; THIP elicits only
hyperpolarizing responses (Alger and Nicoll, 1982); and ethylenediamine on the
contrary elicits depolarizing responses (Blaxter and Cottrell, 1987). Since, on
hippocampal neurones, synaptic receptors are concentrated on the soma, the
hyperpolarizing response was said to be the result of synaptic receptors activation,
whereas the depolarizing response was due to the activation of extrasynaptic receptors
(Alger and Nicoll, 1982). Extrasynaptic receptors are also found on peripheral nerves
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and their activation produces depolarization of the unmyelinated (Brown and Marsh,
1978) and myelinated (Morris, Di Costanzo, Fox et al., 1983) axons. In
electrophysiological studies, the pharmacology of extrasynaptic myelinated nerve
GABA-A receptors is similar to the central GABA-A receptors. However in binding
studies, there is a marked disparity: neither bicuculline or baclofen displace [3H]GABA
from this binding site (Barolet, Kish and Morris, 1985). There is therefore biochemical
and physiological evidence for different subtypes of GABA-A receptors corresponding
to synaptic and extrasynaptic locations.
- Central and peripheral GABA-A receptors
GABA receptors are present centrally (Curtis and Watkins, 1965; Curtis and
Johnston, 1974) and peripherally on: sympathetic ganglia (Adams and Brown, 1974;
Bowery and Brown, 1974), sensory dorsal root ganglia (Feltz and Raminsky, 1974),
peripheral nerve trunks (Brown and Marsh, 1978; Morris et al., 1983; Barolet et al.,
1985), primary afferent terminals (Barker and Nicoll, 1973), and adrenal chromaffin
cells (Katoaka, Gutman, Guidotti et al., 1984). Nistri and Constanti (1979) proposed
four key compounds to distinguish between two groups of GABA-A receptors:
guanidoacetic acid, p-guanidinopropionic acid, y-aminohydroxybutyric acid, and trans-
1,3-aminocyclopentane carboxylic acid* GABA receptors found in sympathetic ganglia,
spinal motorneurones, and spinal interneurones are rather insensitive to these
compounds whereas GABA-A receptors found in primary afferents terminals, dorsal
root ganglia, cortical neurones are rather sensitive. Another classification based more
simply on the potency of bicuculline and the relative potency of 3-APS, distinguishes
three main types: ganglionic, spinal and supraspinal GABA-A receptors (Krogsgaard-
Larsen, 1988). Ganglionic GABA receptors (sensory or autonomic ganglia) produce
depolarization of the neurone membrane and 3-APS is equipotent to GABA. Spinal
receptors, in spite of small differences between primary afferent terminals,
interneurones and motorneurones, are fairly homogenous: 3-APS is more potent than
GABA itself. Bicuculline acts as a potent competitive antagonist at both ganglionic and
spinal receptors, in contrast to the central GABA receptors where bicuculline acts as a
weak non competitive antagonist. These results illustrate the pharmacological variety of
GABA-A receptors. Since these differences are associated with regional variation, they
may well reflect differences in the physiological role of GABA-A receptors.
- Uptake sites
Three different sites are commonly distinguished: neuronal high affinity uptake,
neuronal low affinity uptake and glial uptake; they-arc all sensitive to bicuculline, but
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present pharmacological properties different from the classical GABA-A receptor
(Iversen and Kelly, 1974; Hitzemann and Loh, 1978; Krogsgaard-Larsen and
Johnston, 1975; Allan, Dickenson andFong, 1986b). For example nipecotic acid, 2,4-
diaminobutyric acid and (3-alanine are inhibitors of GABA uptake; P-alanine is a potent
blocker of glial uptake but not of neuronal uptake and 2,4-diaminobutyric acid is an
inhibitor at the neural uptake sites. These uptake sites are interesting targets since their
specific pharmacological manipulation can lead to a potentiation of GABA
neurotransmission.
- Autoreceptors
The release of GABA from an inhibitory nerve may be regulated by GABA itself
(Mitchell and Martin, 1978). These sites are bicuculline sensitive but present different
pharmacological properties. For example 5-aminolaevulinic acid is a specific agonist at
GABA-A autoreceptors (Brennan and Cantrill, 1979). GABA autoreceptors can also be
manipulated pharmacologically to modulate GABA neurotransmission.
b. Molecular biology
See Stephenson, (1988); Schofield, (1989); Olsen and Tobin, (1990), for reviews.
In purified and solubilized preparations of central GABA receptors, only two protein
bands were originally detected: 50-53 kDa (a) and 55-57kDa ((3) (Schofield, Darlison,
Fujita et al., 1987). The P protein chain was photolabelled with [3H]muscimol and the
a protein chain with [3H]flunitrazepam (Schofield et al., 1987). Cloning and
expression of these subunits suggested that the organization of GABA-A receptor was
of the type 2achains+2pchains (2a2P) (Schofield et al., 1987). However, the cloned
2a2P GABA-A receptors expressed in xenopus eggs, although functional, were only
weakly potentiated by benzodiazepines (Schofield et al., 1987). Recent preparations
have revealed the existence of novel subunits: y, 8 and e, and new subtypes of
subunits: ai, ct2, <*3, 0C4; Pi, P2, P3; yi, and y2 (see Schofield, 1989, for a review).
Molecular cloning techniques confirmed that each subunit and each subtype were
originating from distinct genes. Reconstitution with the cloned subunits aP2y yielded
to functional receptors that were modulated by benzodiazepines. In contrast to the
previous findings, the y but none of the a subunits, are photolabelled by
[3H]flunitrazepam. The combination and expression of these various subtypes of
subunits gives functional receptors with different sensitivities and pharmacological
properties. The molecular biology techniques have therefore confirmed the multiplicity
of GABA-A receptors. Recent in situ hybridization studies have shown that the y2
subunit is encoded in various neuronal subsets known to contain high affinity
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benzodiazepine binding sites (Olsen and Tobin, 1990); localization of mRNA for the 5
subunit also shows a good correlation with the distribution of the high affinity
muscimol binding site. These new results provide strong evidence for the existence of
GABA-A receptor heterogeneity and are based on genie differences. These molecular
differences explain the pharmacological heterogeneity of the GABA-A receptors
described earlier.
Conclusion: GABA-A receptors are complex molecules, some can present binding
sites for benzodiazepines, barbiturates and steroids, and are pharmacologically and
geographically heterogeneous. GABA-A receptor heterogeneity is also seen with
molecular biology techniques. These GABA-A receptors are the product of multiple
genes, and the regulation of their expression in various biological situations may
explain differences in location found with the pharmacological GABA-A subtypes.
2. GABA-B receptor
See Bowery, (1989) for a review. GABA-B receptors also inhibit neuronal activity
but mainly by pre-synaptic inhibition of neurotransmitter release. GABA-B receptors
inhibit the release of neurotransmitter in the peripheral and in the central nervous system
(Bowery and Hudson, 1979; Bowery, Doble, Hill et al., 1980a; Bowery, Hill, Hudson
et al., 1980b). However a post-synaptic physiological role for GABA-B receptors has
been proposed in hippocampal pyramidal cells: activation of post-synaptic GABA-B
receptors results in a slow inhibitory post-synaptic potential mediated by an increase in
K conductance (Dutar and Nicoll, 1988). This contrasts with the fast post-synaptic
inhibitory potential induced by GABA-A activation in the same cells (Dutar and Nicoll,
1988). The physiological role of GABA-B receptors is less well-known than is the role
of GABA-A receptors, but they seem to be specifically associated with depression,
memory and analgesia (Bowery, 1989).
2.1. GABA-B receptors are coupled with Ca or K conductances
GABA-B receptors, in contrast to GABA-A receptors, are not linked to a chloride
channel but are related to Ca or K conductances, and they have a distinct
pharmacological profile. GABA reduces a Ca conductance via GABA-B receptors in rat
dorsal root ganglion (Desarmenien, Feltz, Loeffler et al., 1982) and in rat embryonic
sensory neurones (Dunlap, 1981); but GABA increases a K conductance via GABA-B
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receptors in rat hippocampus (Dutar and Nicoll, 1988). It would seem that the Ca-
coupling is predominant at presynaptic terminals whereas the K-coupling is more
important post-synaptically. In contrast to the GABA-A site, the coupling of GABA-B
receptors with Ca or K conductances, is not direct and involves a second messenger: a
G protein appears to be the best candidate. The fine mechanism is still unknown. One
problem is the existence of contradictory effects on the production of cAMP: GABA-B
receptor activation can either depress the accumulation of cAMP induced by forskolin,
or enhance the formation of cAMP induced by the stimulation of P-adrenoreceptors
(Scherer, Ferkany and Enna, 1988). These two actions may involve different receptors
(Scherer et al., 1988), but whether or not these two mechanisms are related to the
coupling with two different conductances, is not known yet
2.2. Pharmacological profile of the GABA-B receptor
The pharmacological properties of the GABA-B receptors are very different from
those of the GABA-A receptor complex; the main points are;
- Baclofen is a specific GABA-B agonist which has no action on the GABA-A
receptor (Bowery et al., 1980b). [3H]baclofen binds specifically GABA-B receptors
(Hill and Bowery, 1981; Bowery and Hudson, 1983).
- Bicuculline does not antagonize GABA responses at the GABA-B receptors
(Bowery and Hudson, 1979; Bowery et al., 1980a) and does not interfere with
[3H]baclofen binding (Hill and Bowery, 1981, Bowery and Hudson, 1983).
- The rigid analogues of GABA such as, isoguvacine, THIP, and the sulphonic
acid derivatives, 3-APS and P4S, are inactive (Bowery, Price, Hudson et al., 1984).
The partially rigid analogues such as muscimol are less potent than on the GABA-A
receptor (Bowery and Hudson, 1983).
On the basis of the activity of flexible and rigid GABA analogues, Johnston and
Allan (1984) proposed that GABA-A receptors accept the GABA molecule in an
extended conformation, whereas GABA-B receptors accept the GABA molecule in a
folded conformation. Table 3 shows a summary of the main differences between
GABA-A and GABA-B receptors. Baclofen was the first specific GABA-B agonist
discovered (Bowery et al., 1980b). Now phosphinic derivatives of GABA are known
to be potent and selective GABA-B agonists: 3-aminopropane phosphinic acid, is 10-
100 times more potent than baclofen. Surprisingly the phosphonic derivative of
baclofen, phaclofen, does not act as an agonist but as an antagonist (Dutar and Nicoll,
1988). Similarly, the GABA-A agonist DAVA acts as an antagonist on GABA-B
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receptors in rat anococcygeus muscle (Muhyaddin, Roberts and Woodruff, 1982), and
its restricted analogue Z-5-aminopent-2-enoic acid is five times more potent than
phaclofen as a GABA-B antagonist (Dickenson, Allan, Ong et al., 1988).
2.3. Heterogeneity of GABA-B receptors
As mentioned before, there is evidence for heterogeneity of GABA-B receptors; the
agonist 3-aminopropyl phosphinic acid acts as a full agonist in inhibiting the
accumulation of cAMP stimulated by forskolin, but acts as a partial agonist on the
potentiation of cAMP formation by (3-adrenergic agonists. A close analogue: 3-
aminopropyl phosphonic acid mimics the action of baclofen on the accumulation of
cAMP stimulated by forskolin, but is inactive on the potentiation of cAMP formation by
isoprenaline (Scherer et al., 1988). There is also some pharmacological evidence for the
existence of GABA-B autoreceptors (Pittaluga, Asaro, Pelligrini at al., 1987).
Conclusion: GABA-B receptors also appear to be heterogeneous; they have a great
physiological importance and seem to be more involved in analgesia and depression
than GABA-A receptors (Bowery, 1989).
B INVERTEBRATES
Evidence for GABA receptors in invertebrates was discovered very early, since
Florey (1954) detected the inhibitory effects of Factor I on a crustacean stretch receptor
preparation. The study of GABA receptors in invertebrates has mainly been performed
in arthropods, and to a certain extend in molluscs. One characteristic of the GABA
receptors in invertebrate, is the variability of their pharmacological properties, between
and within species. However their common features are (see, Nistri and Constanti,
1979; Simmonds 1983; Walker and Holden-Dye, 1989, for review):
- Invertebrate GABA receptors are directly linked to a CI channel (except
in molluscs, where different ion# conductances can be associated with
GABA receptors).
- Invertebrate GABA receptors are insensitive to baclofen
- Invertebrate GABA receptors are insensitive to sulphonic derivatives
such as the GABA-A agonists P4S and 3-APS.
- Bicuculline has inconsistent effects, and is weak or inactive.
- Picrotoxin is a good antagonist.
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- The presence of modulatory sites, such as benzodiazepine receptor,
associated with the GABA receptor, is inconsistent
1. Insensitivity to baclofen
Baclofen has been shown to be inactive in virtually all invertebrate preparations,
suggesting that invertebrate GABA receptors are not GABA-B receptors. However, to
reject the existence of a GABA-B type of receptor, one would have to test several
compounds, rather than to rely on only one agonist. Invertebrates may possess GABA-
B-like receptors with slightly different pharmacological properties such as weak activity
of baclofen. A baclofen sensitive GABA receptor has been reported in only one
invertebrate study, on the larvae of a sea gastropod (Haliotis rufescens), where it is
involved in the trigger of metamorphosis (Trapido-Rosenthal and Morse, 1986). These
larvae are induced to settle and metamorphose in response to exogenous GABA and a
number of GABA agonists. Binding studies have shown that [3H]baclofen specifically
labelled the chemoreceptors involved (Trapido-Rosenthal and Morse, 1986). More
recently, Benson (1989) described a GABA receptor in the heart of Limulus linked to a
chloride channel on which the specific GABA-B agonist, 3-aminopropyl phosphonous
acid is the most potent agonist; it was also insensitive to bicuculline and baclofen.
These results indicate that receptor classification should not rely on a single compound.
In conclusion, most invertebrate preparations are baclofen insensitive but this does not
exclude the existence of a baclofen insensitive GABA receptors which is
physiologically related to the vertebrate GABA-B receptor.
2. Insensitivity to sulphonic acid derivatives
In contrast to the GABA-A receptor, all invertebrate GABA receptors have shown
an insensitivity towards the sulphonic acid derivatives such as P4S and 3-APS
(Simmonds, 1983; Walker and Holden-Dye, 1989). Obviously, the structural and
electron differences between the tetrahedrally oriented sulphonate group and the planar
carboxylate group (Krogsgaard-Larsen, 1988) play an important role accounting for the
differences of properties between GABA and P4S at invertebrate GABA receptors.
3. Bicuculline sensitivity
Tables 4,5, and 6, summarizes the sensitivity of various preparations to bicuculline
and GABA antagonists. One can distinguish two classes of invertebrate GABA
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receptor: those that are insensitive to bicuculline and those on which bicuculline has a
weak antagonist action.
3.1. Insensitivity of GABA responses to bicuculline
GABA receptors in the central nervous system and at neuromuscular junctions in
insects are insensitive to bicuculline (Scott and Duce, 1987; Lees, Beadle, Neumann et
al., 1987; Satelle, Pinnock, Wafford et al., 1988; Benson, 1988; Wafford, Satelle,
Abalis et al., 1988). In crustaceans, bicuculline is ineffective on the peripheral stretch
receptor neurones (Swagel, Ikeda and Roberts, 1973), but has a weak antagonist effect
at neuromuscular junctions in the crayfish, the lobster (Takeuchi and Onodera, 1972;
Shank, Pong, Freeman et al., 1975; Constanti, 1978) but not in the crab muscle (Earl
and Large, 1974).
3.2. Weak GABA antagonism induced by bicuculline
Crustacean neuromuscular junctions are sensitive to bicuculline (10-250(iM), but in
contrast to the vertebrate GABA-A receptor, bicuculline acts as a non competitive
antagonist (Takeuchi and Onodera, 1972; Shank et al., 1975; Constanti, 1978). In
molluscs, bicuculline antagonizes fast hyperpolarizing responses to GABA (Piggott,
Kerkut and Walker, 1977; Yarowsky and Carpenter, 1978; Vehovszky, Bokisch,
Krogsgaard-Larsen et al., 1989). These responses involve CI channel activation.
However, bicuculline has been reported also to antagonize some depolarizing responses
to GABA, which are due to Na conductance activation or K conductance inactivation
(Pigott et al., 1977). Apart from its weak GABA antagonist properties in some species,
bicuculline has been reported to antagonize nicotinic Na-mediated responses in the
locust (Benson, 1988), and acetylcholine hyperpolarizing Cl-mediated responses in the
snail (Piggott et al.,1977).
4. Picrotoxin sensitivity
Picrotoxin antagonizes most of the GABA responses in invertebrates. The main
difference with the GABA-A receptor lies in the mechanism of action. Several reports
suggest that picrotoxin acts in a competitive manner in crustaceans (Grundfest, Reuben
and Rickles, 1959, Shank et al.,1974, Hori, Ikeda and Roberts, 1978), but it seems
more likely that "mixed" antagonism is involved (Constanti, 1978). At the vertebrate
GABA-A receptor complex, picrotoxin is believed to bind a site located at the chloride
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channel. It is therefore not surprising, that picrotoxin is able to antagonize acetylcholine
induced hyperpolarizing (Cl-mediated) responses in molluscs (Piggott et al., 1977).
However, picrotoxin has been shown to block GABA depolarizing (Na-mediated)
responses in the snail (Vehovszky et al., 1989) and acetylcholine (Na-, K-mediated)
depolarization in the cockroach (Satelle et al., 1988). From these results, it is clear that,
if picrotoxin really interacts with the channel part of the receptor, it is not specific to CI
channels, in invertebrates, specially in molluscs.
5. Modulatory sites
Although benzodiazepine receptors were originally thought to occur only in the
vertebrates (Nielsen, Braestrup and Squires, 1978), they have been described in insects
(Table 7) (Abalis, Eldefrawi and Eldefrawi, 1983; Lummis and Satelle, 1986). They
seem to be associated with GABA receptors since benzodiazepine potentiate GABA
induced currents (Lees et al., 1987) and GABA binding (Satelle et al., 1988).
Barbiturate potentiation of GABA effects has also been demonstrated in insects (Table
7) (Scott and Duce, 1987; Lees et al., 1987; Satelle et al., 1988).
Conclusion: invertebrate GABA receptors are similar to vertebrate GABA-A
receptors: most of the GABA-A agonists such as muscimol, act as agonists, and the
receptors are usually directly linked to a CI channel. The main differences are that
bicuculline is virtually inactive at invertebrate GABA receptors, and that sulphonic acid
derivatives are not potent agonists. There are exceptions to this generalization: mollusc
neurones respond in five different ways to GABA, three responses are excitatory
mediated by Na or K conductance changes, and two responses are inhibitory mediated
by CI conductance changes (Vehovszky et al., 1989). It has been pointed out that most
of the invertebrate GABA receptors are insensitive to baclofen, and this is interpreted as
invertebrate GABA receptors being not GABA-B receptors. However in some cases,
this classification criteria looses its meaning. For example, the GABA-B agonist 3-
aminopropyl phosphonous acid, is the most potent agonist at the GABA receptor in
Limulus heart (Benson, 1989); this does not mean that this receptor is a GABA-B
receptor, since the GABA-A agonists muscimol, isoguvacine and THIP act as agonists,
and baclofen is inactive.
More generally, this short review on GABA receptors shows that receptor
classification is not simple. Classifying a GABA receptor cannot be achieved solely by
using a single drug or technique, but receptor classification, although an
oversimplification, is still required for convenience of communication. In the next
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Sections, the terms of GABA-A and GABA-B receptors will be used, bearing in mind
that GABA-receptor classification is more complex and involve numerous
pharmacological subtypes.
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Table 4:Summary of the effects of GABA antagonists on Insects GABA receptors
INSECTS
Bicuculline Locust muscle ImM, no effect Scott and Duce,
1987





Lees et al., 1987
Benson, 1988
Cockroach neurones lOOpM no effect on
GABA evoked currents






Limulus *heart inactive at lOOpM Benson, 1989




Locust neurones l(iM, antagonized
GABA responses
Lees et al., 1987
Benson, 1988













Limulus *heart inactive at 100(iM Benson, 1989
Pitrazepin Locust neurones 100|xM no effect Lees et al., 1987






Limulus*heait inactive at lOjiM Benson, 1989






SR95103 Limulus* heart inactive at lOOuM Benson, 1989
* Limulus is not an insect but belongs to the class of Chelicerata, which is close to the class of
Arachneidea.
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Crayfish muscle Ki=350|iM Olsen et al., 1975








Picrotoxin Lobster muscle 0.1-10pM mixed
antagonism
Constanti, 1978






Crayfish muscle l-30|iM, true non
competitive
antagonism
* inactive at 300(iM
Takeuchi and
Takeuchi 1969
Olsen et al 1975














Hon et al., 1978
Table 6: Effects of some antagonists on molluscs GABA receptors
MOLLUSCS
Bicuculline Snail neurones 0.1-1000|iM antagonizes H
but not D responses to GABA
80(iM antagonizes, H and
D responses to GABA and





Aplysia neurones 10-1000|iM, antagonizes
the fast hyperpolarizadon
(CI) response to GABA
Yarowsky and
Carpenter, 1978
Picrotoxin Snail neurones 0.1-10pM blocks H and D
GABA responses











Pitrazepin Snail neurones l-lOOpM, no effect Vehovszky et al.,
1989











8(iM, blocks H and D
responses to GABA













Lees et al., 1987






Barbiturates Locust neurones 100|iM
potentiation









I AN HISTORY OF RECEPTOR THEORY
1. The concept of receptor
See Dean, (1987) for a review. The notion of specific receptors for drug molecules
or neurotransmitters started with Langley. In his early studies of salivary secretion,
Langley (1873) speculated on the association of drugs with some part of the tissue:
"...we may, I think, without much rashness, assume that there is
some substance or substances in the nerve endings or gland cells
with which both atropin and pilocarpin are capable offorming
compounds...".
Later, Ehrlich, working on the immune response, formulated the concept of specific
surface groups on cells, that could interact with drug molecules showing specific
binding properties. The term, receptor, was then used (Ehrlich and Morgenroth, 1900):
"...For the sake of brevity, that combining group of the
protoplasmic molecule will hereafter be termed receptor...".
Langley (1905), then referred in his subsequent work on toxins and drugs to Ehrlich's
theory of immunity, and mentioned the existence of receptive substances:
"..J conclude then that in all cells two constituents at least must be
distinguished, (1) substances concerned with carrying out the chief
functions of the cell such as, contraction, secretion, the formation of
special metabolic products, and (2) receptive substances especially
liable to change and capable of setting the chief substance in
action...".
2. Classical models for drug-receptor interaction
Langley (1873) himself suggested that the action of a drug or toxin could follow:
"...some law of which their relative mass and chemical affinity are
some factors...".
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A student of Langley, Hill (1909), applied the law of mass action to describe the
relation between the concentration of an agonist and the amount of compound formed
between this agonist and the "receptive substance". However, it was only 50 years
later, that the first model for drug-receptor interaction was proposed by Clark (1926).
2.1. Clark-Gaddum theory of occupancy
Clark's quantitative study of the action of acetylcholine on isolated frog muscle
showed that the effects of acetylcholine could be expressed as a function of the drug
concentration:
K'x = (100^) <»
where x is the concentration of acetylcholine, y is the response as a percentage of the
maximum response and K is a constant. He related this equation to the Langmuir's
adsorption isotherm, describing the adsorption of a gas at the surface of a solid. By
analogy, Clark interpreted y as the percentage of receptor occupied, and Ka as the
affinity constant of the drug for the receptor:
A + R «« ^ AR
The effect of a drug is therefore related to the proportion of receptors occupied by
this drug; Clark's theory is also called occupancy theory. Authors refer either to
Langmuir's isotherm or to the law of mass action (Hill, 1909). Both equations are the
same. Although there is no evidence that the drug-receptor interaction can be described
by the law of mass action or by Langmuir's isotherm, it is assumed to give a good
approximation.
Gaddum (1936), extended Clark's theory to the antagonist-receptor interaction. He
assumed that antagonist molecules occupy the receptors without any effect. If z is the
percentage of receptors occupied by the antagonist, y is the percentage of receptors
occupied by the agonist, Ci and C2 are the concentrations of agonist and antagonist, K4
and K2 the dissociation constants for agonist and antagonist, then,
A + R r AR
B+R h BR
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with y = Ki Ci.(100 - y - z), z = K2.C2.(100 - y - z) and the relation between agonist
and antagonist is,
Ki Ci = — + (2)l- 1 (100 - y) KZ)
However, although the response is expected to be proportional to occupancy, the
relation between them is not known in most preparations. The work on antagonism was
then mainly carried on by Schild, who first used the notion of null hypothesis: the same
JilS
tissue response should correspond to the same receptor occupancy (see 2.1.).
2.2. Aliens and the concept of "intrinsic activity"
Ariens (1954) introduced the notion of intrinsic activity. Working on the
acetylcholine receptor, he noticed that some compounds showed a dual action: agonist
or antagonist, depending on the tissue to which they were applied. The response
appeared not only dependent upon the fraction of receptor occupied as in the Clark-
Gaddum theory, but also on an intrinsic property of the agonist on a given tissue: the
intrinsic activity,
Ea=0c.[RA]
where Ea is the response, [RA] the fraction of receptors occupied, and a the intrinsic
activity of the compound. A full agonist has an intrinsic activity of 1, whereas a full
antagonist has an intrinsic activity of 0. Compounds with values in between correspond
to partial agonists, a is a property specific to the agonist and the tissue on which it is
applied, whereas the proportion of receptors occupied depends on the receptor affinity.
2.3. Stephenson and the concept of "efficacy"
Stephenson (1956), introduced the idea that the response may not be linearly
proportional to the fraction of receptors occupied, and that drugs may have different
capacities to induce a response. He then defined, e, the efficacy and S, the stimulus.
The stimulus is proportional to the fraction of receptors occupied: S=e.y, where e is the
efficacy and y the proportion of receptors occupied. The response R is an unknown
function of S: R=f(S). This contrasts with Ariens theory, where the response is directly
proportional to the fraction of receptor occupied. Although efficacy and intrinsic activity
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are both characteristics of the agonist and bear some similarities, they are not
equivalent.
Conclusion: Clark-Gaddum, Ariens, and Stephenson theories, are occupancy
theories. The basic assumption is that the drug-receptor interaction is approximated by
the law of mass action (or Langmuir's isotherm). Whereas early theories suggested that
the response was direcdy related to the receptor occupancy, Stephenson introduced the
notion of stimulus and stated that the response is an unknown function of the stimulus.
However, even if the relationship between response and receptor occupancy is not
known, the use of null methods allows the estimation of equilibrium constants and
efficacy.
2.4. Paton and the "rate theory"
Paton (1961), suggested that the stimulus may depend upon the rate of combination
of the drug with the receptor rather than on the receptor occupancy. A compound would
have to form a complex which is rapidly broken up, and the rate constant for the break¬
up would be analogous to the efficacy described by Stephenson (1956). In the
occupancy theories, it is assumed that the response will be produced as long as the
receptor is occupied, whereas Paton suggested that the response will be produced only
when the molecule leaves its binding site. Because, most of the experiments are carried
out at the equilibrium and under the null hypothesis, there is no difference between the
rate theory and the occupancy theory,
y = A + k2/ki (3)
where A is the agonist concentration, y is the fraction of receptors occupied, ki is the
rate of association and k2 the rate of dissociation.
This theory suggested for the first time and before the two-state models and the
allosteric theory, the existence of some structural modifications of the receptor after the
binding of the agonist.
2.5. Hill and the "cooperative model"
The use of more direct approaches and parameters more related to the primary
events following receptor activation, showed that the dose-response curve was not
always hyperbolic, but in some cases distinctly sigmoid (Jenkinson, 1960). It was then
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suggested that the model for cooperative interaction between haemoglobin and oxygen
developed by Hill (1913), could be applied to the drug-receptor theory. Hill (1913),
explained the sigmoidicity of the binding kinetic curve by the possibility of having
several binding sites on the molecule of haemoglobin; the binding of one molecule will
help the binding of the subsequent molecules.
Two cooperative models for drug-receptor interaction are distinguished. The first
one, is equivalent to Hill's model: the binding of the first molecule of agonist helps the
binding of the subsequent molecules, and the receptor is activated (Nistri and
Constanti, 1979),
nA + R p.1 AnR
y = ^_ = _ML_ (4)Rmax xan + Ka
where y is the fraction of receptor occupied, R is the response, Rmax is the maximal
response, xA is the agonist concentration, KA is the apparent dissociation constant for
the complex AnR, and N is the number of sites.
In the second model, the activation of the receptor requires the binding of N
molecules of agonist, but the binding sites are independent (Nistri and Constanti,
1979),
v = ——— = f M (5)y Rmax ^xA + KAJ ^ '
where y, R, Rmax, xA, and N are the same as before, but here KA is the apparent
dissociation constant for one of any of the n sites. In the first model there is a "binding
cooperativity", whereas in the second model, there is a "physiological cooperativity".
In radiolabelled ligand binding studies, cooperativity will be detected only for the first
model.
2.6.Two-state models and the Monod-Wyman-Changeux model
In their experiment on eel electroplax, Changeux and Podleski (1968), suggested
that the cooperativity detected between agonist and the acetylcholine receptor could not
be explained by the Hill cooperative model described above. They related their
observations to the allosteric model developed for enzymes (Monod, Wyman and
Changeux, 1965) This led to the formulation of two-state models (see Colquhoun,
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1973). The receptor is then defined as one or several protomers or subunits. Each
subunit bears a binding site and can exist in two conformations for which the affinity




kt J| I Kr
[T 1
Tn and Rn are the two states of the receptor. L is the equilibrium constant L= j^4r. Kj
and Kr are the microscopic constants for the interaction with binding sites on
protomers in the T and R conformations.
In the dependent subunit model or Monod-Wyman-Changeux model, the n subunits
are linked in such a way that all the subunits are constrained to adopt the same
conformation: "concerted transition" (Monod et al., 1965), so that,
Under simplifying conditions, this model can be described by the Hill equation (5)
(Colquhoun, 1973). In the independent subunit model, the observed cooperativity need
not to involve any interaction between the binding sites. The channel will open only
when all the protomers are in the right conformation.
1
(6)Popen—
where c is the normalized concentration of agonist: c = , and M =
All symbols are as before. Under simplifying conditions this model can also be
described by equation (4) (Colquhoun, 1973).
Conclusion: the occupancy theories adequately described the drug-receptor
interactions until the emergence of new techniques, which allowed the measurement of
more fundamental events following receptor activation. With the discovery of the
allosteric properties of proteins (Monod et al., 1965), the two-state model was
proposed for drug-receptor interaction (Karlin, 1967; Changeux and Podleski, 1968;
Colquhoun, 1973). The consequences of these theories are discussed subsequently in
terms of experimental design and analysis of the results.
D MEASUREMENT OF DRUG-RECEPTOR INTERACTION
This chapter examines the practical application of drug-receptor interaction theories
for the design of experimental procedures. If one wants a correct measure of drug-
receptor interaction, two points are critical: the drug concentration and the response
measured.
1. Drug concentration
In the original occupancy theory, the intensity of a pharmacological effect is
considered to be directly proportional to the number of occupied receptors and this, in
turn, is dependent upon the concentration of the drug in proximity of the receptor. It is
therefore critical to know exactly the concentration in proximity of the receptor. Bath
application of the drugs to a preparation, has the advantage of a known and more even
concentration around the receptor when compared to local administration. However,
uptake, metabolizing systems and diffusion barriers, can locally reduce the drug
concentration around the cell, so that the bath concentration is not equivalent to the
concentration around the receptor.
2. Measurement of the response
To describe qualitatively and quantitatively the interaction between a drug and its
receptor, the choice of the measured response is of crucial importance; too often the
chosen response is not linearly related to the primary event following receptor
occupation. In the case of a receptor directly coupled to an ion channel, such as the
GABA receptor, the primary event following the agonist-receptor interaction is the
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opening of the CI channels, leading to an increase in membrane conductance. The
measurement of the change in membrane conductance is therefore directly related to the
number of receptors activated. The change in membrane potential is a secondary event
following receptor activation and is less related to the number of receptors activated.
The change in membrane potential is also limited by the equilibrium potential for CI.
After several applications of GABA or agonist, CI ions tend to accumulate
intracellularly (if the resting membrane potential of the cell is less negative than the
equilibrium potential for CI), and the membrane potential is shifted to more negative
values. This shift in resting membrane potential is illustrated in the Figur^t Section 5,
where GABA 30|iM has been applied several times to the same cell and shows that the
responses are similar in terms of membrane conductance but not in terms of membrane
potential. (There is also a shift in equilibrium potential for CI to a less negative value,
since the intracellular concentration is increased.)
Ill ANALYSIS OF AGONIST AND ANTAGONIST ACTION
In this chapter, for more clarity, it is assumed that the response measured is the
change in membrane conductance following the activation of a receptor linked to an ion
channel such as the GABA-A receptor.
1. Agonists
The dose-response relationship is more direct when changes in membrane
conductance are measured. All the equations proposed are based on the Hill equation
(4) or (5), and therefore on the assumption of the Langmuir's isotherm. One useful
way to describe quantitatively the action of an agonist is to define the EC50:
concentration which produces 50% of the maximal response. The EC50 is equal to Ka,
Nr—
the dissociation constant, when there is no cooperativity (N=l), but is equal to VKa
when there is binding cooperativity (KA is the apparent dissociation constant of the
complex AnR, see equation 4).
The relation between drug-response and EC50 is illustrated by the modified Hill






where Ag is the change in input conductance, Agmax is the maximum response, EC50
is the concentration of agonist producing 50% of the maximum response, [Xa] is the
agonist concentration and N is the Hill coefficient. Agonist activity is therefore
quantified by three parameters: EC50, Agmax and N.
2. Antagonists
Antagonism has been widely studied and various models have been used (see
Gaddum, 1936; Schild, 1947a, 1947b, 1949, 1957; Arunlakshana and Schild, 1959).
This chapter presents the different approaches to drug antagonism and discusses their
various implications.
2.1. Schild and modified Schild analysis
Schild (1947a) carried on the work started by Gaddum (1936) on drug antagonism.
Its main achievement was to develop a method allowing estimation of the dissociation
constant for an antagonist, in the absence of reliable information on the relationship
between occupancy and response. For this purpose, he applied the notion of dose-ratio
that Clark and Gaddum had already suggested. He defined also the pAx, as the negative
logarithm of the molar concentration of antagonist which reduces the effect of a multiple
dose (x) of an agonist, to that of a single dose of agonist in absence of antagonist, x is
the dose ratio. Schild modified Gaddum's expression to,
log(x-l) = logK2 - pAx (8)
where by definition pAx=-logB, B is the antagonist concentration, K2 is the
dissociation constant for the antagonist. The plot of log(x-l) versus pAx gives a straight
line of slope: -1. He used the pAx values to classify drugs and receptors (Schild,
1947b). The difference between pA2 and pAio can also be used as a test for competitive
antagonism (Schild, 1949),
pA2-pAio=log9
Arunlakshana and Schild (1959), considered the possibility of having n molecules
of antagonist interacting with the receptor. Therefore the slope for the Schild plot:
log(x-l) versus log(XB), could differ from unity :
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log (x-1) = log K2 - npAx (9)
where x, pAX)and K2 are as before, and n is the number of antagonist molecules
required. They even considered the possibility of having different affinity constants for
each antagonist molecule binding the receptor, and showed that log dose-effect curves
would still be parallel. It is interesting to note that in this case, the plot log(x-l) against
logB, would still be linear and with a slope different from 1. But the intercept would
represent a mixture of the affinity constants for the antagonist. In all these cases
described, the log dose-response curves are parallel, with same maximal response.
Their main conclusion was that (Arunlakshana and Schild, 1959):
"...It is always possible to fit an equation for competitive
antagonism to a set of parallel dose-effect curves, although the
equation may be complicated, but on the other hand, parallel dose-
effect curves are no proofofa competitive antagonism...".
The interaction of more than one molecule of agonist and antagonist, was first
considered by Rang (1971):
"...the logarithmic plot of the dose-ratio against the antagonist
concentration would not be linear, having a slope ofM at low dose-
ratios and MIN at high dose-ratios...",
ian-1=k^ (10)
where ta is the dose-ratio (equivalent to x in the Arunlakshana and Schild 1959
formulation), xb is the antagonist concentration, Kb the dissociation constant for the
antagonist, N the Hill coefficient or the number of agonist molecules required to
activate the receptor and M the number of antagonist molecules required to block the
receptor activation (equivalent to n in the Arunlakshana and Schild, 1959, formulation).
However he used this argument to dismiss the modified Langmuir equation which
accounts for cooperative interaction between drug and receptor, since the classical
Schild plot has proved to be linear and with a slope of one for a great variety of
competitive antagonists (Rang 1971):
"...The results are in favour of the simple Langmuir
equation..." .
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But Rang did not explain the regular occurrence of a Hill number higher than 1 found
with some neurotransmitters, like GABA.
It is only recently that Williams, Smith, Burton et al., (1988) gave an example of
bimolecular interaction of agonist and antagonist with the receptor, and formulated the
modified Schild equation:
log(DRN-l) = MlogXB + pKB
where N is the number of agonist molecules required to activate the receptor and: M is
the equivalent of n in the Arunlakshana and Schild formulation (1959); DR is the dose-
ratio; pKB is the negative log of the dissociation constant. In this case the plot;
log(DR-l) versus log XB, is not any more linear, but the log dose-response curves are
still parallel with the same maximal response. Considering all these small variations of
the original Schild equation, it appears that a slope of unity for the Schild plot; log(DR-
1) versus logXB, and even the linearity of the plot, are not necessary requirements for
competitive antagonism. A more fundamental examination of the analysis of
competitive antagonism has followed the realization that some receptors possess
binding sites that may not be equivalent (Jenkinson, 1987). The implications can extend
both to a departure from parallelism in the log dose-response curves and to non-linear
Schild plot (Jenkinson, 1987; and see Appendix). In conclusion these models are
classically used to describe agonist- and antagonist-receptor interactions, although they
may not be representative of the real mechanisms, they nonetheless, provide a
reasonable approximation.
2.2. Determination of the IC50
The estimation of the dissociation constant, is based upon a theoretical model of
drug-receptor interaction. To compare antagonist properties of different compounds
involving different mechanisms of action, a parameter estimated independently of any
theoretical model, such as IC50, is more appropriate. The IC50 is the antagonist
concentration which reduces the response to a given agonist concentration by 50%. In
the case of non competitive antagonism, the IC50 is the only parameter available. The
IC50 can be estimated independently of any theoretical assumption and is widely used
to compare antagonists between each others or between different preparations. One
problem encountered is that IC50 must be estimated graphically from the antagonist
dose-response curve using only one agonist concentration. IC50 may appear better
than Kb since it does not rely on any theoretical model of interaction between drug and
receptor. However if the mechanism of action is competitive, KB estimation is more
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appropriate. The IC50 is only a snapshot of the antagonist-agonist interaction. The
choice between IC50 or Kg depends on use: the IC50 is more appropriate for
comparing antagonists that have different mechanisms of action, or for comparison of
antagonists between different preparations. Kg is more appropriate for comparing
antagonists that have the same mechanisms of action. This is especially true if they
belong to a same chemical family and are tested on the same preparation.
Conclusion: theories have evolved with the advance of new experimental
techniques. The theory of occupancy, in particular, was dramatically shaken by the
emergence of single channel current recording and molecular biology techniques.
Theoretical models are always based on a simplified interpretation. However, even
imperfect models are of value; they provide useful information even if they are only
approximations, and they allow the testing of hypotheses. In contrast to mathematics,
biology is a versatile science, and to quote Jenkinson in his tribute to Heinz Schild
(1987):
"..Jt is sobering that receptor pharmacology can already provide
several examples of fortious agreement between experimental





I COLLECTION AND MAINTENANCE OF THE PARASITES
Specimens of Ascaris suum were collected on a weekly basis from the local
slaughter house. During transport, they were kept in a thermos flask filled with Locke's
solution (solution A: see composition in V) at 372C. In the laboratory, they were kept in
glass tanks filled with Locke's solution placed in a water bath set at 372C. The average
concentration was ten parasites for 100-200ml. The solution was changed every day,
and parasites were usually kept up to four days. Parasites, smaller than 10cm, were
discarded because they were too small to be dissected without damaging the muscle
cells. Very large parasites, longer than 30cm, were also rejected. As a matter of fact,
large parasites did not produce good recordings. One possible reason is that the
connective layer situated at the surface of the musculature was too thick: electrode
penetration could not be achieved easily without damaging the cell, and diffusion of the
drugs was impaired. Parasites showing no swimming behaviour when disturbed, were
also discarded.
fi DISSECTION
A cylindrical section of the worm about 2cm long was obtained from the anterior
part of the parasite, approximatively l-2cm anteriorly to the genital organs. A
longitudinal incision was made under eye control, along one of the lateral line, and the
intestine was gently removed (Martin, 1980). The flap preparation was then mounted in
a Perpex™ experimental chamber situated in a Faraday cage placed on an antivibration
table. The muscle flap was pinned cuticule down onto Sylgard™. The volume of the
experimental chamber in the presence of the flap preparation, was approximatively
2.5ml.
For current- and voltage-clamp experiments: the chamber was continuously
perfused with Ascaris ringer (solution B: see composition in V), at a rate of 10-
15ml/mn. The chamber was maintained at 222C by a surrounding water jacket (Figure
7) connected to a water bath (Grant, BS15 bypass), situated outside the Faraday cage to
eliminate electrical interference. The perfusion system was gravity fed. Polythene
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Figure 7: Schematic diagram of a muscle flap preparation
A section of Ascaris is pinned down onto Sylgard™ in an experimental chamber and
perfused by a Ringer solution. The chamber is fitted with a water-jacket to maintained
the preparation at 22SC. Two microelectrodes are also illustrated. They are placed
intracellularly under the control of a microscope. One was used for current injection,




tubing connected the reservoirs to the bath, and were enclosed with the tubing
containing the circulating water of the water jacket, within a larger isolant tubing.
Temperature was adjusted and checked at the water bath reservoir and resistance by a
thermocouple. The muscle flap was then left for an hour to equilibrate with the ringer
solution. During this equilibration phase, due to the low Ca concentration, the muscle
usually relaxed, and had to be pinned down again before starting the experiment.
For patch-clamp experiments: the chamber was filled with solution D (see
composition in V), in the presence of 350UI/ml collagenase. The temperature of the
water bath was set at 352C. The enzyme treatment was stopped when vesicules started
to form at the surface of the muscle cells membranes, which usually took 20-30mn.
The muscle preparation was then washed several times with extracellular solution
(solution E: see below).
Ill EXPERIMENTAL SET-UP
The experimental chamber was located on an antivibration table. The table consisted
of a metallic frame bearing a concrete tray. The whole table was itself resting on a
concrete base isolated from the rest of the floor. Electrical interference from external AC
sources was prevented by a Faraday cage (approximatively 80cm x 70cm x 60cm),
placed on the table. The light source was situated underneath the Perpex™ chamber,
and the DC power supply (Weir 762-1), outside the cage. Microelectrodes position was
achieved with two micromanipulators (Zeiss), and was controled under a dissecting
microscope (Olympus, x25). A third micromanipulator (Prior) was installed for
microionophoresis in voltage-clamp experiments.
IV MICROELECTRODES
1. Curent- and voltage-clamp microelectrodes
Electrodes were pulled on a vertical glass microelectrode puller (SRI 2001), from
filamented glass tubing (Clarke Electromedical Instruments GC 120f-15: internal
diameter=0.62mm, external diameter= 1.20mm). Once pulled, microelectrodes were
heated with a flame, and bent, before being back-filled with solution C: K acetate, 2M.
They were then placed into Ag/AgCl pellet electrode holders. For current-clamp
experiment, the resistance was typically between 10-30M£2, for voltage-clamp
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experiment, the resistance of the current injecting electrode was 10-15MQ and the
resistance of the recording electrode was 20-50MQ. Ionophoresis electrodes had a
resistance typically of 10-20MQ.
2. Patch-clamp electrodes
Patch-electrodes were made from microhaematocrit capillary tubes (soft glass
Garner glass 7052, internal diameter= 1.15mm, external diameter=1.55mm), pulled on
a two-stage vertical puller (David Kopf Instruments) and had a resistance of 1-5MH.
The pipette tip diameter was checked under microscope (Vickers, x400), and was
approximatively 0.5|im. Electrode tips were manually coated under eye control, with
Sylgard™, to improve the frequency response (typically greater than 2kHz). The
pipette tip was then polished, using a heated filament installed under the microscope
lens (Vickers, x400), heat polishing was stopped when a physical change in the tip
geometry could be detected. The tip was filled by suction with intracellular solution
(solution F: see composition below), and then the pipette was backfilled with the same
solution.
3. Bath electrodes
For current-clamp and voltage-clamp experiments, a Ag/AgCl bath electrode was
used. For patch-clamp experiment, the bath electrode was made with an Agar 150mM
KC1 gel, set into a polythene tube to limit junction potentials. All connections were
made with Ag/AgCl wires.
V SOLUTIONS
Solutions were kept in a cold room and up to one week; except solution C which
was highly concentrated in K, and therefore unlikely to be contaminated by bacteria or
fungi.
1. Solution A: Locke's solution, (mM): NaCl, 155; KC1, 5; NaHCC>3, 1.5;
glucose, 5; CaCl2, 2.
2. Solution B: Ascaris Ringer, (mM): NaCl, 135; KC1, 3.0; MgCl2, 15.7;
glucose, 3.0; TRIS, 5.0; pH adjusted to 7.6 with maleic acid.
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3. Solution C: pipette solution, (M): Kacetate, 2.
4. Solution D: low-Ca extracellular solution, (mM): NaCl, 35; Na acetate, 105;
MgCl2, 2; KC1, 2; HEPES, 10; glucose,3; ascorbic acid, 2; pH=7.2 adjusted with
NaOH.
5. Solution E: extracellular solution, (mM): NaCl, 35; Na acetate, 105; MgCl2,
2; CaCh, 5; KC1, 2; HEPES, 10; glucose,3; ascorbic acid, 2; pH=7.2 adjusted with
NaOH.
6. Solution F: intracellular solution, (mM): CsCl, 145; MgCl2, 3; CaCl2, 1;
EGTA, 11; HEPES 10; pH=7.2 adjusted with CsOH.
VI CHEMICALS
Chemicals were kept according the recommendations mentionifed on the data sheets.
1. Origin
All chemicals used for standard solutions were obtained from Sigma,
collagenase type LA was obtained from Sigma
y-aminobutyric acid, glycine, (3-alanine, 5-aminovaleric acid, e-aminocaproic acid,
guanidoacetic acid, (3-guanidinopropionic acid, y-guanidinobutyric acid, muscimol,
nipecotic acid, imidazole-4-acetic acid, 3-aminopropane sulphonic acid, piperidine-4-
sulphonic acid, (+)bicuculline, (-)bicuculline methiodide, picrotoxin, were obtained
from Sigma.
Isonipecotic acid was obtained from Aldrich.
Trans-aminocrotonic acid, cis-aminocrotonic acid and ZAPA were obtained from Tocris
Neuramine.
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Thiomuscimol, isoguvacine, RS(±)dihydromuscimol, Homo-(3-pro line, THIP, were
gifts from P.Krogsgaard-Larsen.
Baclofen was a gift from Pfizer.
d-tubocurarine was obtained from Wellcome
SR95103: 2-[3-carboxypropyl]-3-amino-4-methyl-6-phenyl pyridazinium chloride
SR95531: 2-[3-carboxypropyl]-3-amino-6 -p-methoxy phenyl pyridazinium chloride
SR42666: 2-[3-carboxypropyl]-3-amino-4-methyl-6-p-methoxy phenyl pyridazinium
chloride
SR95133: 2-[3-carboxypropyl]-3-amino-4-methyl-6-a-naphtyl pyridazinium chloride
SR95132: 2-[3-carboxypropyl]-3-amino-4-phenyl-6-phenyl pyridazinium chloride
SR42627: 2-[3-carboxypropyl]-3-amino-4-methyl-6-p-methyl phenyl pyridazinium
chloride
SR42640: 2-[3-carboxypropyl]-3-amino-5-methyl-6-phenyl pyridazinium chloride
were gifts from SANOFI.
NCS194-83: 2-[4-carboxybutyl]-3-amino-4-methyl-6-phenyl pyridazinium bromide
NCS247-90: 2-[3-carboxypropyl]-3-amino-4-ethyl-6-phenyl pyradizinium bromide
NCS248-90: 2-[3-sulfonylpropyl]-3-amino-(c5,6)-benzocyclohepta-pyridazinium
NCS249-90: 2-[3-sulphonylpropyl] -3-amino-4-methyl-6-phenyl pyridazinium
NCS250-90: 2-[3-sulphonylpropyl] -3-amino-4-ethyl-6-phenyl pyridazinium
NCS251-90: 2-[3-carboxypropyl]-3-amino-4-benzyl-6-phenyl pyridazinium bromide
NCS252-90: 2-[3-carboxypropyl]-3-amino-4-isopropyl-6-phenyl pyridazinium
bromide
were obtained from Pr C.G.Wermuth and J.M.Sitamze from the laboratoire de
neurochimie, CNRS Strasbourg.
RU5135: 3-a-hydroxy-l,6-imino-5-P-17-aza-androstan-ll-one was a gift from
Roussel-Uclaf
2. Solubilization
Compounds stable in solution, were solubilized in Ascaris Ringer (B) and the
stock-solution were kept at -202C. Dilutions were made before the experiments and
kept at 52C no more than a week.
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RU5135 was dissolved in DMSO, 2% final concentration in Ringer (solution B).
Diazepam was dissolved in DMSO, 1% final concentration in Ringer (solution B).
NCS251-90 was dissolved in DMSO, 1% final concentration in Ringer (solution B).
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ACTIVITY OF SOME GABA AGONISTS AT THE
ASCARIS MUSCLE GABA RECEPTOR.
INTRODUCTION
Ascaris suum is a suitable model for pharmacological studies on nematodes. By
comparison with other nematodes, Ascaris suum is a large parasite, and is easy to
collect from pigs slaughtered at the abattoir. Its close resemblance to Ascaris
lumbricoides of humans, make A. suum a particular interesting model. Pharmacological
studies of Ascaris suum muscle started as early as 1926, when Toscano-Rico recorded
the muscle response following the application of santonin, chenopode oil, pilocarpine
and nicotine. Later, Baldwin and Moyle (1947), developed a more elaborate method for
testing potentials anthelminthics, where the drug was applied directly onto the muscle.
An interesting feature of Ascaris suum, is the presence of large muscle cells suitable
for intracellular electrophysiological recording. After the first intracellular recordings of
electrical activity from an Ascaris muscle cell (Jarman, 1959), Del Castillo et al.
(1963a, 1963b, 1964b, 1964c) used intracellular recording techniques to study the
mode of action of acetylcholine, GABA and piperazine.
From the pharmacological studies on Ascaris suum muscle, it was clear that
acetylcholine and GABA receptors, were potential targets for the action of
anthelminthics. Two well known anthelminthics have been shown to interact with
GABA receptor in Ascaris suum: piperazine (Del Castillo et al., 1963b, 1964c; Martin,
1982, 1985;Holden-Dye et al., 1988, 1989) and ivermectin (Holden-Dye et al., 1988;
Martin and Pennington, 1989). However, when this present study started, little was
known of the pharmacology of GABA receptors in nematodes. It was decided that a
study of the pharmacology of the Ascaris muscle GABA receptor, might facilitate the
design of new anthelminthic drugs.
In this section, the action of GABA and various GABA agonists on the Ascaris
muscle GABA receptor, was examined using a current-clamp technique. A modified
Hill equation was used to describe and quantify the agonist dose-response
relationships, and to compare the agonist potencies at the Ascaris muscle GABA
receptor with agonist potencies at vertebrate GABA-A receptors. The modulatory





The muscle dissection is described in the general methods section. The preparation
was bathed in a high-Cl, low-Ca solution (B). The chamber was surrounded by a water
jacket which maintained the preparation at 222C. The temperature was chosen
deliberately low since the electrical activity of the cells is temperature sensitive (Warm,
1987). At 222C, Ascaris muscle cells shows no spontaneous electrical activity which
may interfere with the recording. In contrast to the electrical activity, the resting
membrane potential presents little temperature sensitivity between 20 and 372C (Wann,
1987); this suggests that the mechanisms underlying the maintenance of the resting
potential are not, or only weakly, affected by the temperature, and that changes in
membrane potential can be safely interpreted at 22QC. In the case of this preparation, it
is also important that GABA or an agonist, does not produce indirect effects by an
action on nearby cells or on the nervous system. A low-Ca and high-Mg Ringer (B)
was used to impair synaptic transmission (Katz, 1969), and to avoid any interference
from GABA receptors present on the nerve cells. A low-Ca solution has also the
advantage of limitating muscle movement and the occurrence of Ca-activated CI
channels (Thorn and Martin, 1987). However electrical coupling between cells was not
controlled, and was assumed to have little influence on the cell response.
2. Drug-application
GABA was initially bath-applied using a non-cumulative dose method, with
washing of the preparation between applications. GABA produced, as reported
previously, a dose-dependent hyperpolarization (Del Castillo et al., 1964b) and an
increase in input conductance (Martin, 1980; Wann, 1987; Holden-Dye et al., 1988).
However, one limitation of this technique was that recovery of the resting input
conductance was often incomplete after application of high concentrations of GABA;
this may have been due to slight movement of the muscle flap preparation producing a
decrease in the leak resistance around the electrodes. It was found that recovery after
cumulative application of GABA concentrations, without intermediate washing, was
often more complete. The method involved gentle draining of the bath (volume 2.5ml),
and then flushing the bath with 5ml of the next drug solution. The bath was not
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perfused continuously because of the limited quantities of agonist available. Whether
GABA concentrations were applied this way or by using a continuous perfusion, the




Two microelectrodes were inserted into the bag region of a muscle cell (Figure 7).
One pipette (resistance 10-20MQ) was used to inject hyperpolarizing current pulses
(40nA, 2s, 0.2Hz) under the control of a Digitimer 100 and a Digitimer 2533 isolated
stimulator, the other pipette (resistance 10-20MQ) was used to record membrane
potential. Signals were initially recorded with a laboratory made amplifier (Martin,
1982) and monitored on a Tectronix 2210 oscilloscope and a Lectromed chart recorder.
In later experiments, signals were recorded with an Axoclamp 2A (Axon Instruments)
which permit the use of higher resistance current-injection electrodes: typically 20-
50MQ. The change in input conductance was measured and assumed to be directly
related to the change in membrane conductance since the bag region of the muscle cell
can be approximated by a sphere. In Ascaris muscle, the I/V relationship of the bag
region of the muscle cell, is linear when hyperpolarized current is injected (Figure 8)
(Martin, 1980). Similar results obtained in the presence of GABA (Martin, 1980),
indicate that the GABA response is not voltage-sensitive. Therefore in Ascaris, input
conductance can be determined from the response to hyperpolarizing current pulses and
the agonist induced changes in input conductance is a useful practical method for
studying the GABA receptor in Ascaris muscle.
3.2. Data analysis
The input conductance of the bag was calculated directly from the amplitude of the
plateau of the voltage response to the injected current pulse. The effects of GABA and
agonists were determined by measuring the change in input conductance. Dose-






This figure illustrates the typical W relationship obtained in Ascaris muscle cells using
a current-clamp technique.
Abscissa: amplitude of the injected current.
Ordinate: change in steady-state membrane potential recorded during the current
injection (pulse length 2s, amplitude 40nA).
The relation is linear at hyperpolarizing currents, but shows a delayed rectification at
depolarizing currents. Input conductance (g) was calculated by injecting
hyperpolarizing current pulses and using Ohm's law g = ^ , where I is the current






where Ag is the change in input conductance, Agmax is the maximum response, EC50
is the concentration of GABA producing 50% of the maximum response, [Xa] is the
agonist concentration and N is the Hill coefficient. A non linear regression programme
(patternsearch Colquhoun, 1971) was used to obtain the least square estimates for
Agmax, EC50 and N. Although there may be theoretical reasons why the Hill equation
may not be appropriate, it provides a useful numerical approach for describing dose-
response curves.
II RESULTS
The results reported here are based on the analysis of experiments conducted on
124 muscle cells from 80 preparations. Cells selected had resting input conductances
between 1.2-4.0[iS ( 2.66+ 0.04|iS, mean±SE, n=124). The recordings were rejected
if the resting input conductance failed to return at least 80% of the control after washing
GABA, or GABA-agonist, from the preparation. All the chemical structures illustrated
in Figures 13 to 28, are from Krogsgaard-Larsen, Nielsen and Falch (1986), and
Krogsgaard-Larsen (1988).
1.Effects of GABA
1.1. Dose-dependent hyperpolarization and increase in membrane
conductance
As described before, GABA applied at concentrations greater than 3|iM, induced a
dose-dependent hyperpolarization of the cell (Del Castillo et al., 1964b), and an
increase in membrane input conductance (Martin, 1980; Holden-Dye et al., 1988)
(Figure 9). The EC50 for GABA (EC50=30.2±1.9|iM, mean±SE, n=38), was similar
to the values previously reported (EC50=13|iM, Martin, 1980; EC50=20.2±2.5|iM,
mean±SE, n=6, Holden-Dye et al., 1988). The Hill coefficient (N=2.7±0.2,
mean±SE, n=38) varied from 1.5 to 4.9, and was greater than one in all the cells; this
indicates positive cooperativity between GABA and its receptor, as previously
suggested by Holden-Dye et al. (1988). Agmax was subject to large variations from cell
to cell (1.2 to 10.6|iS). The mean value (Agmax=4.15±0.32p.S, mean+SE, n=38), was
higher than the values reported by Holden-Dye et al., (1988) (Agmax=2.58±0.39|j.S,
mean±SE, n=6) and may reflect the difference in drug application techniques (bath
application in the present study, and local perfusion, Holden-Dye et al., 1988). The
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Figure 9: GABA cumulative dose-response relationship
The upper trace illustrates the change in input conductance during cumulative
application of GABA. The width of the trace represents the change in membrane
potential during the injection of hyperpolarizing current pulses, I=40nA (see methods).
In this experiment, the resting input conductance was 3.0|iS. In presence of GABA
10|lM, Ag=0.2|iS; GABA 30|lM, Ag=1.4^iS; GABA 100(lM, Ag=3.1nS; GABA
300|iM, Ag=3.1|iS. The conductance returned to the resting level after washing. The
chart speed was altered at the marked intervals during the experiment. The lower
diagram shows the dose-response relationship. The experimental values are represented











upper trace in Figure 9, illustrates a typical dose-response relationship obtained from
one cell using cumulative concentrations of GABA and the corresponding fitted
modified Hill equation.
For the various reasons discussed in the methods, GABA and other agonists, were
applied in a cumulative manner, without intermediate washing. Both methods:
cumulative and non-cumulative application of GABA, were compared. Values obtained
for EC50 (non-cumulative application of GABA, EC50=24.9±3.3|iM, mean±SE, n=3;
cumulative application of GABA, EC50=30.2±1.8|J.M, mean±SE, n=38) and N (non-
cumulative application of GABA, N=3.2±0.2, mean±SE, n=3; cumulative application
of GABA, N=2.7±0.2, mean±SE, n=38), were similar. Agmax seemed to be higher
when non-cumulative concentrations of GABA were used (non-cumulative application
of GABA, Agmax=6.0±0.1pS, mean±SE, n=3; cumulative application of GABA,
Agmax=4.15±0.32|iS, mean±SE, n=38), but the difference was not statistically
significant. However, non-cumulative dose-response curves for GABA were obtained
from only three cells. This contrast with the cumulative dose-response curves obtained
from 38 cells, and may explain why the difference is not statistically significant.
1.2. Transient depolarization following the application of low
concentrations
In some cells, low concentrations of GABA (1, 3 or 10|iM) produced a transient
membrane depolarization (Figure 10). The amplitude of the depolarization was very
variable, l-20mV. In the case of two successive applications of low GABA
concentrations, the second depolarization was always smaller, suggesting some sort of
desensitization (Figure 10). The depolarization occurred in the presence of low
concentrations of GABA (Figure 10A), or at the end of the recovery phases following
application of a single concentration or cumulative concentrations of GABA (Figure
10B). The onset of these depolarizations was very rapid and seemed to involve a
voltage-sensitive conductance. On recovery the membrane slowly repolarized, and then
returned abruptly to its original resting value. This was possibly the consequence of the
closing of voltage-sensitive channels. During the membrane depolarization, the
membrane input conductance increased to a maximum at the peak of depolarization, and
progressively decreased to the original value of the resting conductance. When the
depolarization was only a few millivolts, the membrane conductance did not change
(Figure 10, A) or even, slightly decreased. In the recorded cell illustrated in Figure 10,
the peak depolarization was of 7mV (AV=V2-Vo=7mV). The resting conductance was:
gO=2.58|iS and the conductance at the peak depolarization was: g2=3.40p.S. Just
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Figure 10: Depolarizations following the application of low GABA concentrations or
during the recovery phase after cumulative application of GABA (I=40nA).
A. Low concentration of GABA: On this particular cell GABA l|iM produced a
transient depolarization of the membrane of 7mV at its peak. The resting membrane
conductance was: go=2.58|iS; at the lowest membrane potential value the membrane
input conductance increased to: g=3.40|lS. The next application of GABA: 10|iM
produced a smaller depolarization, less than 5mV; the membrane.conductance decreased
slighdy: Ag=0.1|iS, and some spontaneous electrical activity was detected.
B. Depolarization during the recovery phase: In both cases tire depolarization occurred
at the end of the recovery phase. The measure of the depolarization amplitude was not







before the peak depolarization, the membrane conductance decreased transiently to:
g2-2.50|iS. If the current-voltage relationship is assumed to be linear at depolarizing
potentials, the reversal potential of the ion conductance(s) involved in the depolarization
can be estimated by extrapolation:
AV
Erev = 1/gO • l/g2-l/g0' here Erev=+29mV.
However, because its low frequency and the apparent desensitization, this phenomenon
was not further investigated.
1.3. Absence of effects of diazepam, pentobarbitone and Cortisol on the
GABA response
Diazepam (l|iM), pentobarbitone (10|iM) and Cortisol (lOjiM) were tested on
GABA dose-response curves. Control GABA dose-response curves were
systematically obtained before or after application of the test drug. In two experiments,
diazepam (l|iM) had no effect on EC50, Agmax or N (Table 8, Figure 11).
Pentobarbitone (10|iM) (n=3 experiments) and Cortisol (10pM) (n=2 experiments), had
no effect on EC50, N (Table 8, Figure 12). The calculated mean for Agmax was higher
in the presence of Cortisol or pentobarbitone, but the difference from controls did not
reach statistical significance, partly because of the small number of experiments and
partly because of the difficulty in measuring high conductances with accuracy.
2. Inactive compounds
The following compounds had no effects on the membrane conductance at a
concentration of ImM: p-alanine (n=3), glycine (n=2), e-aminocaproic acid (n=2),
nipecotic acid (n=2), 3-APS (n=2), P4S (n=2) and baclofen (n=2) (Figure 13 and 14).
These results are in agreement with a previous report (Holden-Dye et al., 1988).
Thiomuscimol (300|iM), y-guanidobutyric acid (300qM) and THIP (ImM),
produced only a small increase in membrane conductance and a small hyperpolarization
(Figure 15 and 16). To obtain full dose-response curves would have required very high
agonist concentrations. They were not determined for this reason. Among these weak
agonists THIP had been suggested to act as a partial agonist in Ascaris (Holden-Dye et
al., 1988), but for the reasons stated above, these findings could not be confirmed or
rejected.
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Figure 11: Effect of diazepam (lp.M) on dose-dependent responses to GABA.
A. Control GABA response: resting membrane conductance, go=3.3; GABA 3p.M,
Ag=0fiS; IOjiM, Ag=0.3fiS; 30pM, Ag=2.8pS; lOOfiM, Ag=4.7|iS; 30()|iM,
Ag=5.4|iS; recovery of 97% of the resting membrane conductance. The fitted modified
Hill equation gives: Agmax=5.6pS, EC50=22.4pM, N=1.6. (Injected current:
I=40nA)
B. In the presence of lpM diazepam, go=3.4|iS; GABA lOflM, Ag=1.3pS; 30flM,
Ag=3.3pS; lOOpM, Ag=5.4pS; 300pM, Ag=5.4|iM. The fitted modified Hill equation
gives: Agmax=5.2p.S, EC50=28.8|iM, N=2.3. (Injected current: I=40nA). Diazepam
(l|lM) has no apparent effect on dose-dependent GABA response.
2mn
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Figure 12: Effect of pentobarbitone (10|iM) and Cortisol (10p.M) on dose-dependent
responses to GABA.
A. Control GABA response:go=2.6pS; GABA 3|iM, Ag=0.1|iS; l()p.M, Ag=0.6(iS;
30|iM, Ag=3.3|J.S; 100|iM, Ag=5.4|iS; 300|iM, Ag=5.4|iS; 97% recovery of the
resting membrane conductance. The fitted modified Hill equation gives: Agmax=5.5|lS,
EC50=25.0|lM, N=2.3. (Injected current: I=40nA)
B. In the presence of lOfiM pentobarbitone; gO=2.7(lS; GABA 3|i.M, Ag=0. l|iS;
10nM, Ag=0.4|iS; 30(iM, Ag=3.7pS; lOOpM, Ag=6.0(iS; 300|lM, Ag=6.3pS; 100%
recovery of the resting membrane conductance. The fitted modified Hill equation gives:
Agmax=6.2|iS, EC50=26.0(lM, N=2.7. (Injected current: I=40nA). Pentobarbitone
(10|lM) has no effect on EC50, but slightly increased Agmax.
C. In the presence of 10|iM Cortisol,; gO=2.7pS; GABA 3p.M, Ag=0.5fiS; 10|iM,
Ag=0.8|iS; 30(iM, Ag=3.7(iS; 100|iM, Ag=6.0(i.S; 300jiM, Ag=6.3jiS; 80% recovery
of the resting membrane conductance. The fitted modified Hill equation gives:
Agmax=6.4(iS, EC50=25.6(iM, N=2.7. (Injected current: I=40nA). Cortisol (10[iM)




















Table 8: Effect of diazepam (l|i.M), pentobarbitone (10|iM) and Cortisol (10|iM) on
GABA dose-response curves: EC50, Amax and N.
Agmax (|iS) EC50 (|iM) N
Control 6.30±1.10 28.610.2 2.210.5
(n=2)
+ diazepam (lpM) 6.0510.45 21.011.35 2.110.5
Control 4.6010.75 32.415.2 2.410.5
(n=3)
+ pentobarbitone (10pM) 5.5310.57 30.212.9 2.510.1
Control 5.7010.20 24.110.8 2.310.1
(i*3)
+ Cortisol (10|iM) 6.3510.05 24.411,1 2,210.3
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Figure 13: Inactivity of glycine, 3-APS, and (3-alanine on membrane conductance
A. The resting membrane conductance was, go=2.8(iS, in the presence of ImM
glycine, the membrane conductance was not altered: Ag=0fiS. (Injected current:
I=40nA)
B. Same cell, resting membrane conductance, go=2.8nS, in the presence of ImM
3APS Ag=0|lS. (Injected current: I=40nA)
C. Same cell, resting membrane conductance go=2.8|iS, in the presence of ImM [3-
alanine Ag=0. The small depolarization seen after the application of P-alanine was an











Figure 14: Inactivity of nipecotic acid, e-aminocaproic acid and baclofen on membrane
conductance.
A. The resting membrane conductance was, go=2.8p.S, in the presence of ImM
nipecotic acid, Ag=Op.S. (Injected current: I=40nA)
B. Resting membrane conductance, go=2.1|iS, in the presence of ImM e-aminocaproic
acid, the membrane conductance remained unchanged, Ag=0|iS. (Injected current:
I=40nA)
C. Resting membrane conductance, go=3.2p.S, in the presence of ImM baclofen, the
membrane conductance remained unchanged, Ag=0. (Injected current: I=40nA). The
apparent hyperpolarization was not related to the presence of baclofen but rather to an
instability of the membrane potential in this particular cell. Instability of the membrane
potential has to be related with the spontaneous electrical activity of the muscle cells. It
is often seen when the muscle has not been left long enough to equilibrate with the





















All the results presented here are summarized in Table 9 and illustrated in Figures
13 to 28. For all the agonists tested (except imidazole-4-acetic acid), Agmax and N are
not significantly different from the values obtained with GABA (t-test), suggesting that
they act in a similar manner at the Ascaris GABA receptor. They appear to be full
agonists having the same stoichiometry.
3.1. Hill coefficient
For each agonist, the mean value for the Hill coefficient was greater than one and
indicated positive cooperativity between the agonist and the receptor. This result is not
surprising, since Hill coefficients greater than one have been obtained with GABA and
GABA agonists in various vertebrate and invertebrate preparations (see Nistri and
Constanti, 1979, for review). Recently, the purification, cloning and expression, of the
vertebrate GABA-A complex have shown the existence of two subunits able to bind the
GABA molecule (Schofield et al., 1987), and reinforce the hypothesis that at least two
molecules of GABA are required to activate the channel.
3.2. Agmax
The maximal responses obtained with each agonist were subject to large variation
from cell to cell (varying from 0.7 to 22.5(iS), and mainly reflected the differences in
size of the muscle cells and/or their physiological state. No significant variation was
observed between the different agonists tested (except imidazole-4-acetic acid), and
GABA. Partial agonists are expected to produce a smaller Agmax. (3-
guanidinopropionic acid, 5-aminovaleric acid and cis-aminocrotonic acid, were
suggested to act as partial agonists (Holden-Dye et al., 1988), but there is no evidence
for this here. Agmax for: (3-guanidinopropionic acid (4.30±0.82|iS, mean±SE, n=4),
5-aminovaleric acid (3.77±0.94|iS, mean±SE, n=4) and cis-aminocrotonic acid
(Agmax=6.83±2.84fiM, mean±SE, n=3), are not significantly different from Agmax
for GABA (4.15±0.32qS. mean±SE, n=38). It is nevertheless interesting to note that,
the rigid analogues of GABA: muscimol (Agmax=2.48±0.77qS, mean±SE, n=5),
isoguvacine (Agmax=3.60±1.00[iS, mean±SE, n=4), homo-p-proline
(Agmax=2.96±0.39|iS, mean±SE, n=3) and isonipecotic acid (Agmax=2.50±0.70|iS,
mean±SE, n=6), had a lower calculated mean for Agmax than for GABA or other
agonists, but the difference did not reach statistical significance. Only imidazole-4-
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acetic acid showed a significantly greater Agmax than GABA (Agmax=6.77±1.46jJ.S,
mean±SE, n=4, t-test p<0.05). However, Agmax should be carefully interpreted,
because of the possible desensitization of the GABA receptors and the errors associated
with the measurement of high conductance values (see discussion).
3.3. EC50
Table 9 illustrates the various potencies of the different agonists tested, and
compares their relative potencies in Ascaris to their relative potencies in displacing
[3H]GABA from rat brain membranes (Krogsgaard-Larsen, 1988) or in eliciting
contractions of guinea-pig ileum (Allan et al., 1986). Dihydromuscimol is the only
compound more potent than GABA itself (EC50=8.3±1.5|iM, mean±SE, n=5). A
racemic mixture of RS(±)dihydromuscimol was used in this present study, but
according to Holden-Dye et al., (1989), the (+) isomer is more potent than the (-)
isomer, this is similar to the vertebrate central GABA-A receptor (Krogsgaard-Larsen,
1988). The isothiouronium derivative of GABA: ZAPA (EC50=24.1±4.6|iM,
mean±SE, n=3) was not significantly more potent than GABA. This observation agrees
with the previous report of Holden-Dye et al., (1989). All other agonists tested were at
least half less potent than GABA; even the potent GABA-A agonists, muscimol
(EC50=82.5±20.4fiM, mean±SE, n=5) and isoguvacine (EC50=124.2±10.1|U.M,
mean±SE, n=4). Their relative potencies are similar to those reported by Holden-Dye et
al., (1989), (See Table 9).
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Figure 15: Thiomuscimol
The upper trace illustrates the change in input conductance during cumulative
application of thiomuscimol (Injected current: I=40nA). In this experiment, the resting
input conductance was 2.1|iS. In presence of thiomuscimol, 10|iM, Ag=O.OpS; 30|iM,
Ag=0.0|lS; 100p.M, Ag=O.O^tS; 300^lM, Ag=0.3|iS; lOOO^lM, Ag=1.0|iS. The
conductance returned to 100% of the resting value after washing. The chart speed was








Figure 16: y-guanidinobutyric acid and THIP
y-guanidinobutyric acid
The upper trace illustrates the change in input conductance during cumulative
application of y-guanidinobutyric acid (Injected current: I=40nA). In this experiment,
the resting input conductance was 2.8p.S. In the presence of y-guanidinobutyric acid,
100|i.M, Ag=0.4p.S; 300pM, Ag=0.5^rS; 1000|iM, Ag=1.0|lS; 3000|iM, Ag=2.2pS;
1000(lM, Ag=7.2|iS. The conductance returned to 80% of the resting value after
washing. The chart speed was altered at the marked intervals during the experiment.
THIP
The upper trace illustrates the change in input conductance during cumulative
application of THIP (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.3p.S. In the presence of THIP, 10|iM, Ag=0.0(J.S; 30|iM,
Ag=0.0|iS; 100|iM, Ag=0.0(iS; 300|iM, Ag=0.0(iS; 1000(iM, Ag=1.0(iS. The
conductance returned to 100% of the resting value after washing. The chart speed was
altered at the marked intervals during the experiment.
THIP
Figure 17: Dihydromuscimol
The upper trace illustrates the change in input conductance during cumulative
application of DHM (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.3|iS. In the presence of DHM: 3(iM, Ag=0.4p.S; lOpM,
Ag=0.9qS; 30p.M, Ag=3.2p.S; 100|iM, Ag=3.2p.S. The conductance returned to 85%
of the resting value after washing. The chart speed and gain were altered at the marked
intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented by (■); the solid line represents
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The upper trace illustrates the change in input conductance during cumulative
application of ZAPA (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.1|iS. In the presence of ZAPA 3(iM, Ag=0.1pS; 10p.M,
Ag=0.3|iS; 30|J.M, Ag=1.9|iS; lOOflM, Ag=3.8|lS. The conductance returned to 85%
of the resting value after washing. The chart speed was altered at the marked intervals
during the experiment. The lower diagram shows the dose-response relationship. The
experimental values are represented (■); the solid line represents the fitted modified
Hill equation, Agmax=4.0|iS, EC50=31.0|iM, N=2.3.
ZAPA
3|iM 10jiM 30hM 100viM
1 10 100 1000
(liM)
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Figure 19: Trans-aminocrotonic acid
The upper trace illustrates the change in input conductance during cumulative
application of TACA (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.2p.S. In the presence of TACA 10|iM, Ag=0.1pS; 30|iM,
Ag=3.9p.S; IOOjiM, Ag=6.5pS; 300|lM, Ag=7.3|iS. The conductance returned to
100% of the resting value after washing. The chart speed and gain were altered at the
marked intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (•); the solid line represents the
Fitted modified Hill equation, Agmax=7.3|lS, EC50=28.1|iM, N=3.0.
10»lM 30jiM ' — ' 'lOOpM 300jiM
TACA MOH
NH2\_^<0
1 10 100 1000 10000
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Figure 20: Cis-aminocrotonic acid
The upper trace illustrates the change in input conductance during cumulative
application of CACA (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.1|iS (same cell as for TACA). In the presence of CACA, 10(iM,
Ag=0.0pS; 30|iM, Ag-O.O^tS; 100|iM, Ag=0.1(tS; 300|.lM, Ag=1.2pS; lOOOpM,
Ag=7.2(iS. The conductance returned to 91% of the resting value after washing. The
chart speed and gain were altered at the marked intervals during the experiment. The
lower diagram shows the dose-response relationship. The experimental values are
represented (■); the solid line represents the fitted modified Hill equation,
Agmax=7.8|iS, EC50=320.6pM, N=3.3.
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Figure 21: Imidazole-4-acetic acid
The upper trace illustrates the change in input conductance during cumulative
application of IAA (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.7|iS. In the presence of IAA 30pM, Ag=0.3pS; lOOpM,
Ag=7.4pS; 300pJM, Ag=9.9pS; lOOOpM, Ag=9.9pS. The conductance returned to
100% of the resting value after washing. The chart speed and gain were altered at the
marked intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (■); the solid line represents the
fitted modified Hill equation, Agmax=9.9|iS, EC50=75.2pM, N=3.8.
Imidazole-4-acetic acid
30nM lOO^M 300|j.M 1000|aM
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Figure 22: Muscimol
The upper trace illustrates the change in input conductance during cumulative
application of muscimol (Injected current: I=40nA). In this experiment, the resting
input conductance was 2.8|iS. In the presence of muscimol lOfiM, Ag=0.0pS; 30p,M,
Ag=0.6|lS; 100|iM, Ag=1.4|iS; 300|lM, Ag=2.1|lS. The conductance returned to
100% of the resting value after washing. The chart speed was altered at the marked
intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (■); the solid line represents the
fitted modified Hill equation, Agmax=2.4p.S, EC50=75.6(tM, N=1.4.









The upper trace illustrates the change in input conductance during cumulative
application of isoguvacine (Injected current: I=40nA). In this experiment, the resting
input conductance was 2.9|iS. In the presence of isoguvacine 10}iM, Ag=0.0p.S;
30|iM, Ag=0.0p.S; IOOjiM, Ag=l.l|iS; 300jlM, Ag=5.1fiS. The conductance returned
to 100% of the resting value after washing. The chart speed was altered at the marked
intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (■); the solid line represents the





Figure 24: Guanido-acetic acid
The upper trace illustrates the change in input conductance during cumulative
application of guanido-acetic acid (Injected current: I=40nA). In this experiment, the
resting input conductance was 3.1|iS. In the presence of guanidino-acetic acid, 10|iM,
Ag=0.2p.S; 30pM, Ag=0.5pS; lOOjiM, Ag=1.6|iS; 300pM, Ag=3.0|iS; 1000|i.M,
Ag=3.0pS. The conductance returned to 86% of the resting value after washing. The
chart speed was altered at the marked intervals during the experiment. The lower
diagram shows the dose-response relationship. The experimental values are represented










The upper trace illustrates the change in input conductance during cumulative
application of H-P-P (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.3|iS. In the presence of H-P-P, 10|iM, Ag=0.0|iS; 30p.M,
Ag=0.0|iS; lOOfiM, Ag=0.2pS; 300fiM, Ag=0.8|iS; 1000p.M, Ag=1.5(iS. The
conductance returned to 91% of the resting value after washing. The chart speed was
altered at the marked intervals during the experiment. The lower diagram shows the
dose-response relationship. The experimental values are represented (■); the solid line
represents the Fitted modified Hill equation, Agmax=1.6|iS, EC50=292.5p.M, N=2.0.
(M-M)
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Figure 26: 5-aminovaleric acid
The upper trace illustrates the change in input conductance during cumulative
application of DAVA (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.7|iS. In the presence of DAVA, 100p.M, Ag=0.0p.S; 300|iM,
Ag=1.3p.S; lOOOpM, Ag=3.9p.S; 3000|iM, Ag=3.9p.S. The conductance returned to
100% of the resting value after washing. The chart speed was altered at the marked
intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (■); the solid line represents the






Fieure 27: Isonipecotic acid
The upper trace illustrates the change in input conductance during cumulative
application of INA (Injected current: I=40nA). In this experiment, the resting input
conductance was 2.3p,S. In the presence of INA 10|iM, Ag=0.0|iS; 30(iM, Ag=().0|iS;
100p.M, Ag=0.0p.S; 300|iM, Ag=0.4p.S; 1000|iM, Ag=1.5|iS. The conductance
returned to 100% of the resting value after washing. The chart speed was altered at the
marked intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (■); the solid line represents the















Figure 28: P-guanidinopropionic acid
The upper trace illustrates the change in input conductance during cumulative
application of P~GP (Injected current: I=40nA). In this experiment, the resting input
conductance was 3.2jiS. In the presence of P-GP, IOOjiM, Ag=0.1|iS; 300p.M,
Ag=0.6p.S; 1000|J.M, Ag=1.8|lS; 3000|iM, Ag=2.0|iS. The conductance returned to
90% of the resting value after washing. The chart speed was altered at the marked
intervals during the experiment. The lower diagram shows the dose-response
relationship. The experimental values are represented (■); the solid line represents the







Table 9: Summary of GABA agonists potencies in Ascaris
n=number of experiments
RP=relative potency GABA=1
RPh= relative potency on Ascaris muscle, from Holden-Dye et al 1988
RPK= relative potency in displacing [^HJGABA from rat brain synaptic membranes,
from Krogsgaard-Larsen 1988.
RPA= relative potency on guinea-pig ileum (Allan et al 1986)
For DHM, number in italic correspond to the mean calculated value for R(-) and S(+)
isomers, assuming the racemic mixture is 50-50%.
value significantly different from the corresponding GABA value at ** p<0.05, T-test
or * p<0.01




N n RP RPh RPk RPa
DHM 4.48±0.36 8.311.5** 3.010.4 5 3.70 4.19 3.80
ZAPA 3.56±0.34 24.1±4.6 1.910.2 3 1.87 1.46 — 3.50
GABA 4.15±0.32 30.2±1.9 2.710.2 38 1.00 1.00 1.00 1.00
TACA 4.93±1.01 65.7114.5** 2.710.4 11 0.47 0.55 — —
IAA 6.77±1.46* 76.1111.3** 3.010.5 4 0.40 0.20 — —
Muscimol 2.48±0.77 82.5120.4** 1.810.3 5 0.37 0.20 5.00 —
Isoguvacine 3.60±1.00 124.2110.1** 1.910.5 4 0.25 0.19 0.75 —
GuAc 4.32±1.35 135.1118.0** 2.511.0 4 0.22 0.16 — —
H-P-P 2.96±0.39 233.6137.2** 2.210.1 3 0.13 — 0.1 —
DAVA 3.77±0.94 366.5117.6** 2.710.5 4 0.08 0.08 — —
CACA 6.83±2.84 391.8138.6** 2.710.3 3 0.08 0.03 — —
INA 2.50±0.70 409.2183.2** 2.410.3 6 0.07 — — —
P-GP 4.30±0.82 536.5149.7** 1.910.1 4 0.07 0.08 —
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II DISCUSSION
1. Quantitative evaluation of GABA and GABA agonist effects
As highlighted in Section 1 C., two points are critical in the measurement of drug-
receptor interaction: the drug concentration and the type of response measured. These
problems and the quantitative analysis of the data are discussed below.
Bath application of the drugs has the advantage of a known and more even
concentration around the receptor than local administration. Uptake and metabolizing
systems and diffusion barriers, can locally reduce the drug concentration around the
cell, so that the bath concentration is not equivalent to the concentration around the
receptor. In the Ascaris muscle preparation there is no evidence for a GABA-uptake
system (Hewitt, 1987, quoted by Holden-Dye et al., 1989). The presence of connective
tissue on the bag surface may, however, present a barrier for the bath applied drugs, so
that the bath concentration is not strictly equivalent to the local concentration around the
receptor. The existence of such barriers may partly explain why lower concentrations of
GABA are effective in the patch-clamp experiments, where an enzymatic digestion
removes the connective tissue.
In the case of a receptor directly coupled to an ion channel, such as the Ascaris
GABA receptor, the primary event following agonist binding to the receptor is the
opening of the CI channels, leading to an increase in membrane conductance (Del
Castillo et al., 1964b; Martin, 1985; Holden-Dye et al., 1988). The measurements of
the change in membrane conductance is therefore directly related to the number of
receptors activated; the measurement of the change in membrane potential is a
secondary event following receptor activation and depends on the equilibrium potential
for CI (Eci) as well, as the conductance change:
where AV is the change in membrane potential, Ag is the change in membrane
conductance, gm is the resting conductance, Eq is the Nemst potential for CI, Em is the
resting membrane potential.
1.1. Drug-application
1.2. Measurement of the response
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After several applications of GABA or agonist, CI ions accumulate intracellularly
and the Eq is shifted to less negative values. This shift in equilibrium potential is
illustrated in the Figure 34 (Section 5), where GABA 30|iM has been applied several
times on the same cell and shows that the responses are similar in terms of membrane
conductance but not in terms of membrane potential. The change in membrane
conductance is therefore a more appropriate measure of receptor activation than the
change in membrane potential. To estimate the change in membrane conductance, a
current-clamp technique was used.
1.3. Quantification of the results
Agonist activity is therefore quantified by three parameters: EC50, Agmax and N.
a. Agmax:
Agmax is a parameter difficult to estimate. The first problem encountered is its
measurement, g, the membrane conductance, is the inverse of the resistance. Errors
made on g measurement increase when the resistance decreases, so that the error on
Agmax is large compared to Ag produced by lower concentrations of agonist. The
second problem is the interpretation of Agmax. According the occupancy theory, on
which is based the modified Hill equation, Agmax represents the effect produced by the
activation of all the receptors available in the membrane. However, desensitization of
the receptors is a frequent phenomenon. Desensitization may be the result of various
mechanisms, and leads to a diminution of the number of functional receptors, in other
words to a reduction in Agmax. Patch-clamp experiments have shown that Ascaris
muscle GABA receptors undergo desensitization when GABA concentrations higher
than 5[lM were applied (Martin, 1985). However in current-clamp studies, even when
a high-GABA concentration (greater than lOOfiM), is applied for a long time (up to 20
minutes), the membrane conductance remains stable and does not recover
progressively, as it would be expected if desensitization occurred. One plausible
explanation is that desensitization occurs very rapidly: the receptors are already
desensitized before a steady-state is reached, and therefore before the membrane
conductance is stabilized. Patch-clamp experiments in Ascaris, are in favour of a rapid
onset of desensitization. In this case, the electrophysiological responses measured in
Ascaris muscle are desensitized responses, and should be similar whether GABA is
applied in a cumulative or a non-cumulative fashion. There was no statistical significant
difference observed between non-cumulative and cumulative dose-response curves to
GABA. But the number of experiments with non-cumulative application of GABA
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(three) was small, given the large variation of Agmax between cells. Holden-Dye et al.
(1988, 1989), have used a microperfusion technique and non-cumulative drug
application. This technique is supposed to limit desensitization of the response, since
the drug is applied locally and for a short time only. However, the maximal responses
they obtained with GABA were smaller than with the bath application used here. This
discrepancy may result from the short duration of GABA application and the presence
of a diffusion barrier: steady-state is not reached with the receptors at the cell surface
and therefore, only a proportion of the expected response is measured.
The fact that Agmax did not vary significantly for all the compounds tested (except
imidazole-4-acetic acid), does not mean that there is no partial agonist; the variation of
Agmax between the cells for a same compound is too large to allow the detection of
partial agonism. The case of the rigid GABA analogues is however interesting;
although the differences did not reach statistical significance, they all showed a lower
Agmax. They are also much weaker than at GABA-A receptors. Low Agmax and high
EC50, often characterize partial agonists. For example, piperazine, which is 100 times
less potent than GABA, has been shown to act as a partial agonist at the Ascaris GABA
receptor (Martin, 1982). But here, high EC50's are not always associated with low
Agmax, since some very weak agonists have a high Agmax: p-guanidinopropionic acid
(Agmax=4.30±0.82jiS, mean±SE, n=4), cis-aminocrotonic acid
(Agmax=6.83±2.84|iS, mean±SE, n=3). To detect partial agonism, the compounds
should be applied at high concentration on the same cell simultaneously, and then
separately. The maximal response should be smaller when the two agonists are applied
simultaneously, than when they are applied separately. The partial agonist partly
antagonizes the effects of the full agonist
Only imidazole-4-acetic acid showed a higher Agmax than GABA
(Agmax=6.77±1.46p.S, mean±SE, n=4, T-test p<0.05). Imidazole-4-acetic acid is
somehow a semi-rigid analogue of GABA as muscimol, and has a delocalized positive
charge, as the oo-guanidino acids (Krogsgaard-Larsen et al., 1986). There is therefore
no plausible explanation available yet for this result. This isolated result illustrates the
difficulty in interpreting Agmax in this preparation.
Although, Agmax cannot be interpreted as a reliable estimate of the total number of
receptors on the cell surface, it gives, nevertheless, a quantitative information on the
physiological response of the cell to high concentrations of GABA or GABA agonist.
b. Hill coefficient:
There may be theoretical reasons why the Hill equation (or modified Hill equation)
may not be appropriate (see Section l.C), and it would be wrong to interpret the Hill
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coefficient strictly as the number of agonist molecules required to activate the receptor.
Several factors can influence the Hill coefficient. For example, the existence of an
uptake system or a metabolizing system, would increase the apparent Hill coefficient.
In Ascaris muscle, Hewitt (1987) (quoted by Holden-Dye et al., 1989) found no
evidence for a GABA-uptake system when using nipecotic acid, a specific vertebrate
neural uptake inhibitor. However this only means that there is no nipecotic acid
sensitive uptake system. If an uptake or a metabolizing system exist, one expects a
certain amount of specificity and only GABA and may be a few agonists will be
substrates for these systems. It would be unlikely that all the agonists were substrates
for the uptake as for metabolizing systems, and therefore differences between the Hill
coefficients of GABA and the various agonists would be expected. This is not the case
here. In conclusion, the existence of an uptake system could not be demonstrated in this
system using the current-clamp technique, and positive cooperativity between agonist
and the Ascaris GABA receptor is the likely explanation.
c. EC50:
EC50, in contrast to Agmax, is the most useful parameter and its interpretation does
not depend upon any theoretical model: it represents the concentration of GABA or
agonist required to produce 50% of the maximal response. Of course problems arise
when EC50 has to be related to the dissociation constant of the agonist Kq.
Comparison of EC50's is, here, the basis of the discussion on the agonist profile of the
Ascaris GABA receptor.
1.4. Depolarization in the presence of low-GABA concentrations
Depolarization of the membrane was also occasionally seen after the application of
Ringer alone (2 cells). The mechanical disturbance occasioned by the drug application
could be responsible for the membrane depolarization. However, the depolarizations
occurring at the end of the recovery phase cannot be explained by the mechanical
disturbances. It is interesting to note that Del Castillo et al. (1964b), also noticed that
low GABA concentrations produced, small but statistically significant, depolarization
of the membrane.
These depolarizations are unlikely to be due to acetylcholine receptor activation,
since in that case a greater consistency of the response is expected.
The depolarizations seen in this present work, illustrated in Figure 10, resemble the
modulation activity and the square waves described by Weisblat et al. (1976). Low-Ca
and high-Mg solutions induced square waves carried by Na, similar to the spontaneous
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modulation activity carried by Ca or Na (Weisblat et al., 1976). Here, in low-Ca,
depolarization can only involve the entry of Na. Assuming that the current-voltage
relationship is linear at depolarizing potentials, the estimation of the reversal potential
gives a value of +29mV. This assumption may not be valid (see Figure 8), but
nevertheless, even if inaccurate, the extrapolation suggests that a Na conductance is
likely to be involved since the estimated reversal potential for Na is +27mV (values of
intracellular ion concentrations from Brading and Caldwell, 1971: Na: 99.4mM, K:
48.6mM). The conductance involved during the depolarization is permeable to Na and
-Kror that two different conductances: Na and K, are activated at the same time-.
A transient decrease in conductance, associated with a small depolarization was
sometimes noticed just before the peak depolarization. This suggests the closing of
normally open K or more unlikely CI channels. One can relate this to the inward
rectifier K channels (Hille, 1984a). The inward rectifier K channels close with
depolarization, producing further depolarization. If large enough, this depolarization
will in turn, activate voltage-sensitive cations channels, producing a long lasting
depolarization (Hille, 1984a). Inward rectifier K channels are involved in long lasting
depolarizations and participate to the spontaneous activity in some neurones (Hille,
1984a). Here in Ascaris, the initial closing of these putative K channels may be of
crucial importance in starting the square wave. Weisblat et al. (1976), suggested as
well, that a conductance to an opposite ion, may be K, was important in generating the
square waves. The apparent desensitization of the response is not explained, and may
involve another ion conductance associated with a second messenger for example. One
attractive hypothesis is that the effect of GABA, at low concentration, may involve a
second messenger, via an action at a different receptor, like the vertebrate GABA-B
type.
Further investigation of these depolarizations or square waves, may bring
interesting informations on the generation of spontaneous activity associated with
contraction, the role of Ca, and the interactions with neuro-transmitters, such as
GABA.
2. Agonist profile of the Ascaris muscle GABA receptor
In Section 1, it has been shown that vertebrate GABA-A receptors are not
pharmacologically homogeneous, and so it would be inappropriate to compare the
Ascaris GABA receptor to only one subtype of GABA-A receptor. For this reason, the
following discussion is based on some general characteristics of the GABA-A
receptors, which does not imply that all the GABA-A subtypes present these properties.
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A comparison of vertebrate GABA-A and Ascaris muscle GABA receptors, will be
made here, in terms of structure-activity relationships, and the pharmacological
implications will be discussed. Several interesting features can be pointed out from this
present study; it will be shown that Ascaris GABA receptors resemble the vertebrate
GABA-A receptors: baclofen, a specific GABA-B agonist is inactive; the optimal chain
length between the positive and negative charges is approximately 5A; agonists are
more potent in an extended conformation; and the stereoselectivity for a certain number
of compounds is similar. It is also shown that Ascaris GABA receptors differ from the
vertebrate GABA-A receptors with respect to the potency of the sulphonic derivatives
3-APS, P4S; the potency of some rigid analogues: muscimol, isoguvacine, isonipecotic
acid, THIP; and the inactivity of diazepam, pentobarbitone and Cortisol in potentiating
GABA responses.
2.1. GABA-A agonist properties
a. Inactivity of baclofen
GABA-A and GABA-B receptors are the two main classes distinguished in
vertebrate. Baclofen is a specific agonist at the GABA-B receptors in vertebrate and is
inactive at ImM on membrane conductance in Ascaris muscle suggesting the absence of
vertebrate GABA-B type receptors in this preparation. This confirms the results of
Holden-Dye et al. (1988). Previous work has shown that the Ascaris GABA receptor is
associated with CI channels (Del Castillo et al., 1964b; Martin, 1985; Holden-Dye et
al., 1988) like the GABA-A receptors. The lack of activity of baclofen further illustrates
that the Ascaris GABA receptor is more like the vertebrate A type than to the vertebrate
B type.
b. Optimal chain length between the positive and negative
charges
GABA has four carbons between the positive charge of the amine function and the
negative charge of the carboxylic function; the charges are separated by a distance of
4.7A (Krogsgaard-Larsen and Johnston, 1978; Wermuth and Rognan, 1987).
Aminoacids with a shorter chain length, such as in glycine (3C) and (3-alanine (2C) are
totally inactive at ImM. Amino-acids with longer chain, are not potent either: e-
aminocaproic acid (6C) is inactive, 8-aminovaleric acid (5C) is a weak agonist.
Compounds with longer chains but with the positive charge delocalized, possess a
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some activity, as in the case of the co-guanidinoacids: (3-guanidinopropionic acid (4C,
IN), guanidoacetic acid (3C, IN). These results confirm previous findings obtained in
Ascaris (Holden-Dye et al., 1988), and are in good agreement with the observations in
other invertebrates (Takeuchi and Takeuchi, 1975; see Nistri and Constanti 1979, for a
review) and vertebrate preparations (see Nistri and Constanti, 1979; Krogsgaard-
Larsen, 1988, for a review). The optimal chain length between the positive and
negative charges on Ascaris GABA receptor is similar to that of the vertebrate GABA-A
receptor and corresponds to a distance close to 4.7A.
c. Extended conformation of GABA
GABA has great flexibility and can adopt various conformations. Structure-activity
studies have suggested that GABA interacts with the GABA-A recognition site in a
extended conformation (Steward, Player, Quillian et al., 1971; Johnston and Allan,
1984). In Ascaris, the use of the two isomers of the aminocrotonic acid, suggests that,
like the GABA-A receptor, the Ascaris muscle GABA receptor is activated
preferentially by the extended form (trans-aminocrotonic acid, EC50=65.7±14.5(iM,
n=ll), the folded form is very weak (cis-aminocrotonic acid, EC50=391.8±38.6|iM,
n=3). These results are in good agreement with previous work on Ascaris (Holden-Dye
et al., 1988). It must be noted that in vertebrate preparations, some baclofen-insensitive
GABA receptors do not prefer the folded conformation. Johnston and Allan (1984),
reported the GABA-like neuronal depressant activity of cis-aminocrotonic acid and
other folded compounds via receptors named GABA-C (Johnston, 1986). These
GABA-C receptors are furthermore insensitive to the GABA-A antagonist bicuculline.
d. Stereoselectivity
Holden-Dye et al. (1989), studied the relative potencies of stereoisomers in Ascaris.
They showed that the Ascaris GABA receptor has a stereoselectivity similar to that of
the central GABA-A receptors for RS(±)dihydromuscimol and RS(±)4-methyl trans-
aminocrotonic acid. However, the stereoselectivity shown by the Ascaris GABA
receptor for RS(±)3-hydroxyGABA, was similar to that seen at the spinal GABA-A
receptors. S(+)dihydromuscimol, R(-)3-hydroxy GABA and S(-)4-methyl trans
aminocrotonic were the most potent stereoisomers in Ascaris.
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2.2. Differences with the GABA-A receptors
a. Inactivity of sulphonic derivatives
In this study, the two sulphonic acid derivatives 3-APS and P4S were found
inactive at ImM in Ascaris, as reported previously by Holden-Dye et al. (1988). These
sulphonic acid derivatives are very weak or inactive in other invertebrate preparations
(see Simmonds, 1983; and Walker and Holden-Dye, 1989, for review). In vertebrate
brain preparation, P4S, in contrast to GABA, does not stimulate benzodiazepine
binding (Krogsgaard-Larsen, 1988); this difference has been explained by the existence
of a distinct type of GABA-A receptor coupled to benzodiazepine receptor (Karobath,
Placlieta and Lippitsh, 1979). Krogsgaard-Larsen (1988), however, proposed a
different explanation and suggested that:
"...the mechanisms underlying the effects of GABA-A
agonists containing the tetrahedrally oriented sulphonate
groups are somehow different from other agonists
containing planar carboxylate groups...".
It is pointed out that Krogsgaard-Larsen's conclusion is partly based on Curtis's
personal communication; and these views remain to receive further support. Obviously,
the structural and electron differences between sulphonic acid and carboxylic acid
moieties play a role in the differences of properties between GABA and P4S; but the
existence of different populations of GABA-A receptors, more or less sensitive to
sulphonic acid derivatives, can explain, in itself, the differences in agonist properties.
Moreover, sulphonic acid derivatives are not the only compounds with little activity on
benzodiazepine binding: isoguvacine and THIP were reported as weak stimulators of
[3H]diazepam binding while being potent antagonists of [3H]GABA binding (Karobath
et al., 1979). The existence of structural differences in the receptor itself is more likely
to explain the inactivity of sulphonic acid derivatives at the Ascaris GABA receptor, and
more generally at invertebrate GABA receptors.
The low potency of the sulphonic acid derivatives 3-APS and P4S, can be
considered as a characteristic of invertebrate GABA receptors, and not as a special
feature of the Ascaris muscle GABA receptor.
b. Loss of activity by rigid GABA-A agonists
May be, the most important observation here is the loss of activity, in Ascaris, of
some of the potent and rigid GABA-A agonists: muscimol, thiomuscimol, isoguvacine,
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isonipecotic acid and THIP. In vertebrates, these rigid or "conformationally frozen"
compounds (Krogsgaard-Larsen et al., 1986), are considered as potent and specific
GABA-A agonists. Because of their rigidity they are restricted to a certain conformation
and therefore, are prevented from interacting with binding sites accepting GABA in a
slightly different conformation. For example, these compounds do not interact, or
weakly interact, with GABA uptake sites or GABA-B sites (see Krogsgaard-Larsen,
1988, for review). Muscimol and thiomuscimol were more potent than GABA itself, in
inhibiting [3H] GABA binding at rat brain synaptic membranes, and in inhibiting the
firing of cat spinal intemeurones (Krogsgaard-Larsen, 1988). In the same experiments,
isoguvacine was found to be equipotent with GABA; isonipecotic acid and THIP were
found less potent than GABA (Krogsgaard-Larsen, 1988). In invertebrate preparations,
there is a great variability between species and even between tissues of the same
species. For example, in arthropods, isonipecotic acid is more potent than GABA in
Limulus central neurones, but not in Periplaneta (Roberts, Krogsgaard-Larsen and
Walker, 1981). In Limulus, GABA receptors in the central nervous system (Roberts et
al., 1981), and GABA receptors found in the heart (Benson, 1989), have different
characteristics: THIP is as potent as GABA in Limulus central neurones, but inactive at
eliciting hyperpolarization in Limulus heart (Roberts et al., 1981).
These variations of agonists potencies, reflect well the heterogeneity of vertebrate
GABA-A and invertebrate GABA receptors already highlighted in the Section 1 B.
Holden-Dye et al. (1989), compared the relative potencies of various GABA
agonists in Ascaris muscle to their relative potencies in vertebrate preparations: binding
studies using rat synaptic membranes (Krogsgaard-Larsen, 1988), or at the guinea-pig
ileum (Allan, Dickenson, Hiern et al., 1986a). They suggested that the order of
potencies in both systems are positively correlated (Figure 29A). The relative potencies
of the sulphonic derivatives, 3-APS and P4S, were not included in the calculation of
the correlation coefficient, on the basis of a fundamentally different mechanism of
interaction between these compounds and the GABA receptor (Krogsgaard-Larsen,
1988). The sulphonic group confers different properties to these compounds; but the
structural differences in binding sites are more likely to be responsible for the inactivity
of the sulphonic acid derivatives in Ascaris, and in invertebrate more generally. The
rejection of these compounds from the comparison between the two systems does not
seem justified. In addition, several vertebrate systems were used used for the
calculation of the correlation coefficient: displacement of [3H]GABA from rat brain
membranes for most of the compounds (Krogsgaard-Larsen, 1988); and contraction of
the guinea-pig ileum for ZAPA (Allan et al., 1986a). These two systems are not
equivalent, especially in respect to ZAPA; the relative potency of ZAPA in the guinea-
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Figure 29: Correlation between the relative potency of some agonists in Ascaris and in
vertebrate preparations
A. From Holden-Dye et al., (1989)
Abscissa: relative potency in Ascaris muscle
Ordinate: relative potency in vertebrate preparations; displacement of [3H]GABA from
rat brain membranes (Krogsgaard-Larsen, 1988), except for ZAPA: contraction of the
guinea-pig ileum (Allan et al., 1986). Slope=1.02, correlation coefficient r=0.74,
p<0.01.
B. This present study.
Abscissa: relative potency in Ascaris muscle (this study for: H-p-P, IAA, muscimol,
INA, isoguvacine, thiomuscimol, p-GP, ZAPA, RS(±)dihydromuscimol, and Holden-
Dye et al., 1988; 1989, for: S(-)-me-TACA, R(+)-me-TACA, S(+)-OHGABA, R(-)-
OHGABA, S(+)-dihydromuscimol, R(-)-dihydromuscimol, P4S, 3-APS, THIP)
Ordinate: relative potency in vertebrate; displacement of [3H]GABA from rat brain
membranes (Krogsgaard Larsen et al., 1986; Krogsgaard Larsen,1988).
Correlation coefficient, r=0.80, slope=0.87, p<0.01, regression coefficient Ra2=0.64.
Note that because of the use of logarithmic coordinates, the linear regression was not




































































pig ileum, is: 3.50 (Allan et al., 1986a), whereas in binding studies, it is only: 0.43-
0.50 (Krogsgaard-Larsen et al., 1986; Allan et al., 1986a). Figure 29B shows the
correlation between the relative potencies of GAB A agonists at the Ascaris muscle
GABA receptor (this study, and Holden-Dye et al., 1988; 1989) and in binding studies
on rat brain membranes (Krogsgaard-Larsen et al., 1986; Krogsgaard-Larsen, 1988).
The sulphonic acid derivatives P4S and 3-APS were included in the calculation. The
relative potency of ZAPA to displace [3H]GABA was chosen, instead of its potency in
eliciting contractions in the guinea-pig ileum. Both systems are found also positively
correlated, with a slope of 0.87±0.15 (mean±SE, n=19, F-test, r=0.80, p<0.01,
Ra2=0.64), indicating also that the Ascaris GABA receptor is related to vertebrate
central GABA-A receptors, in terms of agonist potencies.
c. Inactivity of diazepam, pentobarbitone and Cortisol
Diazepam (l|iM), pentobarbitone (lOfiM) and Cortisol (10|4M), did not significantly
potentiate, or antagonize the response to GABA. The concentrations used are low,
especially for the barbiturate, pentobarbitone, which is not normally a strong potentiator
of the GABA response. Holden-Dye et al. (1989), used higher concentrations of
pentobarbitone: 100|iM, and of the benzodiazepine, flurazepam: 100|iM. But they
could not find any significant enhancement of the GABA response. This is in
agreement with the fact that, among invertebrates, benzodiazepine or barbiturate
potentiation of GABA responses, is only found in insects (see Section 1,B). Cortisol
had only been recently shown to interact with the GABA-A receptor complex in
vertebrates. The concentrations required are much lower than for barbiturates.
However, Cortisol possesses a dual action: potentiator of the GABA response at low
concentrations, and GABA-antagonist at high concentrations (Ong et al., 1987). To
investigate more seriously the actions of Cortisol, or of other putative modulators, on
GABA response in Ascaris, a wider range of concentrations should be applied.
The small increase in Agmax seen with pentobarbitone and Cortisol, was not
statistically significant. This has to be related to the difficulty in measuring Agmax, and
to the small number of experiments. The use of a more sensitive technique, such as the
patch-clamp technique, for example, should be considered before any final statement on
the presence or not of modulatory sites in Ascaris.
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CONCLUSION
Whether or not the Ascaris GABA receptor belongs to the vertebrate A receptor type
cannot not be decided only on a basis of agonist potencies. More practically, the
similarities between Ascaris GABA receptor and the GABA-A receptors indicate that
the exploration of Ascaris GABA receptor agonist properties is unlikely to lead to the
discovery of a potent and selective agonist suitable for a new generation of
anthelmintics.
In the next sections, the antagonist properties of the Ascaris muscle GABA
receptor will be investigated. It will be shown that they are fundamentally different
from the vertebrate and other invertebrate GABA receptors, they might therefore be
exploited in anthelminthic drug research.
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SECTION 4:
INACTIVITY OR WEAK POTENCY OF CLASSICAL
GABA-A ANTAGONISTS AT THE ASCARIS MUSCLE
GABA RECEPTOR
INTRODUCTION
In the present section the activity of some classical GABA-A antagonists such as
(+)bicuculline, picrotoxin, the amidine steroid RU5135, were examined. The activity
of some related compounds has also been examined: (-)bicuculline, usually less potent
than the (+) isomer, and (±)d-tubocurarine, a classical acetylcholine nicotinic




The muscle dissection has been described in the general methods Section and in
Section 3. As for the experiments with agonists, the muscle flap was bathed in high-
Cl, low-Ca Ringer (solution B), and maintained at 222C.
2. Drug application
Because of the limited quantities of antagonist available, the muscle was not
perfused continuously. The experimental chamber (2.5ml) was carefully drained, and
then flushed with 5ml of the next drug solution. When dose-response curves were
required, drugs were bath-applied in a cumulative manner, without intermediate




The technique used here, has been described previously in Section 3. In some
experiments, signals were recorded with an Axoclamp 2A (Axon Instruments) which
permits the use of higher resistance electrodes for current injection: typically 20-50MQ.
3.2. Analysis
a. GABA
The effect of GABA was determined by measuring the change in input
conductance. When dose-response relationships were required, they were described by
the modified Hill equation (Nistri and Constanti, 1979), and estimates for Agmax,
EC50 and N were obtained using a non linear regression programme (Patternsearch
Cold!(houn, 1971). See Section 3 for details.
b. Antagonists
- Screening
Initially, the action of ImM antagonist was examined on the change in membrane
conductance induced by GABA 30|lM. The percentage antagonism was then estimated:
% antagonism = 100.(l-^|nt)
where Agc is the change in membrane input conductance produced by GABA 30|iM,
and Agant is the change in membrane input conductance produced by GABA 30|iM +
antagonist ImM, measured after ten minutes application of the antagonist. Compounds
detected as reasonably potent antagonists with this method, were then tested at several
concentrations on GABA dose-response curves.
- Evaluation of IC50
The effect of RU5135 has been examined on GABA dose-response curves.
Because of the natural variation of Agmax and N, a control GABA dose-response
curve was usually obtained from the same cell, before, or sometimes after the
antagonist application. The IC50 was estimated according Schild's method
(Arunlakshana and Schild, 1959).
Ill
4. Statistical test
Means and standard errors were calculated. Statistical significance was assessed
using a two-tailed independent t-test.
II RESULTS
The results presented here are based on the analysis of experiments conducted on
17 cells from 8 preparations. Cells selected for recording and analysis had resting
membrane potentials greater than -20mV and resting input conductances between
2.2(iS and 3.2(lS (2.9+0.1(0.S, mean+SE, n=17). Recordings were also rejected if the
resting input conductance failed to return to at least 80% of the control.
1. Inactive compounds
(+) bicuculline 100[iM (n=4), picrotoxin 300|iM (n=3), (-)bicuculline methiodide
200|iM (n=2), (+)d-tubocurarine ImM (n=2), applied for ten minutes, were found
inactive on the change in membrane conductance induced by GABA 30}iM. Because of
its instability in solution (Curtis et al., 1970), (+)bicuculline was used within two
hours. Figure 30 illustrates the inactivity of (-) bicuculline, picrotoxin and d-
tubocurarine. The inactivity of GABA-A competitive antagonist: (±)bicuculline
methiodide (10|iM) in Ascaris muscle had been previously reported (Holden-Dye et
al., 1988). Picrotoxin, the non competitive CI channel blocker, had been also shown
unable to block GABA responses in Ascaris muscle at 10|iM (Holden-Dye et al.,
1988) and at lOOjlM (Wann, 1987). These results contrast strongly with the vertebrate
GABA-A receptors where picrotoxin and (+)bicuculline are potent antagonists.
(-)bicuculline methiodide and tubocurarine were ineffective, but they are also weak
antagonists at the vertebrate GABA-A receptors (Simmonds, 1982; Krogsgaard-
Larsen, 1988).
2. RU5135 antagonizes GABA (30fiM) induced change in membrane
conductance
RU5135 (Hunt and Clements-Jewery, 1981), is the most potent competitive
GABA-antagonist known at the vertebrate GABA-A receptor. To detect any
antagonistic activity, the effects of lmM RU5135, on the conductance change induced
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Figure 30: Inactivity of (-)bicuculline, picrotoxin and d-tubocurarine as GABA
antagonists in Ascaris muscle
A. Effect of (-)bicuculline 200[iM (I=40nA):
go=3.1|iS; GABA 30|lM, Ag=4.2|iS, GABA 30|J.M + (-)bicuculline 200[lM,
Ag=4.2|iS; %antagonism=0.
B. Effect of picrotoxin 300flM (I=40nA):
go=2.9|iS; GABA 30jxM, Ag=3.8p.S; GABA 30|iM + picrotoxin 300(iM, Ag=3.8jiS;
%antagonism=0.
C. Effect of d-tubocurarine ImM (I=40nA):




by 30|iM GABA, were examined. Figure 31, illustrates the antagonism of the GABA
response by RU5135. In this cell, the resting membrane conductance was 2.3|iS. In
presence of GABA 30|iM, the conductance increased to 5.3|iS, giving a change in
conductance of 3.0(iS. The application of RU5135 decreased the conductance to
2.6p.S, and Ag to 0.3(iS. In this experiment, 90% of the GABA response was
antagonized by RU5135 ImM. The effects of RU5135 were fully reversed by
perfusion of GABA 30(i.M alone, Ag returned to 3.0|iS. The resting input conductance
returned to 2.4|iS in drug free solution, indicating that the membrane had not been
damaged.
3. Effect of RU5135 on dose-response curves to GABA
In order to further characterize the antagonism of RU5135, the effects of 70, 210
and 700(iM RU5135 on GABA dose-response curves were examined. The effects of
RU5135 were investigated in five different cells. The EC50 for GABA was
30.3±1.8(iM (mean±SE); Agmax was 4.9±0.5(iS (mean±SE); and the Hill coefficient
N was 2.2±0.3 (mean±SE).
As illustrated in Figure 32, GABA dose-response curves, in the presence of 210
and 700|iM were shifted to the right in a non parallel manner with an apparent
reduction of the maximum response, suggesting a non-competitive antagonism. In five
different preparations, RU5135 70(iM, did not significantly affect the GABA
response, whereas 210 and 700(iM significantly increased the EC50 to 98.2±19.4|iM
and 315.6±26.9jiM respectively (mean+SE, n=5, p<0.01, T-test). Agmax was
significantly reduced in the presence of 700p.M RU5135 to Agmax=3.3±0.4jiS
(mean±SE, n=5, p<0.05, T-test). The Hill coefficient was also decreased, but not
significantly. These results are summarized in Table 10, and show that RU5135 acts as
a non competitive antagonist, with an estimated IC50=117p.M.
II DISCUSSION
1. Inactivity of the classical GABA-A antagonists: picrotoxin,(±)bicuculline, and
the related compound (±)d-tubocurarine
The results presented in this study confirm the lack of potency of bicuculline
(Holden-Dye et al., 1988) and picrotoxin on Ascaris muscle (Wann, 1987; Holden-







Figure 32: Dose-response curves to GABA and GABA + RU5135 at 70, 210 and
700jxM.
Ordinate: change in membrane conductance Ag (pS).
Abscissa: GABA concentration (M), log scale.
Dose-response curves were obtained from the same cell and the experimental values
were fitted by the modified Hill equation. The plain line describes the fitted modified
Hill equation.
GABA control EC50=28.1pM
GABA + RU5135 70pM EC50=30.6pM
GABA + RU5135 210pM EC50=100.4pM
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preparations (see Section LB). But picrotoxin is usually potent at antagonizing GABA
responses in invertebrates (see Section l.B). An early voltage-clamp study reported
that picrotoxin antagonized GABA applied by ionophoresis (Martin, 1982); anyhow
the antagonism produced was small and not fully reversible.
Besides bicuculline and picrotoxin, other classical GABA-A antagonists were
found inactive at the Ascaris GABA receptor: the competitive antagonists: securinine
(10|iM), pitrazepine (10|iM), TBPS: (IOjiM) (Holden-Dye et al., 1988) and the
channel blocker: dieldrin (lOOfiM) (Colqhoun et al., 1989).
Picrotoxin and TBPS act at the channel level (see Section 1) and their inability to
block the GABA responses in Ascaris suggests that the CI channel itself differs from
the vertebrate and even from most invertebrate GABA-associated CI channels. These
results indicate that the CI channel in Ascaris may be also an interesting target for new
anthelmintic compounds. Recently 5-nitro-2-(3-phenylpropylamino) benzoic acid (5-
NPB), known to block CI transport in renal tubules, has been shown to act as a non¬
competitive GABA-antagonist (IC50=69|iM), in Ascaris (Colquhoun et al., 1989).
However, 5-NPB is not a specific blocker of Ascaris GABA-gated Cl-channel, since it
blocks also non-GABA gated CI channels in vertebrates.
2. RU5135 acts as a weak non-competitive GABA antagonist in Ascaris
muscle
RU5135 is known as a potent antagonist at the vertebrate GABA-A receptor: it is
500 times more potent than bicuculline in displacing [3H]GABA from its binding site
in rat brain membranes (Hunt and Clements-Jewery, 1981), and 200 times more potent
in electrophysiological studies on rat cuneus nucleus (Simmonds and Turner, 1985).
Like bicuculline, RU5135 inhibits [3H]muscimol, [3H]GABA binding and the
enhancement of [3H]diazepam binding by GABA, pentobarbitone and etazolate (Hunt
and Clements-Jewery, 1981; Olsen, 1984; Simmonds and Turner, 1985). But RU5135
also interferes more strongly with the glycine receptor: in vitro with [3H] strychnine
binding (Hunt and Clements-Jewery, 1981; Simmonds and Turner, 1985), and in
vivo on the firing of interneurones in the cat spinal cord (Curtis and Malik, 1985).
In Ascaris muscle, there is no evidence for glycine receptors (see Section 3 and
Holden-Dye et al., 1988), RU5135 can therefore only interfere with the GABA
receptors. This present study shows that RU5135 acts as a weak non competitive
GABA antagonist at Ascaris GABA receptor. The concentrations required to block the
GABA response in Ascaris muscle (IC50=117(iM), are much higher than those
required to block GABA responses in the rat cuneate nucleus (IC50=5nM) (Simmonds
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Figure 31: Effects of GABA 30p.M and GABA 30(iM + RU5135 ImM on membrane
input conductance.
Resting membrane input conductance go=2.3|iS; GABA 30|lM induced an increase in
membrane conductance, Ag=3.0(iS; when RU5135 is added, the membrane
conductance decreased and stabilized at g=2.6|iS, giving Ag=0.3|lS; GABA recovered
its full effect after RU5135 was washed away, Ag=3.0|iS. (I=40nA).
Table 10: RU5135: Effect on dose-response curves parameters, EC50, Agmax and N.
Mean and standard errors for EC50, Agmax and N.
* and ** significantly different from the control GABA dose-response curve at p<0.05
and p<0.01 respectively.
EC50 (|iM) Agmax (pS) N












The low potency of RU5135 as a GABA antagonist on Ascaris muscle, associated
with the inactivity or low potency of other classical GABA-A antagonists (bicuculline,
picrotoxin, TBPS, pitrazepine, securinine, SR95531 (Holden-Dye et al., 1988, 1989),
confirms that the Ascaris GABA receptor differs pharmacologically from the vertebrate
GABA-A receptor. Since on the basis of its agonist properties, the GABA recognition
site in Ascaris is related to the GABA-A site, RU5135 should be able to bind the
Ascaris GABA site and therefore should behave as a competitive antagonist. One
possible explanation of its low potency is that its rigid GABA-like structure may not be
well accepted by the GABA binding site in Ascaris.
CONCLUSION
All the classical GABA-A antagonists are inactive or have a low potency on the
Ascaris GABA receptor. These results contrast markedly with the agonist properties,
where Ascaris muscle GABA receptor and vertebrate central GABA-A receptors are
correlated. The inactivity of non-competitive antagonists such as picrotoxin or TBPS
can be explained by differences in the CI channel and not in the GABA binding sites.
However the inactivity of the competitive antagonists bicuculline, pitrazepine and
securinine is surprising. One possible explanation is the existence of accessory binding
sites (Ariens, Beld, Miranda et al., 1979), responsible for the antagonists properties.
Differences in accessory binding sites between Ascaris and vertebrate receptors might
explain the inactivity of classical GABA-A competitive antagonists.
RU5135 was the only compound tested, found to antagonise GABA responses.
But RU5135 acts as a weak non-competitive antagonist at the Ascaris muscle GABA
receptor: IC50=117|iM, being 20000 times less potent that in the vertebrate
preparations (rat cuneate nucleus IC50=5nM, Simmonds and Turner, 1985). These
observations suggest that the Ascaris GABA receptor differs pharmacologically from
the vertebrate GABA-A receptors. These differences in antagonist properties might be
exploited for therapeutic purposes.
The next Sections explore the antagonistic properties of pyridazine derivatives of
GABA at the Ascaris GABA receptors, and further suggests the existence of different
accessory binding sites responsible for antagonist properties in Ascaris.
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SECTION 5:
THE EFFECTS OF THE ARYLAMINOPYRIDAZINE-
GABA DERIVATIVES, SR95103 AND SR95531, ON THE
ASCARIS MUSCLE GABA RECEPTOR: THE RELATIVE
POTENCY OF THE ANTAGONISTS IN ASCARIS IS
DIFFERENT TO THAT AT THE VERTEBRATE
RECEPTOR.
INTRODUCTION
The previous sections have shown that, in terms of agonist potencies, the Ascaris
GABA receptor is related to the vertebrate GABA-A receptors, in spite of some small
pharmacological differences. However, in terms of antagonist profile, none of the
classical GABA-A antagonists was potent. These results suggested that compounds
with potential GABA-antagonist properties are certainly more promising in the search
for a new and specific anthelminthic drug. This Section explores the antagonistic
properties of two pyridazine derivatives of GABA, SR95531 and SR95103 (Figure
33), on GABA responses in Ascaris muscle using a current-clamp technique. The
actions of arylaminopyridazine derivatives have been investigated in the mammalian
central nervous system, where they are potent and selective competitive antagonists of
GABA-A receptors (Chambon, Feltz, Heaulme et al., 1985); SR95531 is the most
potent of the series. However, the action of this series of compounds remains to be
fully explored in Ascaris and more generally in invertebrates.
I METHODS
1. Muscle preparation
The muscle dissection has been described in the general methods and in Section 3.
As for the experiments with GABA-agonists, the muscle flap was bathed in high-Cl,
low-Ca Ringer (solution B), and maintained at 222C.
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Because of the limited quantities of antagonist available, the muscle was not
perfused continuously. The experimental chamber (2.5ml) was carefully drained, and
then flushed with 5ml of the next drug solution. When dose-response curves were
required, drugs were bath-applied in a cumulative manner, without intermediate
washing between the concentrations (see Section 3).
2.2. Ionophoresis
In voltage-clamp experiments, GABA was applied ionophoretically as an cation
from a micropipette (10-20MQ) using a standard pulse of 300nA, 500ms (micro-
ionophoresis programmer Model 160 WP instruments). GABA was used at
concentration 2mM, pH=2.5 adjusted with HC1. A retaining current of lOnA was used.
Ionophoresis does not allow an accurate estimation of the drug concentration; but it did
permit an estimation of the voltage-sensitivity of GABA antagonism produced by an
arylaminopyridazine derivative of GABA, SR95103. Ionophoretic application of
GABA was chosen in order to deliver the GABA to a local area under control of the
voltage-clamp, since the geometry of Ascaris muscle cells does not permit a total space




The technique used here, has been described previously in Section 3. In some
experiments, signals were recorded with an Axoclamp 2A (Axon Instruments), which
permits the use of higher resistance electrodes for current injection: typically 20-50MQ.
3.2. Analysis
a. GABA
The effect of GABA was determined by measuring the change in input conductance.
Dose-response relationships were described by the modified Hill equation (Nistri and
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Constanti, 1979), and estimates for Agmax, EC50 and N were obtained using a non




Initially, the action of ImM antagonist was examined on the change in membrane
conductance induced by GABA 30|iM. The percentage of antagonism was then
estimated:
% antagonism = lOO.Cl-^jp1)
where Agc is the change in membrane input conductance produced by GABA 30p.M,
and Agant is the change in membrane input conductance produced by GABA 30pM +
antagonist ImM, measured after 10 minutes application of the antagonist. Compounds
detected as reasonably potent antagonists with this method, were then tested at several
concentrations on GABA dose-response curves.
- Quantitative evaluation
The effect of SR95103 was examined on GABA dose-response curves. Because of
the natural variation of EC50, Agmax and N, a control GABA dose-response curve was
obtained from the same cell, before, or sometimes after the antagonist application.
Dose-ratios were measured and, examined using a Schild plot (Arunlakshana and
Schild, 1959) or a modified Schild plot (Williams et al., 1988).
. Schild analysis
When dose-response curves are parallel without apparent reduction in the maximal
response, the dose-dependent nature of the antagonism is tested using a Schild plot
(Arunlakshana and Schild, 1959):
log(DR-l) = pKs + log(XB)
where DR is the dose-ratio, pKe is the negative logarithm of the dissociation constant
of the antagonist-receptor complex and Xb is the concentration of the antagonist.
However, this analysis does not account for cooperative interaction between GABA
and its receptor (see Section l.C).
. Modified Schild analysis
The dose-ratios were further examined using a modified Schild plot (Williams et
al.,1988) which accounts for cooperativity between the agonist and its receptor:
log(DRN-l) = pKb + Mlog(XB)
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where N is the Hill coefficient, M is the number of antagonist molecules interacting
with the receptor, and the other symbols are the same as before.
Although physically plausible models for the interaction of agonist and antagonists
do not predict a simple or integral value for these plots, they provide a reasonable
approximation if simplifying limitations can be applied (see Section 1, C.).
4. Voltage-clamp
Due to their morphology, the space-clamping in Ascaris muscle cells may not be
complete (see Martin, 1982). Current responses following GABA application can be
interpreted only if the activated receptors are in close proximity to the microelecrodes;
this necessitates the use of a microapplication method.
4.1. Technique
The current electrode was pulled to a resistance of 10M£2 and the voltage electrode
to 20-50MQ. Microelectrodes were back-filled with Kacetate 2M, and were inserted
into the bag region of a muscle cell. Signals were amplified by an Axoclamp 2A (Axon
Instruments) used in voltage-clamp mode (TEVC). The gain was lOOmV/mV. Capacity
compensation and phase were adjusted for each cell to give the optimal voltage stability.
The holding potential were -lOmV, OmV and -1-lOmV. Voltage-steps to -80 or -90mV,
were made for 500ms at 1Hz under control of an isolated stimulator Digitimer 2533.
Signals were displayed on a Tectronix 2210 oscilloscope and on a Lectromed chart
recorder.
4.2. Data-analysis
The peak responses at the holding potential and at the step potential were measured
from the envelope of the current trace. The voltage sensitivity (Vs) of the antagonism
was expressed as:
_ 1 _ %ant VhqM"
%ant Vstep
where, %antVnold = percent antagonism at the holding potential; and %ant Vstep =
percent antagonism at the step potential
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5. Statistical test
Means and standard errors were calculated for EC50,Agmax, N values for GABA
alone and in the presence of different concentrations of antagonist. Statistical
significance was assessed using a two-tailed independent t-test.
II RESULTS
The results reported here are based on an analysis of experiments conducted on 18
muscle cells from 13 preparations. Cells selected for recording and analysis had resting
membrane potentials greater than -20mV and resting input conductances between 1.9-
4.0(j.S (2.5±0.1|iS, mean±SE, n=18). Recordings were also rejected if the resting
input conductance failed to return to at least 80% of the control.
1. SR95103 and SR95531 have no effect on membrane conductance
SR95103 and SR95531 (ImM) applied onto the muscle in the absence of GABA,
did not produce any change in membrane conductance. The absence of effect of
arylaminopyridazine GABA derivatives on membrane conductance is illustrated in
Section 7, Figure 50.
2. SR95531 and SR95103 as GABA antagonists
In mammalian preparations, SR95531 is the most potent arylaminopyridazine
derivative GABA-A antagonist; it acts competitively and antagonizes
electrophysiological responses to GABA (Chambon et al., 1985; Desarmenien, Feltz,
Loeffler et al., 1987; Michaud, Mienville and Chambon, 1986; Hamann, Desarmenien,
Desaulles et al., 1988), as well as inhibits GABA binding in rat brain preparations
(Chambon et al., 1985; Heaulme, Chambon, Leyris et al., 1986a). In Ascaris, the
application of ImM SR95531 had little effect on conductance changes produced by
GABA 30(iM (Figure 34).
SR95103 is less potent than SR95531 at the GABA-A vertebrate receptor in rat
brain membranes (Heaulme et al., 1986a; Heaulme, Chambon, Leyris et al., 1986b)
and rat dorsal root ganglion cells (Chambon et al., 1985). This contrasts with the
effects seen in Ascaris (Figure 34), where SR95103 ImM produces nearly complete
antagonism. The antagonism reverses completely after washing. SR95103 reduced the
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Figure 34: SR95103 is a more potent antagonist than SR95531
A: SR95103. The resting input conductance is 2.2[lS. In the presence of GABA 30|lM,
Ag=4.4|iS. SR95103 ImM antagonized 86% of the GABA response. The antagonism
was completely reversed when the preparation was washed in 30fiM GABA.
(I=40nA).
B: SR95531. SR95531 was tested on the same cell. The resting input conductance was
2.2p.S. In the presence of 30p.M GABA, Ag=4.4|i.S. SR95531 ImM antagonized only
36% of the response to GABA. This effect was completely reversed after the










response by 92.3±3.2% (mean±SE, n=5) and SR95531 reduced the response by
46.2±6.7% (mean±SE, n=5). To further characterize the properties of
arylaminopyridazine derivatives of GABA on the Ascaris GABA receptor, the effects of
various concentrations of SR95103 on GABA dose-response curves were examined.
3. SR95103 acts as a competitive antagonist
3.1.Dose-dependent nature of the SR95103 antagonism
The dose-dependent nature of the antagonism was tested by examining the effects
of 100, 300 and lOOOpM SR95103 on cumulative dose-response curves. Figure 35
shows the typical effects of lOOqM SR95103 where there is a parallel shift to the right
with no reduction in the maximum response. Both control and 100|iM dose-response
curves were obtained from the same cell. Table 11 shows pooled results with the mean
and SE values for the parameters of the Hill equation used to describe the dose-
response curves. It can be see that N and Agmax were not significantly altered by the
presence of SR95103, and EC50 was increased in a dose-dependent manner.
3.2. Schild-plots
Dose-ratios were determined from the change in EC50 values and a classical Schild plot
obtained, Figure 36 (Arunlakshana and Schild, 1959). This was characterized by an
apparent linear relationship between log(DR-l) and log(XB), and an intersect at the
abscissa giving an apparent pA2 of 4.0. However this plot was characterized by a slope
0.45±0.15 (mean±SE, n=14) significantly less than one (p<0.05, T-test). Thus the
dose-ratios were smaller at higher antagonist concentrations than predicted by the
Schild equation. One interpretation of this result is that SR95103 might not be acting in
a competitive manner. However, the classical Schild analysis does not account for
cooperative models of agonist action involving two agonist binding sites (Williams et
al.,1988). A modified Schild analysis was therefore canied out, where it was assumed
than two molecules of agonist were required to bind the receptor and the slope of the
plot gives an indication of the stoichiometry for the interaction antagonist-receptor. The
slope was 0.62±0.17 (mean±SE, n=14) and not significantiy different from one
(p<0.05, t-test). These results are consistent with a model which involves the activation
of the receptor by two molecules of agonist but only one molecule of antagonist is
required to block this effect. Although these results do not establish such a mode of
action for SR95103, it describes the interaction antagonist-receptor and permits the
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Figure 35: Effect of SR95103 on the cumulative GABA dose-response relationship
(♦): control GABA responses and modified Hill fit: Agmax=5.8|iS, EC50= 24.4(J.M,
N=1.7
(o): GABA dose response curve in the presence of 100|lM SR95103, Agmax=5.8|lS,
EC50=66.2pM, N=1.5.





Table 11: SR95103: Effects on GABA dose-response curve parameters
Parameters for the modified Hill equation used to describe cumulative GABA dose-
response curves in the presence of SR95103. ** indicates p<0.05, T-test














Figure 36: SR95103: Schild and modified Schild plots
Schild plot:
The plot of log(DR-l) against logXg appears linear with a slope of 0.45±0.15
(mean±SE, n=14). The slope is significantly less than one (p<0.01, t-test). The linear
regression value had a p value of 0.008 (F test). The goodness of the fit can be
represented by the regression coefficient: Ra2=0.46.
Modified Schild plot:
The plot of log(DR2-l) against logXg appears linear with a slope of 0.62±0.17
(mean+SE, n=14). The linear regression had a p value of 0.0041 (F test). The fit was




estimation of an apparent dissociation constant Kg, estimated from the modified Schild
equation assuming N=2 and M=l:
and Kg was 64±13(iM (mean±SE, n=14).
The modified Schild plot also gave a better fit (Ra2=0.54), than the classical Schild
plot (Ra2=0.51).
3.3. Voltage sensitivity
The two-microelectrode voltage-clamp technique with the ionophoretic application
of GABA (Martin, 1982), was used to examine the voltage-sensitivity of the
antagonism produced by bath application of 0.1-lmM SR95103. If SR95103 were
acting predominantly as an anion to produce a channel block, then it would be expected
that the degree of channel block would decrease at more negative potentials. However
the antagonism showed little evidence of voltage sensitivity: Vs=0.05±0.17 (mean±SE,
n=4).
II DISCUSSION
The main findings in this Section, are that: SR95103 is more potent than SR95531
as a GABA antagonist in Ascaris muscle with a pA2 of 4.0 and an apparent Kg of
64qM. The study also shows that the potency of the arylaminopyridazine GABA
analogues can vary at the Ascaris GABA receptor. In a previous study with SR95531
(Holden-Dye et al., 1988; 1989), it was also found that SR95531 was not a potent
antagonist in Ascaris. However, it was suggested that this class of compounds does not
recognize the Ascaris GABA receptor, although no other arylaminopyridazine GABA
derivative was examined.
1. SR95103 is more potent than SR95531 in Ascaris: comparison with
mammalian preparations
It has already been pointed out that GABA-A receptors may be heterogeneous
(Levitan, Schofield, Burt et al., 1988; Pritchett, Luddens and Seeburg, 1989; see
Krogsgaard-Larsen, 1988, for review). But it is still useful to compare the Ascaris
receptor to a typical GABA-A receptor. The greater relative potency of SR95103
compared to SR95531 contrasts with the relative potency for the vertebrate GABA-A
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receptor. In binding studies, SR95531 displaces [3H]GABA from rat brain membranes
with a global dissociation constant Kb=0.15jiM (Heaulme et al., 1986a), and SR95103
has a Kg of 2.2p.M (Chambon et al., 1985). In electrophysiological experiments on rat
dorsal root ganglion cells (Chambon et al., 1985; Hamann et al., 1988), SR95531 has
a pA2 close to 7.0 and SR95103 a pA2 close to 5.0. By comparison, SR95103
IC50=100(lM, in Ascaris is only ten times less potent than in vertebratef(IC50=10|lM
estimated from Chambon et al., 1985).
SR95531 is similar in structure to SR95103 (Figure 33) but has a methoxy group
on the 6-phenyl substituent of the pyridazine ring, and no 4-substituent. SR95103 has
no substituent on the 6-phenyl, but has a methyl group in 4-position. The difference in
structure and the greater relative potency of SR95103 on the Ascaris GABA receptor,
indicates that its structural requirements for antagonist properties are different to the
vertebrate GABA-A receptor. The lack of effect of the classical GABA-A antagonists:
bicuculline (Holden-Dye et al., 1988), picrotoxin (Wann, 1987, Holden-Dye et al.,
1988), pitrazepine, securinine, TBPS (Holden-Dye et al., 1988), also supports this
view. Although GABA-A and Ascaris receptors appear to have similar structure-activity
relationships for agonists (Holden-Dye et al., 1989).
Ariens et al. (1979), have argued that the binding to accessory sites on hydrophobic
regions of the receptor are responsible for the antagonists properties of competitive
antagonists; the structure of the moiety binding to the GABA recognition site becomes
less critical than for agonists. The structure-activity relationship for
arylaminopyridazine GABA derivatives at the vertebrate GABA-A receptor (Wermuth,
Bourguignon, Schlewer et al., 1987), is strongly in favour for the presence of
accessory binding sites responsible for the antagonists properties of this series of
compounds. The hypothesis of different accessory binding sites in Ascaris muscle
would explain why the classical GABA-A antagonists are inactive whereas most of the
GABA-A agonists are active. The evidence given here by SR95531 and SR95103
needs to be confirmed by a more complete structure-activity study of
arylaminopyridazine GABA derivatives on Ascaris muscle. Further exploration of the
pharmacology of these compounds in Ascaris GABA receptor may be useful for the
design of new anthelmintic agents.
2. SR95103 acts as a competitive antagonist
The examination of the antagonism shown by SR95103 was not described by a
classical Schild plot with a slope of one. However, this observation cannot be used to
exclude a competitive mode of action (see Section l.C). The modified Schild analysis
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was consistent with two molecules of GABA, but one molecule of antagonist
interacting with the receptor. Intuitively, this is reasonable, if binding of two molecules
of GABA to different sites are required to open the channel and binding of a single
molecule of antagonist at either site would be sufficient to prevent opening.
Arylaminopyridazine GABA derivatives are competitive antagonists at the vertebrate
GABA-A receptor. They displace [3H]GABA or [3H]muscimol from their binding sites
(Chambon et al., 1985; Heaulme et al., 1986a; 1986b), and displace physiological
dose-response curves to GABA to the right in a parallel manner without reduction of
the maximal response (Chambon et al., 1985). [3H]SR95531 labels specific binding
sites, from which it is displaced by GABA, GABA-agonists and bicuculline,
suggesting that the GABA binding site is involved. A patch-clamp study on bovine
chromaffin cells, showed as well that SR95531 acted mainly as a competitive GABA-
antagonist at the single channel current level (Hamann et al., 1988). Although SR95103
is less potent in Ascaris than in mammalian preparations, the same mechanism of action
seems to be involved.
3. Only one molecule of SR95103 antagonizes the action of two molecules of
GABA
Like the Hill equation, the Schild or modified Schild equations are based on
simplified theoretical models of drug-receptor interaction. Such theoretical models may
not be valid, but are believed to provide a reasonable approximation of antagonist-
receptor interaction. Both equations involve the same hypothesis (see Section l.C); the
difference is that the modified Schild equation allows a stoichiometry greater than one
for the agonist and/or antagonist interaction with the receptor. There is strong evidence
from the agonists studies (see Section 3), that two molecules of GABA interact with the
Ascaris GABA receptor. The modified Schild equation is therefore more appropriate
than the classical Schild equation to describe the data This seemed to be confirmed here
by slope less than one for the classical Schild plot; and by the fact that the modified
Schild analysis gave a better fit for the linear regression. The Schild plot and modified
Schild plot were used in this study, to describe the interaction antagonist-GABA
receptor. However, the Kg was estimated using the theoretical predicted equation, and
not the fitted equation: i.e. with N and M fixed to integral values, according to the best
estimates (Waud and Parker, 1971). This method limits the error made on Kg
estimation.
Williams et al. (1988) applied the modified Schild equation to results obtained on
the glutamate receptor. They reported that, apparently, only one molecule of the
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glutamate antagonist 2-amino-5-phosphonopentanoic acid (AP-5) was required to block
the effects of two molecules of quinolinate or NMDA. However, a stoichiometry of one
means also that only one molecule of antagonist can actually bind the receptor. This is
more difficult to explain especially since competitive antagonists are supposed to
interact with the agonist binding site in the same manner than the agonist itself. One
possible explanation is the non equivalence of the agonist binding sites. There is
already biochemical evidence for the non equivalence of the two a subunits on the
torpedo nicotinic receptor, and that an antagonist, MBTA, labels only one of the
subunit (Raftery, Conti-Tronconi, Dunn et al., 1984). Purification of these subunits
confirmed that they were not strictly equivalent (Raftery et al., 1984). In the case of the
vertebrate GABA-A receptor, purification, sequencing, and cloning of the various
subunits, predict that the GABA binding sites may be slighdy different, since several
types of subunits have been isolated, [31, (32, (33 (see Schofield, 1989, for review).
However, if the two GABA binding sites were different in Ascaris, some agonists
could be more selective for one site or the other. Such compounds would show a Hill
number not greater than one. All the GABA agonists tested in Section 3, even the rigid
ones, showed a Hill number greater than one, suggesting that they can bind both sites.
However, this does not exclude the possibility of having two non-equivalent GABA-
binding sites in Ascaris. It is however surprising that SR95103, which has a very
flexible GABA moiety, can only bind one site. Structure-activity studies in vertebrate
strongly suggested that the antagonist properties of arylaminopyridazine derivatives of
GABA rely on the presence of accessory binding sites (Wermuth et al., 1987). It is
conceivable that only one set of accessory binding sites is present on the receptor; so
that only one molecule of antagonist can bind effectively the receptor. Another plausible
explanation is that the presence of one large molecule of SR95103 bound to the
receptor, blocks the access for another antagonist molecule to the second GABA
binding site. All three explanations are plausible, but the existence of only one set of
accessory binding sites on the receptor seems the most attractive. Identification and
study of these putative sites, may be achieved by examining the protein domains of
each subunits.
CONCLUSION
The Ascaris GABA receptor appears under two aspects: like the GABA-A receptor
in terms of agonist properties, and unlike the GABA-A receptor in terms of antagonists
properties. The Ariens theory of accessory binding sites would explain the lack of
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potency of the competitive antagonists bicuculline, pitrazepine, securinine and the order
of different potency found with SR95531 and SR95103.
The quantitative analysis of SR95103 antagonism is consistent with a competitive
mechanism where only one molecule of SR95103 is required to block the action of two
GABA molecules. In order to obtain more informations on the type of antagonism
involved, the actions of SR95103 were explored at the single channel level and are the
subject of the next section.
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SECTION 6:
EFFECTS OF SR95103 ON GABA-ACTIVATED SINGLE-
CHANNEL CURRENTS FROM ASCARIS SUUM
INTRODUCTION
In the previous section the action of SR95103 on the GABA receptor of Ascaris
muscle has been examined using a current-clamp technique. SR95103 was shown to
produce a parallel shift to the right in conductance dose-response curves, but that the
classical Schild plot (Arunlakshana and Schild, 1959) had a slope less than one. This
observation however did not exclude competitive antagonism since it was possible to
use a modified Schild plot (Williams et al., 1988) to describe the observations. In order
to investigate further the action of SR95103 on Ascaris GABA receptors, a patch-clamp
study was carried out to look at effects at single-channel level. It appears that most of
the antagonism was competitive but evidence for a small non-competitive component is
seen at high concentrations.
I METHODS
1. Preparation
The muscle dissection has been described in the general methods Section. Clean
membranes were obtained by collagenase treatment (350UI/ml). The enzyme was
applied for 20-30 minutes in extracellular solution without added calcium (solution D)
and the temperature was maintained at 352C. The enzyme treatment was stopped when
vesicules started to form at the surface of the muscle cells membranes. The preparation
was then maintained in extracellular solution (solution E) and at 22QC. Patch-pipettes
were filled with intracellular solution (solution F). So an outside-out patch has a cation
concentration of 149mM on both side of the membrane; an outside CI concentration of
51mM (extracellular concentration), and an inside CI concentration of 153mM
(intracellular concentration), giving a Nemst potential for CI of +27.9 mV. GABA-
activated CI channels were recorded with a membrane potential of -50mV, the resulting
driving force for CI ions corresponded to a difference in potential of -77.9mV. EGTA
was used in the pipette solution to buffer the intracellular concentration of Ca and limit
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the occurrence of Ca-activated CI channels present in Ascaris muscle cell membrane
(Thorn and Martin, 1987).
2. Drug-application
Drugs were applied via a perfusion system in the small experimental chamber
containing the membrane patch. After the formation of an outside-out patch, the patch
pipette was transferred to a small chamber which could be isolated from the rest of the
preparation by a separation so that the whole muscle flap was not exposed to the drug.
3. Patch-clamp
3.1. Technique
a. Outside-out patch formation
Standard patch-clamp techniques were used to obtain outside-out patches (Hamill,
Marty, Neher et al., 1981). The formation of an outside-out patch is illustrated in
Figure 37. A giga-seal (resistance greater than 1 GO) was obtained by gentle suction
applied to the electrode. A high voltage step (100mV) was then applied to the patch
electrode, to break the membrane. The reading of a negative patch-pipette potential
allows to check that the membrane had broken and the electrode had penetrated the cell
(the potential was close to the value of membrane potential, -20 to -30mV). Once inside
the cell, the patch-pipette was slowly lifted up and the membrane reformed a giga-seal
but in an outside-out conformation.
b. Recording technique
Patch electrodes were made from micro-haematocrit capillary tubes (Garner glass
7052) pulled on a two stage vertical puller (David Kopf) and had a resistance of 1-
5M£2. Sylgard™ was used to coat electrodes, to improve the frequency responses
(typically greater than 2kHz). Currents were recorded with a List EPC-7 and a modified
Sony Betamax video system. An agar-plug electrode made with Agar 150mM KC1 set
in a polythene tube, was used to minimize junction potentials.
c. Data-processing
Records on tape were played back into a CED 1401 interface, connected to a DCS
286 PC computer and under the control of PAT software (Dr J.Dempster, Strathclyde
University). Records were filtered by a laboratory made 8-pole Bessel filter, -3dB at
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Figure 37: Diagram illustrating the making of an outside-out patch
(From Ogden and Stanfield, 1987) A gigaseal is formed by contact with the membrane
and a slight suction applied to the micropipette. A high voltage pulse (lOOmV), is then
applied to break the membrane. Once inside the cell, the micropipette is then carefully
lifted until the membrane reseal in die outside-out conformation.
(1) Formation of a gigaseal by gentle suction
(2) Breaking of the membrane by applying a high-voltage pulse
(3) Reseal (whole cell conformation)
(4) The pipette is gently pulled and a membrane patch is formed in the outside-out
conformation.
Formation of an outside-out patch
1kHz, and sampled at an interval of 100|is. When the signals were filtered at 1kHz
(-3dB), the rise-time of the 8-pole Bessel filter was 0.36ms and the dead-time of the
system was 0.20ms.
The PAT software was used to obtain current amplitude histograms which were
used to measure proportions of the time when 1,2,3,...N channels were open. Records
with less than 5% of all openings appearing as simultaneous openings were selected
and used to measure channel open- and closed-times; the double openings were edited
and not used for analysis. The threshold for detection was set at 50% of the unit
channel current. This method of detecting the transition between open- and closed-
times is different to that described previously on the same preparation (Martin, 1985).
The "effective mean open times" described previously (Martin, 1985) approximates to
the mean "long" bursts in this study. The PAT software produced files of open and
closed durations, which were transferred to a mainframe computer for further analysis.
3.2. Data analysis
Before any kinetic analysis, the records must be checked for stationarity. Non-
stationarity of channel behaviour can be defined as a systematic drift in the channel
open- or closed- states durations. Channel behaviour by definition is a probabilistic
process so that open and closed states durations vary, but they do so in a non systemic
way.
a. Stationarity
It was possible to examine open times and closed times in sequence and to test for
changes in their properties with time. Desensitization, for example, may produce after a
delay, an increase in the mean closed-time and a reduction in the probability of the
channel being open. CUSUM plots (Glasbey and Martin, 1986) were used to test for




for j=l,...,n; where Xi is the rank order of the ith closed time, Xmean is the mean
rank. A random fluctuation about 0 is expected for channels which show stationarity
behaviour. The significance of the deviation may be tested by determining Da, the
5.
maximum value of i where a=9, 1 and 1/9 and then estimating the three p
l+«x-l).£
-24aDa2
values for the maximum deviations: p = 2 exp[ ——] (see Glasbey and Martin,
n%n+l)
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Figure 38: CUSUM plot of closed and open times
A: Closed times; ordinate, CUSUM; abscissa, observation number. The p values were
0.17,0.95 and 0.13. The closed times were considered to be in random order.
B: Open times; ordinate, CUSUM; abscissa, observation number. The p values were
0.12; 0.89; and 0.39. The open times were considered to be in random order.












J i I i I




/v ,v 'A., A
V/a> "—Vx^v
iJ-X.
-I 1 L _L J
80 160 240 320 400
Observation number
140
1986). An example of these plots is shown in Figure 38; it can be seen that there is no
evidence of change in channel properties throughout the record. This and similar
observations on other patches, showed no evidence of non stationarity throughout the
records.
b. Independence of channel open probability
If channels in a patch have the same probability of being open and are independent,
then the distribution of the proportion of time, Pr, that 0,1,2,...N, channels are open
will be described by the binomial distribution:
where p is the probability that an individual channel is open and N is the number of
channels present. The probability (p) of an individual channel being open was
calculated from the areas under the amplitude histograms. If the proportions of total
recording time spent with 1,2,....N, channels open were Ti,T2,...TNthen:
Ti+2T2+...+NTN
P= N
The fraction of time which r channels and only r channels were open was calculated
from the T values. The binomial distribution was the used with the value of p to predict
the proportion of time with only 0,1,2,...N channels open.
c. Exponential curve-fitting
In these experiments, individual channel activations were interrupted by short
closed-times. Bursts of openings were therefore defined as groups of openings
separated by closed times shorter than a specified time, Tcrit- Tcrit was chosen to make
the proportion of long closing misclassified (as short) equal to the proportion of short
intervals misclassified (as long), by solving numerically the equation:
2_g(Tcrit/Ts) = g(-Tcrit/Tm)
(Colquhoun and Sakmann, 1985), where Ts and Tm are short and intermediate time
constants in the distribution of all closed times. An interval of l-2ms was used so that
only brief closings were classified as gaps in bursts. After Tcrit had been determined,
the files of open and closed times were rearranged to give files of burst durations.
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The next stage in the analysis was the fitting of exponentials to the distributions of
closed and burst durations. Only events greater than 0.5ms (twice the dead time) were
used to fit 1,2,3 or 4 exponentials to each data file to see which was the best fit. A
maximum likelihood procedure was used to estimate the parameters of the probability
density function (p.d.f.) which best describes the distributions:
k
p.d.f. = \1 -^-.e(-l/Ti)
A-t Ti
i=l
where aj represents the area of the i1*1 component (£a=l), Ti is the fitted time constant,
t is the time in milliseconds and k is the number of exponentials fitted. A decrease of
three log units with each additional component fitted was taken as a significant
improvement in the fit.
d. Correction for missed events
After the exponentials had been fitted to the burst and closed times, it was possible
to correct for missing events, using the method described below (Colquhoun and
Sakmann, 1985). It was assumed that very short closings and openings will be missed
in the usual analysis of open and closed times because of the limited resolution of the
recording technique. The number of short events was estimated by extrapolation from
the data which had been recorded.
- The total number of closed times and burst times were estimated from the
observed number of events; this was done separately for the closed and burst times by
the use of the following equation:
^ai(e("tmin/Ti)-e("tmaxfri))
i=l
where n is the number of observed events greater than the threshold time (tmin^Orims)
during the recording period (tmax) and N is the estimated number of events; at and Tj
are the area and time constant of the i1^ component, respectively.
- The total time spent in gaps within bursts mxs, i.e., gaps shorter than Tcrit,
including those undetected, was calculated using:
k
hits ~ Ngaps. [XaiTi-ai(Tcrit+Ti).e(-Tcrit/ri)]
i=l
where Ngaps is the total number of closed times estimated previously; the other symbols
have defined above and refer to the closed times.
142
 




where ai and Ti refer to the areas and time constants of the two components of the burst
duration distribution.
- The corrected total open time Copen> was calculated using:
where NgapS is the estimated total number of gaps. The corrected mean open time
estimated in this way is shorter than the mean open time estimated in any other way
because it allows for missed short events and reduces the mean value.
- If it is assumed that there are few gaps in the "short" bursts, the corrected
mean length of an individual opening in a long burst is then:
m _ N'-Jong" bursts- T"i0ng" bursts ■ HITS*° N short gaps + ^"long" bursts
where N"iong" bursts is the estimate number of long bursts, T"iong" bursts is the mean
duration of the long bursts and Nsh0rt gaps is the estimated total number of short gaps.
IIRESULTS
The following report is based on the analysis of experiments performed on 11
outside-out patches obtained from separate parasites.
1. GABA (3|iM) activated channels
Non-symmetrical CI concentrations across the patch (41mM outside, 153mM
inside) were used throughout this series of experiments to increase the amplitude of the
single channel currents (at -50mV) and to further test the identity of the ions flowing
through the channels. Figure 39 shows a representative I/V plot of the main (most
frequent) conductance state seen in a particular patch. The plot shows inward
rectification and a reversal potential of +27mV; the rectification and a reversal potential
close to this is predicted by the Goldman constant field equation (Hille, 1984a) for a CI
Copen — (Nburst- mb) ~ mTS
where Nburst is the estimated total number of bursts.
- The corrected mean open time Cmot» was calculated using:
1.1. Single channel current-voltage relationship
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Figure 39: Main state GABA channel I/V relationship
A: Channel openings to the main state at four potentials from +50 to -50mV.
B: Plot of main state channel currents at different potentials. The reversal potential was
near +27mV, the Nernst CI potential. The solid line shows a plot of the I/V relationship
predicted by the Goldman-Hodgkin-Katz constant fields equation with a single channel
permeability of 6.3 10"14cm3s_1. Note the inward rectification.
50mV 10mV ■10mV -50mV
/*Mf
paLS/W 20ms
ion-channel under these conditions. The CI estimated permeability for CI is
6.3xl0"14cm3s"1, assuming that the permeability for other ions is insignificant.
1.2. Main state conductance
GABA channels in Ascaris are characterized by the presence of more than one
conductance state (Martin, 1985). Figure 40 shows example of the main conductance
state and two less frequently observed subconductance states. The main state at -50mV
had an amplitude of 1.7pA, which corresponds to a chord conductance of 22pS, if a
driving force of 77mV is assumed. The two subconductance states had amplitude of
1.0 and 0.5pA at -50mV (conductances of respectively 13 and 6.5pS). In the following
analysis, the main state conductance was used because it occurred most frequently. The
small subconductance state was automatically rejected during analysis, whereas records
had to be edited manually in the case of the larger subconductance state since its
amplitude: l.OpA corresponded to the threshold set for open and closed states
detection.
1.3. Channels have the same Popen
The application of 3(iM GABA to outside-out patches produced the simultaneous
opening of up to three channels. If GABA channels in a patch have the same probability
of being open and are independent, then the distribution of the proportion of time, Pr,
that 0,1,2,...N, channels are open will be described by the binomial distribution.
Figure 41 shows predicted and observed values of Pr from a typical patch record with
three channels present, and p=0.082. It can be seen that observed and predicted values
are close; this supports the hypothesis that the channels behave independently and have
the same open probability. Similar results were obtained from all the patches. As a
result of these observations, the GABA channels were assumed to be homogenous.
2. Effects of SR95103 on GABA activated channels
2.1.Reduction of channel opening frequency
a. SR95103 decreases the opening frequency
Figure 42 shows the inhibitory effect of SR95103 on opening frequency of GABA-
activated channels at -50mV. At this time scale, openings are seen as clusters of inward
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Figure 40: GABA channel main state and subconductance states
The closed state (C); the 0.44pA subconductance state, (Si); the 1.45pA
subconductance state, (S2); and the 2.24pA main state conductance (at -50mV).
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Figure 41: Independence of the channels
Observed and binomial distribution of the proportion of time channels were, predicted
to be, open in a patch. The horizontal bars are the observed values for the % time spent
with 0,1, 2 and 3 channels open. The arrows indicate the values predicted by the
bino^al distribution with n=3, the total number of channels present in the patch, and









Figure 42: Inhibitory effect of SR95103 on GABA channel opening
A: control; GABA 3^tM, Popen=0.036
B: GABA 3|xM + SR95103 30nM, Popen-0.025
C: GABA 3^iM+SR95103 100|lM, Popen=0.001













Figure 43: GABA channel current-amplitude histograms and the lack of effect of
SR95103
A: Control, GABA 3p.M, I=-1.74±0.02pA (mean±SE)
B: GABA 3^iM + SR95103 30tiM, I=-1.64±0.04pA (mean±SE)
C: GABA 3(lM + SR95103 IOOjiM, I=-1.72±0.03pA (mean±SE)
Current(pA)
current spikes (Figure 42A). SR95103 30(iM reduced the frequency of opening
(Figure 42B). The addition of SR95103 100|iM further reduced the frequency of
opening (Figure 42C). When the antagonist was washed from the preparation, the
opening frequency returned to normal (Figure 42D). The proportion of time an
individual channel is open can be estimated from the current histogram (see above). In
this experiment illustrated in Figure 43, the control p was 0.036 (Figure 43A); in the
presence of 30fiM antagonist p was reduced to 0.025 (Figure 43B) and in the presence
of 100|iM antagonist, p was 0.001 (Figure 43C). In order to compare the level of
antagonism between the experiments, the percentage antagonism was defined as:
p
% antagonism = 100.(1 - -5s1)"c
where Psr is the probability of an individual channel being open in the presence of
SR95103, andPc is the control probability in the absence of antagonist. In the presence
of SR95103 30p.M, the percentage of antagonism was 53±11.6% (mean±SE, n=4); in
presence of SR95103 100|iM, it was 77.8±8.2% (mean±SE, n=5). The degree of
antagonism was shown to be dose-dependent.
b. The modified Hill equation describes the action of SR95103
Figure 44 shows the dose-response relationship for the percentage of antagonism
and the fitted modified Hill equation. With 3(iM GABA as the agonist, the Hill
coefficient was 0.98, suggesting that only one molecule of SR95103 combines with the
GABA receptor; the concentration producing half saturation, IC50, was, 24(iM. The
estimated percentage of inhibition at saturating concentrations of antagonist was 97%.
The fact that the maximum antagonism is near 100% suggests that most, but perhaps
not all of the antagonism is produced by an action at a single site on the GABA
receptor.
2.2. Effect on channel amplitude
The lack of effect of SR95103 on the amplitude of GABA single-channel currents is
illustrated in Figure 43, which shows the current amplitude histograms for the traces
shown in Figure 42. The current amplitude histograms were fitted and described by
Gaussian distributions. The control amplitude was -1.74±0.02pA (mean±SE) (Figure
43A); in the presence of SR95103 30qM it was -1.67±0.04pA (mean±SE) (Figure
43B); in the presence of SR95103 100qM, it was -1.72±0.03pA (mean±SE) (Figure
43C). Similar results were obtained for all the other experiments. It was concluded that
SR95103 does not affect single-channel conductance.
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Figure 44: Percent inhibition dose-response curve
Ordinate: percent inhibition in the presence of 3|0,M GABA of <3>pe/nn<j proloahi /itj
Abcsissa: SR95103 concentration.
The line fitted was a least-squares estimate of parameters for the modified Hill equation:
maximum percent inhibition, 97%; IC50, 24p.M; N, 0.98. The number besides each
mean value is the number of experiments performed with this concentration of
antagonist.
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2.3. Effects of SR95103 on burst distributions
Bursts were defined as the total duration of a sequence of openings and closings,
with the openings separated by closings less than Tcrit, a burst always starting and
ending by an opening. With a higher time resolution it can be seen that the burst
duration was reduced in the presence of SR95103 100|J.M, but not at 30)iM (Figure
45). The main apparent effect was a reduction in the mean burst length at IOOjiM
concentration of the antagonist.
The effects of SR95103 on burst-times were further explored by examining the
burst time distributions. The main result is that 30|iM has no significant effect on burst
duration and burst distribution, but 100|iM significantly reduced the burst duration by
increasing the proportion of brief bursts. This effect was described quantitatively by
fitting exponential distributions. In the experiment illustrated in Figure 46, the control
GABA 3|iM distribution was best described by the sum of two exponentials:
where pdfburst is the burst probability density function and t is time in milliseconds.
Thus there appears two types of burst: "short" and "long"; 56.5% of the bursts were of
the short type with a mean duration of 3.1ms; the long type of burst had a mean
duration of 33.2ms, and comprised 43.5% of the bursts. The short bursts appeared to
be mostly single short openings, whereas the long bursts were mostly multiple
openings, the effect of SR95103 30|iM on this distribution was small (Figure 46B), in
contrast to the effect of SR95103 100(iM (Figure 46C), where the burst distribution
was best fitted by:
The main effect was to increase the proportion of short bursts, in this experiment
from 57 to 82%. Similar results were obtained in other experiments and are
summarized in Table 12. The Table 12 shows that there is a statistically significant
increase in the proportion of short bursts with 100(iM but not 30(J.M SR95103, and that
there is no significant effect on the mean duration of the short or long bursts at either
concentrations. It is evident that the increase in the proportion of short bursts in
presence of 100|iM SR95103, is responsible for the reduction in mean burst duration.
This increase in the proportion of short bursts can be reversed by increasing the
agonist concentration. In one experiment, SR95103 60(iM, produced an increase in the
proportion of short bursts from 25% to 83%; an increase in GABA concentration from
3(J.M to 6(iM then, partially reversed the effect of the antagonist and decreased the




Figure 45: Effects of SR95103 on channel currents seen at high time resolution.
A: Control GABA 3|iM
B: GABA 3^iM + SR95103 30^iM
C: GABA 3fiM + SR95103 100|iM, note the short bursts













Figure 46: Frequency histograms: burst distributions
A: Control GABA 3p.M, pdf = e^3'1^ + 3^ e^"^33 2\ mean burst duration=16.1ms
B: GABA 3^M + SR95103 30^tM, pdf = e( t/16) e{ t/26J\ mean burst
duration= 19.4ms




Table 13. These observations were consistent with a surmountable action of SR95103
at the single channel level.
2.4.Effects of SR95103 on closed times distribution
The antagonism of SR95103 is associated with a dose-dependent increase in long
closed times as illustrated in Figure 42. The effects of SR95103 on closed-times
distributions were examined by fitting exponentials to describe the p.d.f.. Control
GABA 3|iM were best described by three exponentials. In one representative patch the
result was:
_ °-29 (-t/0.7) , 0-16 (-t/6.0) 0.55 (-1/63)p.d.f.ciosed = xy c ' e + 63 e"
where p.d.f.ci0sed is the closed time probability density function and t the time in ms.
This result is comparable to that reported previously (Martin, 1985), and shows that
there are at least three closed states giving rise to the brief (mean duration 0.7ms),
intermediate (mean duration 6.0ms) and long (mean duration 63ms) types of closings.
The effect of 30 and 100(iM SR95103 on the distribution of closed times of this patch
was to increase the duration of the intermediate and long closings. The closed time
distribution for the same patch with 30pM SR95103 was best described by:
n d f , . _ M P("t/1.7) 036 (-t/15.4) 054 (-1/133)p.a.i.closed 15 4 133
The mean closed time increased from 35.8ms to 77.7ms; the mean duration of the
intermediate closings increased from 6 to 15.4ms and the mean duration of the long
closings increased from 63 to 133ms.
At lOOpM, the mean closed time increased to 99.6ms; the mean intermediate closed
time to 21.8ms and the mean long closed time to 215ms. The closed time distribution
was best described by:
n a f , , _ Ml (-t/0.7) 022 (-t/21.8) 0A4 (-1/215)p.a. i.closed ~ 07 21 8 215
No increase in the number of components was required to describe the closed times
distributions in this or other patches; therefore no increase in the number of closed
states in presence of the antagonist could be detected. The effects of SR95103, 30(iM
and lOOpM on the other patches was very similar and was characterized by an increase
in the duration of intermediate and long closings. However, there was a large variation
in mean estimates for the intermediate closings and long closings, due to the variation in
the number of channels present in the patch. In contrast, SR95103 had no consistent
effect on the duration of the brief closings (Table 12). In the presence of GABA alone,
an increase in the two long closed time constants is expected when the GABA
concentration is reduced (Martin, 1985) and reflects the decrease in open probability.
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Table 12: Summary of GABA-activated channel properties in the absence and presence
of SR95103. Each observation is the mean from experiments on at least four patches.
* p<0.05 T-test.
Control GABA 3pM + GABA 3|iM+








































Table 13: Effects of SR95103 on GABA channel burst distributions and the partial
reversal by increasing GABA concentration
GABA 3(iM GABA 3|iM GABA 3|iM GABA10|iM
control SR95103 30(iM SR95103 60|iM SR95103 60|iM
Corrected
mean burst 23.8 20.2 2.3 8.7
duration (ms)
pdfburst
abf 0.246 0.241 0.829 0.591
Tbf (ms) 0.5 0.7 0.4 1.0
abs 0.754 0.759 0.171 0.409
Tbs (ms) 31.4 26.4 11.7 19.8
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2.5. Effects of SR95103 on mean open times
One difficulty in measuring open times directly is that unresolved brief closings lead
to bursts appearing as long single openings (see Colquhoun and Hawkes, 1982). This
artefact increases the observed open times. However it is possible to compensate for
these unresolved closings by estimating the true number of closings by extrapolating
from the closed time distributions. The estimated total open time is divided by the true
number of closings to obtain the mean open time. The control mean open time with
GABA 3(iM for one typical patch was 11.9ms; this was unchanged in presence of
SR95103 30|iM : 12.0ms; and reduced to 5.8ms in presence of SR95103 100(iM.
Table 12 shows the mean±SE values obtained from the different patches and shows
that there is a significant decrease in the corrected mean open time in the presence of
100[iM antagonist but not in the presence of 30(iM.
in DISCUSSION
This patch clamp study of SR95103 was carried out to further investigate the mode
of antagonism. The percentage of antagonism dose-response curve was described by
the modified Hill equation with a coefficient close to one. The lower antagonist
concentration (30|iM), reduced the probability of the channel being open without
significantly affecting the burst distribution, the corrected mean open time or the
channel main conductance. The higher (100|iM) antagonist concentration increased the
proportion of short bursts, reduced the corrected mean open time but the reduction in
mean burst duration did not reach statistical significance. As with 30|iM, the channel
conductance was not altered. In the subsequent discussion, it is suggested that
SR95103 acts mostly as a simple competitive antagonist; but at high concentration there
is an additional small non competitive action, possibly a channel block.
1. Possible kinetic scheme for the antagonism
A variety of patch-clamp studies in different preparations have been carried out on
GABA-activated channels where the open time distributions were described by two
exponentials and the closed time distributions described by three exponentials: on
Ascaris (Martin, 1985), mouse spinal cord neurones (Jackson, Lecar, Mathers et al.,
1982; Sackmann, Hamill and Borman, 1983; Mathers, 1985), on chick cerebral
neurones (Weiss and Magleby, 1989), and bovine chromaffin cells (Bormann and
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Clapham, 1985). More recently, MacDonald, Rogers and Twyman (1989), have
described an additional open time component, which suggests a greater complexity in
the interaction GABA-receptor-channel. Molecular biology studies on the GABA
channel structure (Schofield et al., 1987) have shown that the receptor-channel complex
is formed by two a and two (3 protein transmembrane subunits. The (3 subunits were
shown to bind GABA (Barnard, Darlison and Seeburg, 1986), so it was concluded that
two agonist molecules combine with the receptor channel complex. In reality, the
situation is more complex and new subunits have been discovered (see Section IB.);
moreover monomelic receptor-channel complexes are also able to be activated by
GABA, suggesting that not only the [3 subunits can bind GABA. In contrast to GABA,
the results of the current-clamp experiments presented in Section 5, and the percent
inhibition dose-response curve presented here, suggest that only one molecule of
SR95103 binds the receptor and is responsible for most of the antagonism. Figure 47
shows a minimal kinetic scheme which may explain these observations. It predicts
(Colquhoun and Hawkes, 1977; 1982) three components for the closed time
distribution and two components for the open time and burst distributions.The effect of
a competitive antagonist would be associated with: an increase in the number of
components in the closed time distribution; a reduction in the probability of the channel
being open and no change in the open or burst distributions (if the open states and the
closed states which are part of the bursts are the same in the absence as well as in the
presence of the antagonist).
2. SR95103 antagonism
These experiments did not reveal an increase in the number of components in the
closed time distribution in the presence of the antagonist. But, the long duration of
many closed times seen in the presence of the antagonist reduced the number of events
available for analysis and the ability to separate components. There was also the further
complication of different numbers of channels present in each patch; this complication
gave rise to considerable variation in estimates of the mean duration of "intermediate"
and "long" closed-times. Both of these factors would make the detection of any extra
long closed-states in the presence of the antagonist difficult.
2.1. SR95103 (30|iM) behaves as a competitive antagonist
The channel main conductance was not altered in the presence of the antagonist. On
the basis of the Monod-Wymann-Changeux model (Colquhoun and Hawkes, 1977,
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Figure 47: Minimal kinetic scheme for agonist and antagonist action
The receptor channel complex (R) has two sites to which the agonist (A), but one site to
which the antagonist (B), combine. Open states (*) may occur only after isomerization of
the single-bound or double-bound agonist receptor-channel complex. The dissociation
constant for the first agonist molecule to combine (Kqi) is much larger than for the second
agonist molecule (Kd2); the dose-response relationship would then be approximated by the
modified Hill equation with N=2. The channel closing rates are al and a2. al is larger
than a2 so that RA2* is the long open state. The channel opening rates are pi and P2. The




















1982) for GABA-receptor interaction, the addition of a simple competitive antagonist
predicts no change in the channel mean open time or burst distribution. There was no
significant effect of SR95103 (30|TM) on corrected mean open times and burst
distributions, so it is argued that at this concentration, this antagonist behaves as a
competitive antagonist. Moreover a non-competitive mechanism, predicts at the current-
clamp level a reduction in the maximum response and a reduction in the slope dose-
response curves at higher antagonist concentrations; such an effect with concentrations
of SR95103 up to ImM (Section 5) was not detected.
A variety of experimental preparations have been used to look at the action of
arylaminopyridazine GABA derivatives on the vertebrate GABA-A receptor. Binding
studies (Chambon et al., 1985; Heaulme et al., 1986a, 1986b) and electrophysiological
studies (Chambon et al., 1985; Michaud et al., 1986; Desarmenien et al., 1987) have all
indicated that arylaminopyridazine derivatives of GABA act as competitive antagonists
at the vertebrate GABA-A receptor. SR95531, the potent analogue of SR95103 in
vertebrate, has been examined at single-channel level in bovine chromaffin cells
(Hamann et al., 1988). It was found that SR95531 reduced the open probability of
GABA channels without affecting the channel main amplitude and open times and burst
durations kinetics, an effect compatible with competitive antagonism. Therefore the
antagonism produce by SR95103 (30|iM) is compatible with a competitive mechanism
at the channel level.
2.2. SR95103 (100|iM) antagonism shows a non-competitive
component
In contrast to 30|iM, the effects of 100|iM SR95103, are not compatible with a
simple competitive mechanism, because they are associated with significant reduction
of the corrected mean open time and increase in the proportion of short bursts.
At the single-channel level, the effects of a channel block on the burst duration
depends on the duration of the blocked state. If the blocked state is brief (less than
Tcrit)) the burst duration and the number of gaps per burst would increase, but that was
not detected However if the blocked state is longer than Tcrit, the observed mean long
burst duration would get shorter and the mean open time in the long burst would
decrease. Although the observed reduction in mean long burst duration did not reach
statistical significance, there was a significant reduction in the corrected mean open time
in the long bursts: — . To estimate the corrected mean open time in the long bursts, all
«2
brief closings were assumed to occur in the long bursts (see Methods). Figure 48
shows the observed linear relationship between the reciprocal of this duration and the
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Figure 48: Effect of SR95103 on mean open time in long bursts
Ordinate: reciprocal of mean open times in long bursts.
Abscissa: concentration of antagonist. The slope (obtained by least-squares regression was
l.^M-^s*1 and could be interpretated as the channel bloccking rate at -50mV.
 
concentration of SR95103. The reciprocal of this duration approximates to the sum of
the rate constants leading from the open state, providing there is little interconversion
between the monomelic open state and the dimeric open state (Colquhoun and
Hawkes, 1982). The slope of the plot in Figure 48 is then an estimate of the channel
blocking rate constant: 1.44M_6s"1. Although these findings may be in favour for a
channel block mechanism at this concentration, they do not predict the observed
increase in proportion of short bursts.
SR95531 has shown an antagonism compatible with competitive mechanism at
single channel-current level, however, an additional channel block mechanism could
not be excluded at high concentration of SR95531, but the potent action of SR95531
did not allow further analysis (Hamann et al., 1987).
Arylaminopyridazine derivative of GABA are said to be highly specific for the
GABA-A receptor, but a small inhibitory effect on glycine receptors as well as on the
GABA receptor, of rat cortical neurones has been described for SR95103 by Michaud
et al., (1986), but not for other analogues such as SR95531. GABA and glycine both
conduct CI, Barker and Mac Burney (1979) suggested that the CI channels were
identical, so that the channel could be a common site of action. These two reports raise
the question of a channel block mechanism in addition to the competitive antagonism of
SR95103. In light of the molecular biology results, it appears that recognition site and
channel are not two separate entities which can be coupled or uncoupled, but are
formed by the complex organization of protein subunits. This, however does not
exclude similarities between GABA- and glycine-receptor-channel complex (Schofield
et al., 1987).
Conclusion: although SR95103 may act in part as non competitive antagonist, this
cannot play a big role in the antagonism of GABA conductance responses, since high
concentrations of SR95103 did not depress the maximum response seen in current
clamp experiments, and no voltage-sensitivity was detected in voltage-clamp
experiments (see Section 5). This study shows that SR95103 antagonism is compatible
with a competitive mechanism but there is an additional non competitive element at high
concentration, which shares some of the properties of a channel block.
This Section shows further evidence that SR95103 is mainly a competitive
antagonist at the Ascaris GABA receptor. Thus, SR95103 appears to have a mechanism
of action similar to that at vertebrate GABA-A receptors.
Current-clamp and patch-clamp studies of the antagonism produced by SR95103
strongly suggest a competitive mechanism. This result is important, since SR95103 and
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more generally arylaminopyridazine derivatives of GABA were shown to be
competitive at vertebrate GABA-A receptors. The same mechanisms seem to be
involved in Ascaris and vertebrates.
The next Section explores the antagonist properties of various pyridazine GABA
derivatives and study their structure-activity relationship on Ascaris muscle. It will be
shown that the structure-activity relationships of pyridazine GABA derivatives are
different in Ascaris, and that all the potent compounds behave like SR95103.
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SECTION 7:
ANTAGONIST PROPERTIES OF AMINOPYRIDAZINE
DERIVATIVES AT THE ASCARIS MUSCLE GABA
RECEPTOR
INTRODUCTION
In Section 5, the arylaminopyridazine GABA derivative SR95531 was shown to be
very weak at antagonizing GABA responses in Ascaris, but its close analogue
SR95103 was more potent with a Kb=64|iM. This contrasts with the vertebrate
GABA-A receptor, where SR95531 is the most potent antagonist, approximately 20
times more potent than SR95103 (Heaulme et al., 1986b). It was suggested then, that
arylaminopyridazine GABA derivatives may show structure-activity relationships in
Ascaris different from those found at the vertebrate GABA-A receptor. In this section,
other arylaminopyridazine derivatives obtained from SANOFI were tested, and their
relative potency in Ascaris muscle and in mammalian were compared. The results
obtained with these compounds reinforced the hypothesis of the presence of different
accessory sites on the Ascaris GABA receptor. To further explore the structure-activity
relationships of arylaminopyridazine derivatives in Ascaris, a collaboration was set up
with Professeur C.G.Wermuth from the "Laboratoire de Neurochimie du CNRS",
Strasbourg University, France. New pyridazine derivatives were synthesized in
Strasbourg by J.M.Sitamze and Dr M.Schmitt, and then tested by myself on Ascaris




The muscle dissection has been described in the general method (Section 2) and in
Section 3. As for the experiments with GABA-agonists, the muscle flap was bathed in
high-Cl, low-Ca Ringer (solution B), and maintained at 222C.
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2. Drug application
Because of the limited quantities of antagonist available, the muscle was not
perfused continuously. The experimental chamber (2.5ml) was carefully drained, and
then flushed with 5ml of the next drug solution. When dose-response curves were
required, drugs were bath-applied in a cumulative manner, without intermediate
washing between the concentrations (see Section 3).
3. Current-clamp
3.1. Technique
The technique used here, has been described previously in Section 3, all signals
were recorded with an Axoclamp 2A (Axon Instruments) in current-clamp mode, which
permits the use of higher resistance for the electrodes: typically 20-50MQ.
3.2. Analysis
a. GABA
The effect of GABA was determined by measuring the change in input conductance.
When dose-response relationships were required, they were described by the modified
Hill equation (Nistri and Constanti, 1979), and estimates for Agmax, EC50 and N were
obtained using a non linear regression programme (Patternsearch, Colqhoun, 1971).
See Section 3 for details.
b. Antagonists
- Screening
Initially, the action of ImM antagonist was examined on the change in membrane
conductance induced by GABA 30|lM. The percentage of antagonism was then
estimated:
% antagonism = 100.(1-^^)
where Agc is the change in membrane input conductance produced by GABA 30|iM,
and Agant is the change in membrane input conductance produced by GABA 30)iM +
antagonist ImM, measured after 10 minutes application of the antagonist. Compounds
detected as reasonably potent antagonists with this method, were then tested at several
concentrations on GABA dose-response curves.
167
Figure 49: Structure of pyridazine derivatives
Code name r1 r2 r3 r4
sr95103 -C3H6COOH -ch3 -H -c6h5
sr95531 -C3H6COOII -H -H -c6h40ch3
sr42666 -C3H6COOH -ch3 -H -c6h40ch3
sr95132 -c3h6cooh -C6H5 -H -c6h5
sr42640 -c3h6cooh -H -ch3 -C6H5
sr42627 -c3h6cooh -ch3 -H -C6h4ch3
sr95133 -c3h6cooh -ch3 -H -CioHs
ncs194-83 -c4h8cooh -ch3 -h -c6h5
ncs247-90 -c3h6cooh -ch2ch3 -H -c6h5
ncs248-90 -c3h6so3 -H -C9H10
ncs249-90 -c3h6so3 -ch3 -h -c6h5
ncs250-90 -c3h6so3 -ch2ch3 -H -c6h5
ncs251-90 -c3hgcooh -ch2c6h6 -h -c6h5
ncs252-90 -c3h6cooii -chch3ch3 -h -cfihs
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- Quantitative evaluation
The effect of SR42666, SR95132 and NCS247-90, were examined on GABA
dose-response curves. Because of the natural variation of EC50, Agmax and N, a
control GABA dose-response curve was obtained from the same cell, before, or after
the antagonist application. Dose-ratios were measured and, examined using a Schild
plot (Arunlakshana and Schild, 1959) or a modified Schild plot (Williams et al., 1988),
see Section 5 for more details and Section l.C for discussion.
4. Statistical test
Means and standard errors were calculated. Statistical significance was assessed
using a two-tailed independent t-test.
5. Chemicals
Details can be found in Section 2. For the pyridazine derivatives, the full chemical
names are also given in Section 2; but Figure 49 summarizes their chemical structures.
ItRESULTS
The results reported here are based on the analysis of experiments recorded from 59
cells from 40 preparations. Cells selected for recording and analysis had a resting
membrane potential greater than -20mV and a resting input conductance: 2.34±0.06|i.S,
mean±SE, n=59. Recordings were also rejected if the resting input conductance failed
to return to at least 80% of the control
1. Pyridazine derivatives are inactive on membrane conductance
SR95103, SR95531, SR42666, SR42640, SR42627, SR95133, NCS194-83,
NCS247-90, NCS248-90, NCS249-90, NCS250-90, NCS251-90 and NCS252-90,
were initially tested at ImM, in the absence of GABA or any GABA-agonist. No
change in membrane conductance was produced. Figure 50 illustrates the inactivity of
ImM: SR42666 (A), SR95531 (B), SR95132 (C), on membrane conductance.
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Figure 50: Inactivity of arylaminopyridazine derivatives of GABA on membrane
conductance
A. SR42666: go=2.2p.S; in the presence of ImM SR42666 for ten minutes, Ag=0p.S.
B. SR95531: go=2.2|iS; in the presence of ImM SR95531 for ten minutes, Ag=0|iS.








2. Potency of a series of arylaminopyridazine GABA derivatives in Ascaris
muscle
Figures 51 and 52, illustrate the effects produced by ImM SR95133, SR95132,
SR42666, SR42627, and SR42640, on the GABA (30pM) response,.
SR42640 was the weakest compound, and antagonized 7.5±7.5% of the GABA
response (mean±SE, n=2). SR42627 was not very potent either, with only 21.0±8.0%
of the GABA response antagonized (mean±SE, n=2).
SR95133, the a-naphtyl derivative, antagonized 58.0±8.0% of the GABA
response (mean±SE, n=4), and was therefore more potent than SR95531 (44.2±6.1%,
mean±SE, n=5, see Section 5).
The two most potent antagonists were, SR42666, and the 4-phenyl derivative,
SR95132, with an antagonism of 76.6±6.6% (mean±SE, n=5), and 89.0±3.4%
(mean±SE, n=5), respectively. All these results are summarized in Table 14.
Figures 53, 54, 55 and 56, illustrate the effects of ImM of the newly synthesized
compounds: NCS194-83, NCS247-90, NCS248-90, NCS249-90, NCS250-90,
NCS251-90, and NCS252-90, on the change in membrane conductance produced by
30(iM GABA.
The two sulphonic acid derivatives: NCS249-90 (n=2) and NCS250-90 (n=2),
were totally inactive, both producing 0% antagonism. NCS248-90 is very weak, ImM
antagonized 13.7±5.1% of the response produced by GABA 30pM (mean±SE, n=6).
NCS 194-83, the 5-aminovaleric derivative, antagonized 45.5±9.3% (mean±SE,
n=4) of the response produced by 30[iM GABA. NCS 194-83 is therefore not a potent
antagonist at the Ascaris GABA receptor, but retains some activity considering the
change in the structure of the side-chain.
NCS247-90 ImM antagonizes nearly 100% of the response produced by 30|aM
GABA, 95.2±3.1% (mean±SE, n=5).
NCS252-90 and NCS251-90 antagonized respectively, 80.9±2.5% (mean±SE,
n=4) and 99.2+0.8% (mean±SE, n=3), of the response to GABA (30|iM).
Thus, SR95132, NCS247-90, NCS251-90 and NCS252-90 are the most potent
compounds, being apparently as potent as SR95103. SR42666 also retains a certain
degree of antagonism.
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3. SR95132, SR42666 and NCS247-90, like SR95103, antagonize GABA
responses in an apparent competitive manner
In vertebrates, arylaminopyridazine derivatives act as competitive antagonists, they
displace [3H]GABA and [3H]muscimol from their binding sites (Chambon et al., 1985;
Heaulme et al., 1986a; Heaulme et al., 1986b) and decrease [3H]diazepam binding
stimulated by GABA (Heaulme et al., 1986a). Section 5 shows that in Ascaris,
SR95103, 100|iM, 300|J.M and 1000|iM, displaces GABA dose-response curves to the
right in a parallel manner without a decrease in the maximum response. The dose-
dependency was best described by the modified Schild equation (Williams et al.,
1988), suggesting that the mechanism was competitive and that only one molecule of
SR95103 interacted with the GABA receptor. The actions of the three more potent
compounds: SR95132, SR42666, and NCS247-90, were therefore examined at 100,
300, and 1000(iM, on GABA cumulative dose-response curves.
SR95132, SR42666 and NCS247-90, displaced GABA dose-response curves to
the right in a parallel manner without a reduction in the maximal response, suggesting a
competitive mechanism.
Figure 57 illustrates the antagonism produced by SR95132, A is the control GABA
responses, B and C are the GABA responses in the presence of respectively 100(iM
and 300(iM SR95132. All three recordings were obtained from the same cell. Dose-
ratio were calculated for each cell, as the ratio of EC50s estimated for the GABA dose-
response curves in the absence and presence of antagonist. Figure 58 shows the dose-
response curves for the traces shown in Figure 57.
The dose-dependent antagonism produced by SR42666 is illustrated in Figure 59,
where A is the control GABA response, B, C and D are the GABA responses in the
presence of respectively, 100, 300, and 1000|J.M. The corresponding dose-response
curves are illustrated in Figure 60.
Figure 61 illustrates the dose-dependency of NCS247-90 antagonism, where A is the
control GABA dose-response, B, C, and D, the GABA dose-response in the presence
of respectively 100, 300, 1000|iM NCS247-90. The corresponding dose-response
curves are illustrated in Figure 62. As expected, GABA dose-response curves were
displaced to the right in a parallel manner and without decrease in the maximal
response: there was no variation of N or Agmax (t-test, p<0.05), only EC50 was
significantly increased in the presence of 100, 300 and 1000|iM NCS247-90 .
The classical Schild plots for SR95132 and SR42666: log(DR-l) against logXg,
were linear but with a slope different from one: 0.73 for SR42666 (n=13), and 0.74 for
SR95132 (n=9). However, the classical Schild plot does not account for a
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Figure 51: Effects of ImM SR42666, SR42640, SR95133 and SR95132 on the change in
membrane input conductance produced by GABA 30|iM.
A. Effect of SR42666 ImM: resting input conductance, g0=2.2|iS; GABA 30|iM,
Ag=5.0fJ,S; SR95103 ImM + GABA 30|iM, Ag=1.0|iS; %antagonism=8()%.
B. Effect of SR42640 ImM: resting input conductance, g0=2.2p,S; GABA 30|iM,
Ag=4.6jiS; SR95133 ImM + GABA 30p.M, Ag=3.9|iS; %antagonism=15%.
C. Effect of SR95133 ImM: resting input conductance, go=2.0|iS; GABA 30|iM,
Ag=3.7(iS; SR95103 ImM + GABA 30(iM, Ag=2.2p.S; %antagonism=35%.
D. Effect of SR95132 ImM: resting input conductance, go=2.0(iS; GABA 30(iM,
Ag=3.7p.S; SR95103 ImM + GABA 30jiM, Ag=0.7|iS; %antagonism=81%.
QABA 30nM SR95132 ImM
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Figure 52: Effect of ImM SR42627 on the change in membrane conductance produced by
GABA 30|J.M.
Resting input membrane conductance, go=2.2pS; GABA 30|iM, Ag=4.4(iS; SR42627
lmM + GABA 30|J.M, Ag=3.1|iS; %antagonism=29%.
GABA30jxM
SR42627ImM
Figure 53: Effect of ImM NCS247-90 on the change in membrane input conductance
produced by 30(iM GABA
Resting membrane conductance go=2.7pS; GABA 30|iM, Ag=1.9|iS; ImM NCS247-90 +
30(iM GABA, Ag=OpS; 100% antagonism.
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Figure 54: Effect of ImM NCS248-90 and NCS194-83, on the change in membrane input
conductance produced by 3()|iM GABA
A. NCS248-90: resting membrane conductance go=1.9|iS; GABA 30[iM, Ag=1.9|iS;
ImM NCS248-90 + 30pM GABA, Ag=1.7(iS; 10% antagonism.
B. NCS 194-83: resting membrane conductance go=2.0p.S; GABA 30|iM, Ag=1.3}iS;
ImM NCS 194-83-90 + 30|iM GABA, Ag=0.8p.S; 38% antagonism.
OABA30jiMNCS248-90ImM
GAM30}xMNCS194-83imM
Figure 55: Effect of ImM NCS249-90, NCS250-90 and NCS252-90 on the change in
membrane input conductance produced by 30|lM GABA
A. NCS249-90: resting membrane conductance go=3.2|iS; GABA 30|lM, Ag=1.3p.S;
ImM NCS249-90 + 30pM GABA, Ag=1.4pS; 0% antagonism.
B. NCS250-90: resting membrane conductance go=3.2p.S; GABA 30|iM, Ag=1.8|iS;
ImM NCS250-90 + 30|iM GABA, Ag=1.8[iS; 0% antagonism.
C. NCS252-90: resting membrane conductance go=3.1|iS; GABA 30|iM, Ag=1.4(iS;






Figure 56: Effect of ImM NCS251-90 on the change in membrane input conductance
produced by 30|iM GABA
Resting membrane conductance go=3.2|iS; GABA 30}lM, Ag=0.8|J.S; ImM NCS251-90 +
3()p.M GABA, Ag=0}iS; 100% antagonism. Note that antagonism is stabilized rapidly
within five minutes. The small hyperpolarization seen at the start of the washing phase
may be an artefact due to the start of the perfusion.
 
stoichiometry greater than one between GABA and its receptor (see Section l.C and
Section 5). The modified Schild equation was therefore used (Williams et al 1988), and
log(DR.2-l) was plotted against logXB. The plot yielded a better fit for SR95132
(Ra2=o.66 against Ra2=0.62 for the Schild plot). The linear fit was not improved for
SR42666 (Ra2=0.61), but for both compounds, the slopes of the modified Schild plots
were close to one: 1.02 for SR42666 (n=13) and 1.06 for SR95132 (n=9).
Schild and modified Schild analysis were also used for NCS247-90. The best fit
was obtained for the modified Schild plot with N=2, Ra2=0.77 (against Ra2=0.74 , for
the classical Schild plot). Unexpectedly, the slope of the classical Schild plot was,
1.00±0.1 (meaniSE, n=13), and the slope of the modified Schild plot was,1.5010.23
(meanlSE, n=13). However the fit was better with N=2.
These results are consistent with a model which involves the activation of the
receptor by two molecules of GABA, but only one molecule of SR42666, SR95132,
and possibly NCS247-90, interact with the receptor to block this effect. This is in
goodagreement with previous results obtained with SR95103 in Section 5. Although
these results do not establish such mode of action, they provide a good description of
the interaction antagonist-receptor, and allow the estimation of apparent dissociation
constants. The dissociation constant, Kb, was estimated, assuming N=2 and M=l:
SR42666: KB=104.8119.7|iM (meanlSE, n=13), for SR95132: KB=65.0120.3qM
(meaniSE, n=9), NCS247-90: KB=54.6116.2|iM (meanlSE, n=13).
NCS247-90 appears therefore more potent than SR95103 and SR95132, but the
difference is not statistically significant. Whereas SR42666 is definitely less potent than
SR95103 (t-test, p<0.05).
SR42666, SR95132 and SR95103 act in a competitive-like manner on the Ascaris
GABA receptor. SR95132 is equipotent to SR95103 (KB=63.8il2.9[iM, meanlSE,
n=14) and both are the most potent of the series, whereas SR42666 is less potent.
Since arylaminopyridazine GABA derivatives seem to act as competitive antagonist at
the Ascaris GABA receptor, as they do at the vertebrate GABA-A receptor, it is of
interest to compare and discuss their respective structure-activity relationships.
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Figure 57: Effects of 100 and 300|lM SR95132 on GABA dose-response relationship.
A. Control responses to cumulative application of GABA. Note the small depolarization
observed with 3p.M GABA, there was no detectable change in membrane input
conductance.
B. In the presence of SR95132 100|J.M.
C. In the presence of SR95132 300|iM.














Figure 58: Dose-dependence of the antagonism produced by SR95132.
The lines correspond to the fitted modified Hill equation, whereas the points are the
experimental data.
A. GABA dose-response curves
Control GABA dose-response curve, values estimated for the modified Hill equation are
Agmax=2.8|xS, EC50=19.8^M, N=2.6.
GABA dose-response curve in the presence of lOOjiM SR95132, values estimated for the
modified Hill equation are: Agmax=2.8p.S, EC50= 37.6|iM and N=3.2.
GABA dose-response curve in the presence of 300|iM SR95132, values estimated for the
modified Hill equation are: Agmax=2.8|iS, EC50=77.2|jM and N=3.5.
B. Schild and modified Schild plot;
(0) Schild plot, log(DR-l) versus logB, B is the concentration of antagonist. Correlation
coefficient, r=0.71; slope=0.74±0.25, p=0.02 (F test); Ra2=0.62.
(■) Modified Schild plot, log(DR2-l) versus logB. Correlation coefficient r=0.75;





Figure 59: Effects of 100, 300 and lOOOfiM SR42666 on GABA dose-response
relationship.
A. Control responses to cumulative application of GABA, go=2.2|i.S. Note the transient
depolarizing response in the presence of 10(J.M GABA and the gain change in the presence
of 300 and 1000|iM (one unit is 2mV).
B. In the presence of 100|iM SR42666. Not the gain change in the presence of 1000|iM
(one unit is 2mV).
C. In the presence of 300|iM SR42666. Note the gain change in the presence of 300 and
1000pM (one unit is 2mV).
D. In the presence of IOOOjiM SR42666. Note the gain change in the presence of 300 and
lOOOfxM (one unit is 2mV).
The corresponding dose-response curves are illustrated in Figure 60A.
lOO^M30(^M10(X)^M
Figure 60: Dose-dependence of the antagonism produced by SR42666.
The lines correspond to the fitted modified Hill equation, whereas the points are the
experimental data.
A. GABA dose-response curves
Control GABA dose-response curve, values estimated for the modified Hill equation are
Agmax=4.9|lS, EC50=39.9p.M, N=2.1.
GABA dose-response curve in the presence of 100|iM SR42666, values estimated for the
modified Hill equation are: Agmax=4.1|iS, EC50= 59.8p.M and N=1.7.
GABA dose-response curve in the presence of 300pM SR42666, values estimated for the
modified Hill equation are: Agmax=4.3p.S, EC50=89.7|iM and N=1.8.
GABA dose-response curve in the presence of 1000|iM SR42666, values estimated for the
modified Hill equation are: Agmax=4.3|iS, EC50=134.4p.M and N=3.2.
In this particular cell Agmax appears to be smaller in the presence of SR42666. However,
in other cells, Agmax can be higher in the presence of SR42666, than for the control. This
obviously illustrates the difficulty in measuring accurately high membrane conductance.
SR42666 as the other arylaminopyridazine GABA derivatives tested quantitatively, did not
affect Agmax or N significantly.
B. Scliild and modified Schild plot;
(o) Schild plot, log(DR-l)/logB, B is the concentration of antagonist. Correlation
coefficient, r=0.78; slope=0.73±0.17, p=0.001 (F test); Ra2=0.62.
(■) Modified Schild plot, log(DR2-l)/logB. Correlation coefficient r=0.78;





Figure 61: Effects of 100, 300 and 1000p.M NCS247-90 on GABA dose-
relationship.
A. Control responses to cumulative application of GABA.
B. In the presence of lOOpM NCS247-90.
C. In the presence of 300p.M NCS247-90.
D. In the presence of 1000p.M NCS247-90.
The corresponding dose-response curves are illustrated in Figure 62A.
 
Figure 62: Dose-dependence of the antagonism produced by NCS247-90.
The lines correspond to the fitted modified Hill equation, whereas the points are the
experimental data.
A. GABA dose-response curves
Control GABA dose-response curve,values estimated for the modified Hill equation are
Agmax=2.4|iS, EC50=31.2^tM, N=1.8.
GABA dose-response curve in the presence of 100|iM NCS247-90, values estimated for
the modified Hill equation are: Agmax=2.6|iS, EC50= 71.2|iM and N=1.7.
GABA dose-response curve in the presence of 300pM NCS247-90, values estimated for
the modified Hill equation are: Agmax=2.6|iS, EC50=85.6|lM and N=2.0.
GABA dose-response curve in the presence of 1000|lM NCS247-90, values estimated for
the modified Hill equation are: Agmax=2.8}iS, EC50=265.0[iM and N=1.9.
B. Schild and modified Schild plot;
(o) Schild plot, log(DR-l)/logB, B is the concentration of antagonist. Slope=1.00±0.17,
p<0.001 (F test); Ra2=0.74.
(■) Modified Schild plot, log(DR2-l)/logB. Slope=1.50±0.23, pcO.OOl, (F test);




■ + NCS257-90 lOOpM
□ + NCS247-90 300mM





1. Order of potency of the arylaminopyridazine GABA derivatives: comparison
with the vertebrate GABA-A receptor
When applied at ImM against 30(iM GABA, SR42627, SR42640, SR95133,
SR95132 and the two derivatives tested in Section 5, SR95103 and SR95531, present
an order of potency different from what it is observed at the vertebrate GABA-A
receptor (Wermuth et al., 1987):
at the Ascaris GABA receptor,
SR95103=SR95132>SR42666>SR95133>SR95531>SR42627>SR42640
at the mammalian GABA-A receptor
SR95531>SR42666>SR42627>SR95103>SR95133>SR42640>SR95132.
SR95531, the most potent displacer of [3H]GABA in the mammalian brain with a Kg
of 0.15|iM, is a weak antagonist on Ascaris muscle since only 44.2±6.1% of the
GABA (30[iM) response is antagonized by SR95531 ImM (mean±SE, n=5).
Similarly, SR42627, a rather good displacer of [3H]GABA in the mammalian brain
with a Kb of 0.55|iM, is one of the weakest antagonist in Ascaris muscle: 21.0±8.0%
of the GABA (30pM) response is antagonized (mean±SE, n=2). In contrast SR95103
and SR95132, respectively a moderate (Kb=2.20jiM) and a virtually inactive
(Kb=100|iM) antagonist at the vertebrate GABA-A receptor, are the most potent
compounds in Ascaris muscle; SR95103 antagonized 93.4±2.7% (mean±SE, n=5) and
SR95132, 89.0±4.4% (mean±SE, n=4) of the response to 30|iM GABA.
The measurement of the percentage of antagonism can be compared to a snapshot of
the antagonist-receptor interaction, since only one concentration of antagonist and
agonist are tested together. For that reason, it does not provide any information about
the type of antagonism involved or any real quantitative information. However, within
a family of compounds supposed to act in a similar manner such as the
arylaminopyridazine derivatives of GABA, the percentage of antagonism can be used to
determine their potency sequence.
The method is nonetheless a sensitive technique for detecting antagonism. The
GABA concentration used, 30|iM, is near to the EC50 for GABA, and therefore in the
middle of the linear part of the log dose-response curve. Because of positive
cooperativity between GABA and its receptor, the slope is greater than one, and as a
consequence the linear part of the curve is steep. For these reasons, any antagonism
would be very easily detected. Compounds producing nearly 100% antagonism or on
the contrary 0% antagonism, cannot be compared with each other since they are out of
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Table 14: Comparison of some arylaminopyridazine GABA derivatives potencies in
vertebrate with Ascaris suum muscle
(1) [3H]GABA displacement from rat brain membranes, Kg = dissociation constant
(Wermuth et al., 1987)
(2) %antagonism of the GABA 30|iM response, produced by lmM antagonist, in
Ascaris
(3) Kg = dissociation constant estimated from the modified Schild analysis, in Ascaris
VERTEBRATE ASCARIS MUSCLE
Kb (|iM) %antagonism Kb (|iM)
(1) (2) (3)
SR95531 0.15 44.2±6.1 (n=5) —
SR42666 0.31 76.6±6.6 (n=5) 104.8±19.7 (n=13)
SR42627 0.55 21.0±8.0 (n=2) —
SR95103 2.20 92.8±3.2 (n=5) 63.8±12.9 (n=14)
SR95133 2.60 58.0±8.0 (n=4) —
SR42640 10.40 7.5±7.5 (n=2) —
SR95132 100.00 89.0±3.4 (n=5) 65.0±20.3 (n=9)
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the linear part of the antagonist dose-response curve. The only solution is to change the
antagonist concentration and to use a lower concentration, in the case of two potent
antagonists, or a higher concentration, in the case of two weak antagonists. For
example, in the case of NCS251-90 which appeared to be a potent antagonist with an
antagonism of 99.2±0.8% (mean±SE, n=5) when tested at ImM, a lower
concentration, 100|iM, was tested in the same manner and the antagonism produced
was only 28%. Compared with SR95103 100|iM tested also in the same manner,
where only 11% of the response was antagonized, NCS251-90 does not appear much
more potent. It was decided that only compounds presenting a significant increase in
potency will be quantitatively tested on GABA dose-response curves.
The use of the percentage of antagonism is therefore a good screening technique,
providing the GABA concentration is chosen in the linear part of the log dose-response
curve, but should not be used for quantitative purpose.
2. Arylaminopyridazine GABA derivatives are competitive antagonist at the
Ascaris muscle GABA receptor
In Ascaris, the three most potent analogues: SR95103, SR95132 and SR42666,
have been shown to displace GABA dose-response curves to the right without a
decrease in the maximal response. The modified Schild plot, which accounts for the
positive cooperativity between GABA and its receptor, was linear with a slope of one,
suggesting a competitive mechanism in which only one molecule of the antagonist was
required to block the effects produced by two molecules of GABA. Although plausible
models for the drug-receptor interaction do not predict simple relationships as described
by the Schild and modified Schild plots; under simplifying limitations they can be
approximated by these plots and provide a reasonable description of the antagonist-
receptor interaction. In the patch-clamp study, 30pM SR95103 was shown to
antagonize GABA-activated channels, in a manner consistent with a competitive
mechanism but with an additional non competitive component detectable at a higher
concentrations (see Section 6). This non competitive component may represent only a
small proportion of the total antagonism since detected only at high concentration, and
may remain undetected with a less sensitive technique such as the current-clamp
experiments. In conclusion, on the basis of the results obtained with SR95103,
SR95132, SR42666, and NCS247-90, the mode of action of arylaminopyridazine
derivatives of GABA in Ascaris is considered to be competitive. The difference in
relative potencies for these compounds between the vertebrates and the Ascaris GABA
receptors gives evidence for their different structural requirements. However these
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structural differences do not involve the GABA binding site, since the flexible GABA-
like moiety of the pyridazine derivatives supposed to interact with the GABA
recognition site, is the same for all the analogues tested (except NCS248-90, NCS249-
90, NCS250-90 and NCS194-83). In vertebrate preparations, antagonist properties
rely on other parts of the molecule and may be interpreted in terms of Ariens theory of
accessory binding sites (Ariens et al., 1979). The differences in potency between
mammalian preparations and Ascaris are in favour of the presence of different
accessory binding sites.
3. Structure-activity relationship of a series of arylaminopyridazine GABA
derivatives on Ascaris muscle
The structure-activity relationships of pyridazine derivatives have been investigated
in great details in the vertebrate nervous system (Wermuth et al., 1987), and discussed
in terms of Ariens theory of accessory binding sites. The substituents on the pyridazine
ring appear to be of prime importance. Refer to Figure 49 for the chemical structures.
3.1. 6-substituent
In vertebrates, a very important role is played by the substituent in the 6-position
(Wermuth et al., 1987). In this study, all the analogues tested had a phenyl, substituted
or not, in 6-position on the pyridazine ring except SR95133 and NCS248-90. The role
played by the 6-substituent has been associated with the existence of additional binding
interactions with the receptor, involving 7t electrons (Wermuth et al 1987); in other
words, an accessory binding site as defined by Ariens et al. (1979). The naph^l 6-
substituent found in SR95133, presents, as well, 7t electrons for interaction with the
receptor, and may explain why SR95133 retains some antagonist properties. NCS248-
90 presents 7t electrons, but is a very weak antagonist. However, this compound
possesses a sulphonic acid group instead of a carboxylic group; and it has been shown
by the inactivity of NCS249-90 and NCS250-90 that the presence of a sulphonic group
instead of a carboxylic group, is strongly detrimental.
3.2. 6-phenyl substituent
The substituent effects on the 6-phenyl can influence the potency. For example
substituents increasing the electron density (-CH3 as in SR42627) or the aromatic
system (-OCH3 as in SR95531), increase the potency in mammalian preparation, in
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contrast to electron-withdrawing substituents (Wermuth et al., 1987). In vertebrate, the
order of potency for the 6-phenyl substituents is:
-OCH3 > -CH3 > -H
(SR42666 > SR42627 > SR95103)
and in Ascaris it is:
-H > -OCH3 » -CH3
(SR95103 > SR42666 > SR42627)
suggesting an opposite effect.
However, in Ascaris, the 6-phenyl substituent is not the limiting factor for the
antagonist properties, the presence of a 4-substituent on the pyridazine ring is more
important.
3.3. 4-substituent
The role played by the 4-substituent in Ascaris is illustrated by the potent
antagonists in Ascaris: SR95103, SR95132, NCS247-90, NCS251-90 and NCS 252-
90, all substituted on the 4-position of the pyridazine ring, respectively with a methyl, a
phenyl, an ethyl, a benzyl, and an isopropyl group. This contrasts with the vertebrate
preparations where the substitution by a methyl or a phenyl group on 4-position on the
pyridazine ring, was always detrimental to the antagonist potency (Wermuth et al.,
1987). Among these analogues, only SR95132, SR95103, and SR95531, have been
tested on mammalian preparation, and the order of potency for the 4-substituent is:
-H > -CH3 » -C6H5
(SR95531 > SR95103 > SR95132)
By comparison in Ascaris, it is:
-C6H5 - -CH3 »-H
(SR95132 - SR95103 » SR95531)
To illustrate the importance of the 4-substituent in Ascaris, one can compare the
potency of SR42666 and SR95531: their chemical structure is identical except for the 4-
methyl present on SR42666, but not on SR95531. SR42666 is more potent than
SR95531 in Ascaris, than in mammalian preparations. The presence of a 4-substituent
appears to be a prerequisite for the antagonist potency of pyridazine GABA derivatives
in Ascaris, whereas the opposite situation is found in vertebrates (Figure 63).
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Figure 63: Structure and activity of arylaminopyridazine GABA derivatives in Ascaris.
The percentage indicated besides each analogue is the percentage of antagonism of the
response to GABA (30p.M) produced by ImM antagonist. All the potent GABA antagonist
in Ascaris present a 4-substituent. The comparison between SR42666 and SR95132
illustrates the different structural requirements at the Ascaris GABA receptor: SR42666 and
SR95531 are identical except for the 4-methyl present on SR42666, and SR42666 is more


















Section 3 has shown that sulphonic acid derivatives of GABA are inactive in
Ascaris. The two sulphonic acid derivatives, NCS249-90 and NCS250-90, are
identical respectively to SR95103 and NCS247-90, except for the sulphonic acid
group. They are totally inactive at ImM. NCS248-90 presents also, a sulphonic acid
function on the side chain, and was found to be a very weak antagonist. This
compound presents also a large substituent in the 6- and 5-positions on the pyridazine
ring. 5-substituents (see compound SR42640) are usually detrimental in vertebrates
(Wermuth et al., 1987) and in Ascaris .
The presence of a sulphonic acid group instead of a carboxylic acid group is
therefore highly detrimental to the antagonistic properties of pyridazine GABA
derivatives.
3.5. Side-chain length
As illustrated by NCS194-83, a longer side-chain (5C, like S-aminovaleric acid) is
detrimental to the potency of the compound (NCS 194-83 is equivalent to SR95103
except for the side-chain length). Despite this some antagonistic activity remains,
suggesting that the molecule can still recognize the GABA binding site. A similar
situation is found in the vertebrate where the side chain length of arylaminopyridazine
GABA derivatives can be altered without a complete loss of activity (Wermuth et al.,
1987).
4. Computer graphics modelling
In vertebrates, computer graphic modelling of the pyridazinyl GABA-derivatives
and other known GABA antagonists was used to illustrate a plausible model for the
interaction of competitive antagonists with the GABA-A receptor (Figure 64, Wermuth
and Rognan, 1987). The superimposition of (+)bicuculline, pitrazepine, iso-THAZ,
SR95531, RU5135, securinine and tubocurarine shows the existence of a cationic and
an anionic system separated by 4.7A, which may mimic the GABA molecule and bind
the GABA recognition site (Wermuth and Rognan, 1987). The antagonist properties
can be explained by the presence of additional binding sites corresponding to the
various aromatic or aliphatic rings of these compounds. The free access zone situated
beneath the anionic and cationic systems is required for the interaction with the GABA-
A binding site. The inactivity of 4-substituted aminopyridazine GABA derivatives and
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Figure 64: Superimposition of some GABA-A antagonists using computer graphic
modelling (photographs from Wermuth and Hoffmann, Centre de Neurochimie du CNRS).








The superimposition of (-t-)bicuculline, pitrazepine, securinine, RU5135, SR95531, iso-
and THAZ shows the existence of a cationic and an anionic systems separated by
approximately 4.7A, which may mimic the GABA molecule and bind the GABA
recognition site. The antagonist properties can be explained by the presence of additional
binding sites corresponding to the various aromatic or aliphatic rings of these compounds.
The free access zone situated beneath the anionic and cationic systems is likely to
correspond to the zone of interaction with the GABA-binding site.
194
Figure 65: Supcrimposition of SR95132 and SR95531
The superimposition of these two analogues shows that the 4-substituent is found in
proximity of the GABA recognition site. The inactivity of 4-substituted analogues at the
vertebrate GABA-A receptor was explained in terms of restriction of the free access zone
required for interaction with the receptor. The volume occupied by the phenyl group of
SR95132 is visualized. (Photographs from Wermuth and Hoffmann, Centre de
Neurochimie du CNRS).
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some stereoisomers: (-)bicuculline, virosecurinine, allosecurinine, on the vertebrate
GABA-A receptor is explained by a restriction of this free access zone due to the
presence of substituents in this region (Wermuth and Rognan, 1987). Figure 65 shows
the superimposition of SR95531 and SR95132; the lack of activity of SR95132 on the
vertebrate GABA-A receptor, may be explained by the obstruction of the free access
zone required for receptor recognition by the phenyl group in the 4- position (Wermuth
and Rognan, 1987). Obviously this is not the case in Ascaris, and the 4-substituent is a
requirement for the antagonistic activity.
CONCLUSION
Applied to other known GABA-A antagonists such as iso-THAZ, RU5135,
pitrazepine, securinine, (+)bicuculline and its analogue (+)tubocurarine, the hypothesis
of accessory binding sites also seems to hold. In all these compounds, a slight
structural resemblance to GABA can be found: an electron rich area is separated by a
distance of 4.7A from a positively charged centre. All these antagonists also present
several aromatic or alicyclic ring systems, which are either close to the electron rich side
of the molecule (RU5135 and pitrazepine), or close to the cationic site (securinine), or
even on both sides (bicuculline and tubocurarine).
The existence of different accessory binding sites responsible for antagonist
properties in Ascaris can explain the inactivity of the classical competitive GABA-A
antagonists: bicuculline, pitrazepine, securinine (Holden-Dye et al., 1988),
tubocurarine and RU5135 (Section 4); in contrast, GABA-A agonists in Ascaris have
relative potencies similar to that on the vertebrate GABA-A receptor.
These differences are obviously of great interest in the search for new anthelminthic
drugs, and could lead to the synthesis of a potent GABA antagonists in Ascaris, which
are inactive in mammals and therefore without toxicity or secondary effects in the host.
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GENERAL DISCUSSION
In this study, the pharmacology of the Ascaris muscle GABA receptor has been
studied using an electrophysiological approach. Despite some differences: inactivity of
sulphonic acid derivatives, loss of relative potency of rigid analogues of GABA, the
agonist profile of the Ascaris GABA receptor is correlated with the vertebrate GABA-A
type. In contrast, the antagonist properties of the Ascaris GABA receptor appeared very
different from those of the vertebrate GABA-A type. None of the classical GABA-A
antagonists is potent, and the structure-activity relationships of the arylaminopyridazine
derivatives is different in Ascaris. These differences may be explained by the existence
of different accessory binding sites responsible for antagonist binding at the Ascaris
GABA receptor. More generally, the GABA recognition site appears to have been well
conserved throughout evolution (Walker and Holden-Dye, 1989); whereas the
antagonist accessory binding sites show a greater variation across species. This seems
to be valid for receptors of pharmacological interest, and more generally for "reactive
proteins", as stated by Black (1987):
"...I expect that hormones will turn out to be very similar to other
reactive proteins, enzymes, carriers and so on where only the reactive
sites are highly conserved across species with respect to amino-acid
composition. Therefore, whitfk. we may be entitled to expect the
functionality of hormones and their conjugate receptors to be highly
conserved across species, no such expectation is reliable when
exploring receptors with competitive antagonists, because a reasonable
interpretation ofmany structure-activity studies of agonists, antagonists
is that the antagonists can explore wider molecular areas of the receptor
than the native hormone can...".
Two important implications can be drawn from this statement. Firstly, the study of
comparative pharmacology gives some indications on where the selection pressure
exerts. To this respect, antagonists do not seem to exert a strong selection pressure; and
the main reason is because they are rarely naturally present in living organisms. When
naturally present in an organism, antagonists must be inoffensive. They may be strictly
localized to a specific organ, such as tetrodotoxin, which is highly concentrated in the
ovaries of the puffer fish (Sphareoides sp.), or like a-bungarotoxin, an acetylcholine
nicotinic blocker, which is localized in the venom glands of the Elapid snake, Bungarus
multicinctus. Antagonists may be also found in organisms which are not sensitive to
their action; this is the case of many plants which are obviously not sensitive to
neurotoxins. For example, among the GABA-A antagonists, picrotoxin is found in the
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seeds of a climbing shrub, Anamirta cocculus (Goodman and Gilman, 1985);
securinine is also found in a schrub, Securinega suffructicosa (Goodmann and Gilman,
1985) and bicuculline can be extracted from plants of the gender Corydalis (sp.)
(Curtis, Duggan, Felix et al., 1970). These examples also illustrate the role played by
antagonists in living organisms: they are not aimed at the host, but are targeted towards
potential predators or prey.
It is true that antagonists are rarely naturally occurring in an organism or in its
biotope. However, it would be wrong to say that antagonists are not able to exert any
kind of selection pressure. There are some cases where animals have developed
resistance to antagonists. Although tetrodotoxin is highly concentrated in specific
organs, it is also present in the whole organism and has access to nerves and muscle.
This was demonstrated accidentally in the course of embryological experiments on
interspecific grafts on salamanders, with species that make tetrodotoxin (Taricha and
Triturus) and species that does not (Ambystoma) (see Hille, 1984b). When a piece of
Ambystoma was grafted onto Taricha, the graft became paralysed, suggesting that the
toxin is freely diffusible and that the two kinds of salamanders have a major difference
in the toxin sensitivity of their Na channels. Saxitoxin, also a Na channel blocker, is
another example; it is synthesized by marine dinoflagellates which do not have Na
channels. In some conditions, these microorganism multiply and increase the toxin
concentration in the sea. In warm waters of the Pacific Northwest, toxic concentrations
in the sea can be found for major periods of the year. As a consequence, some animals
in the food chain have evolved and show some resistance to saxitoxin (see Hille,
1984b).
Parasites, with special reference to internal parasitism, have been subject to a
specific evolution. When compared to the free living species, they have evolved lately,
and are under a very high selection pressure. One characteristic and general tendency in
the evolution of internal parasites is that they tend to express the same phenotype than
their host, in order to avoid any harmful interference with the host and its resultant
rejection or destruction (Rogers, 1962):
"...The host-parasite relationship might be regarded as ultimately
reaching a steady-state in which two genotypes reach to give a common
phenotype on which selection might act. In response to selection a
change in phenotype might react differently on the two genotypes,
though in this state they could not react independently..."
But parasites have also to deal with life conditions specific to their nature. The
metabolism of intestinal parasites usually requires an adaptation to an anaerobic
environment. The adaptation to parasitism is therefore characterized by two apparently
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opposite tendencies; the necessity to evolve specific features related to its parasitic
nature, and the necessity to mimic the environment, to avoid host reaction. This is not
without implication on the strategies developed in antiparasitic drug research:
successful drugs act on a metabolism or enzyme specific of the parasite (Urquhart et
al„ 1987):
Benzimidazoles, such as thiabendazole, mebendazole, and
probenzimidazoles, such as, fenbedazole, albendazole, oxibendazole
etc... act by preventing the tubulin isomerization and desorganize the
cell endoskeleton.
Organophosphates, such as, dichlorvos, haloxon, trichlorfon, act as
anticholinesterase agents.
Salicylanilides, such as, nitroscanate, closantel interfere with enzymes
specific to the parasites in the ATP production.
Imidothiazoles and tetra-hydropyrimidines, such as, tetramisole,
levamisole, pyrantel, morantel, are specific agonists at the acetylcholine
receptor.
In the case of the GABA receptor, it appears that this receptor in Ascaris presents
strong similarities, in terms of its agonist profile, with the host GAB A-A receptor. It
would seem therefore that GABA receptors in parasites are not a good target for
anthelminthic drugs. However, Black's statement has a second important implication of
therapeutical order: an antagonist is more likely than an agonist to be successful,
especially since selectivity is an important factor in the therapeutic success of
antiparasitic agents. In insects, the GABA receptor-complex is already considered as a
target for insecticides: a primary target for toxaphen and cyclodiene, and a secondary
target for lindane and type II pyrethroids (Eldefrawi and Eldefrawi, 1987). All these
toxicants antagonize the GABA response by an action at the channel level. In Ascaris
muscle, TBPS and the pyrethroid, dieldrin, were found without effect on GABA
response (Colquhoun et al., 1989). This suggests that the GABA-gated CI channel in
Ascaris, differs from the vertebrate GABA-A-gated CI channel and from the GABA-
gated CI channel in insects. The CI channel associated with the GABA receptor in
Ascaris may be also a potential target for anthelminthic drugs. Already a chloride
transport blocker in renal tubules has been shown to antagonize GABA responses in
Ascaris probably by an action on the channel site (Holden-Dye et al., 1989). In
Ascaris, the GABA receptor itself is also a potential target for anthelminthic drugs,
providing these are antagonists. In fact, among the antiparasitic drugs acting on the
GABA-receptor complex in parasites, piperazine is a specific GABA agonist and even
if ivermectin antagonizes GABA, (Holden-Dye et al., 1988), its therapeutic mechanism
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of action is not clearly known. In conclusion, there is no GABA antagonist among the
actual anthelminthic drugs available. One possible reason for the absence of antagonist
in the actual anthelminthic pharmacopoeia, is that they are less frequently studied than
agonists. Antagonists are rare, they are usually large and complex molecules, and also
they are more difficult to study. Therefore structure-activity studies have not frequently
been carried out for antagonists. It must be said also, that most anthelminthics were
discovered well before that their mechanism of action was understood. The main
strategy in drug research is to modify the chemical structure of a known anthelminthic,
with the consequence of developing analogues with the same mechanism of action. To
this extent, benzimidazoles represent a very successful family of anthelminthics. In
contrast, to piperazines where piperazine itself is the only GABA agonist, its analogue
diethylcarbamazine has a different mechanism of action despite a structural
resemblance. This is in agreement with the fact that GABA agonists are not likely to be
successful as anthelminthics.
The story of the arylaminopyridazine derivatives is very unusual. Aminopyridazine
derivatives are known to interact with a great variety of receptors in the mammalian
nervous system. Some will be selective agonist at the serotonin, dopamine,
acetylcholine, noradrenaline, or benzodiazepine, receptors, (Wormuth, Bourguignon1,
Chambon ct al., 1989): Pyridizanyl GABA derivatives were developed with the
objective of designing GABA-mimetic drugs able to penetrate the central nervous
system, but quite surprisingly these compounds turned out to be specific and
competitive GABA-A antagonists (Chambon et al., 1985; Heaulme et al., 1986a,
1986b; Michaud et al., 1986; Gynther and Curtis, 1986; Mienville and Vincini, 1987;
Desarmenien et al., 1987; Hamann et al., 1988). When arylaminopyridazine GABA
derivatives are compared to other competitive GABA-A antagonists, they appear among
the most potent and specific GABA-A antagonists. The classical bicuculline for
example is not such a potent GABA antagonist (Enna and Snyder, 1977), and is not
highly specific to the GABA-A receptor either, since it has been shown to interfere with
glycine receptors (Goldinger and Muller, 1980; Michaud et al., 1986). Some GABA-A
antagonists are potent but not specific: pitrazepine (Gahwiler, Maurer and Wutrech,
1984), and the steroid amidine derivative RU5135 (Hunt and Clements-Jewery, 1981),
both interfere strongly with the glycine receptor (Hunt and Clements-Jewery, 1981;
Olsen, 1984; Simmonds and Turner, 1985; Curtis and Malik, 1985; Kemp, Marshall,
Wong et al., 1985), and to a less extent with the benzodiazepine binding site (Hunt and
Clements-Jewery, 1981). One is highly specific to GABA-A receptors, but has a low
affinity: securinine (Beutler, Karbon, Brubaker et al., 1985). Arylaminopyridazine
GABA derivatives are therefore potent and specific GABA-A antagonists in mammalian
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preparations. However, when administered in vivo, by IV or IP, these compounds
have a relatively low potency in eliciting clonico-tonic seizures suggesting that they do
not readily cross the brain blood barrier (Chambon et al., 1985). For this reason,
arylaminopyridazine GABA derivatives have no therapeutic application in mammals
yet.
Arylaminopyridazine derivatives of GABA appear as good candidates for a new
family of anthelminthic drugs. One of them, SR95132, has been shown in this study to
act specifically at the parasite GABA receptor. The structure-activity study of these
compounds has also shown that the structural requirements in mammals seem
incompatible with the structural requirements in Ascaris: gain in antagonistic activity at
the parasite site is associated with a parallel loss of activity at the mammalian site.
This study has shown that there are differences between the Ascaris and vertebrate
GABA receptors which might be usefully exploited in antiparasitic therapeutic. But one
question arise: is there really a need for new anthelminthic drugs? Another alternative
is vaccination (see Gutteridge, 1989). Parasites vaccines are potentially safer, cheaper
and more efficacious as prophylactics than drugs. Parasite vaccines already exist in two
cases in veterinary medicine:against piroplasmid protozoa and dictyocaulid nematodes,
however they are far from being developed for human purpose. The need of
antigenically defined vaccine, and the complex immunological responses of both the
host and the parasites, have introduced a delay in the discovery of acceptable human
vaccines. Nevertheless drugs will still be required for people or animals already
infected, for parasitic diseases for which vaccines have not been developed and for
people or animals that became infected because of failure or contre-indication of the
vaccine (Gutteridge, 1989).
Although the actual pharmacopoeia is rich in good antiparasitic drugs, there is a
need for new anthelminthics. Earlier, it was stated that the main strategy in drug
research is to modify the chemical structure of a known anthelminthic, with the
consequence of developing analogues with the same mechanism of action. One
detrimental consequence of this strategy, is the development of drug-resistance by
selection of the resistant strains of parasites. Concerning nematodes, benzimidazoles
are the chief compounds in that matter. Until now, antiparasitic drug-resistance was not
considered seriously, mainly because it occurred only locally and remained confined to
Australia and New-Zealand, where climatic conditions are favourable to the apparition
of such resistances (Waller, 1985). However, benzimidazoles resistance has now
spread in Europe, mainly in sheep and horses (Waller, 1985). No doubt that the
compensatory use of other available anthelminthics such as ivermectin, will produce a
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selection pressure and select resistant strains. Naturally occuring ivermectin-resistant
strains of Haemonchus contortus have already been reported in Brazil (Echevarria and
Trindade, 1989). There is therefore a constant need for drugs especially with new
mechanisms of action.
The GABA receptor in Ascaris, with special reference to its antagonist properties,
appears to be a potential target for anthelminthic drugs. To this respect, the exploration
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APPENDIX:
Some quantitative aspects of competitive antagonism are developed in this
appendix. The relationship between the dose-ratio and the antagonist concentrationin
particular will be considered.
Schild (1947a; 1947b; 1957) applied the notion of Null hypothesis and dose-ratio
to the analysis of competitive antagonism (see Section l.C). This work led
Arunlakshana and Schild (1959), to formulate a relationship between the dose-ratio and
the antagonist concentration. Their analysis is based on a very simple and non-
cooperative model for drug-receptor interaction, but is still widely used to determine
whether an antagonist is competitive or not. Although cooperativity between some
drugs and their receptors, such as GABA or acetylcholine, is now well established (see
Colqhoun, 1973); it is only recently that the modified Schild analysis, which account
for cooperativity, has been proposed as an alternative for the classical Schild analysis
(Williams et al., 1988). The emergence of new techniques, such as single channel
recording, has led to further complication of the models for drug-receptor interaction.
Here, the existence of the channel in two states: open and closed, and the existence
of intermediate complex, will be also considered. The relationship between the dose-
ratio and the antagonist concentration will be examined in these cases, and it will be
seen that the Schild plot is not always linear with a slope of one.
I Classical Schild equation
The classical Schild analysis is based on a simple model of drug-receptor
interaction:
Kb Kd
RB-c =»-R-^ ^RA (Ml)
where, R is the receptor not occupied; RA* is the receptor occupied by one molecule of
agonist; RB is the receptor occupied by one molecule of antagonist (*) signals that the
receptor is in an activated form; for example, in the case of GABA-A receptors, the
channel is open. Kd is the dissociation constant for the agonist, and Kb is the
dissociation constant for the antagonist. At equilibrium, by applying the law of mass
action, the proportion of channels open in can be expressed in function of the agonist
concentration, Xa, and in function of the antagonist concentration, Xb-




where [R]o is the total concentration in receptor: [R]o = [R]+[RA*]
[RA*] can be expressed in function of Xa:
IRA.*! - , and [ R)0 = [R].[l+|^]




In the presence of the antagonist, the proportion of channels open is:
Po. = IM!1
[R]+[RA*]+[RB] '
and [RB] can be expressed as a function of the antagonist concentration Xb, since at
equilibrium and by applying the law of mass action:
[R].XR
[RB] = °






In the presence of the antagonist, the proportion of channels open is smaller than in
the absence of antagonist. To obtain the same Po in the presence of the antagonist, the
concentration of agonist must be increased to a value Xa'. For the same proportion of
channels open, the ratio of the agonist concentration in the presence, Xa', and in the
absence, Xa, of antagonist, Xb, is the dose-ratio, DR = ^A-.ka




Kd Kd „ xbn
then'xI=^aW
and Xa'.Kd - kd.xa+Kd'^'Xb (A3).
Xb
If (A3) is divided by Xa and Kq, DR =1+t^, which can be written under the form ofkb
the classical Schild equation,
log(DR-l) = logXB - logKs (A4).
The same logical steps will be followed in the subsequent developments, but for the
sake of simplicity, the demonstrations are not presented.
II The modified Schild equation
The modified Schild equation is based on a similar model, but several molecules of
agonist or/and antagonists are allowed to bind the receptor. For example in the case of
two molecules of agonist and one molecule of antagonist:
ii
RB v Kb •* Rv K°^RA *
2 (M2),
where RA2* is the receptor activated and occupied by two molecules of agonist; Kd is
the dissociation constant of RA2*, and Kb is the dissociation constant of RB.
The relationship between dose-ratio and Xb becomes,
DR2 = 1+^ , which can be written:Kb
log(DR2-l) = logXB - logKB (A5).
If there were two molecules of antagonist, the relationship would be:
Xr2DR2 = l+TT-, which can be written:
kb
log(DR2-l) = 2 logXB - logKB (A6).
And more generally, if N molecules of agonist and M molecules of antagonist, bind
the receptor:
kr kD
RB^ ^R^ =-RA t^ N (M3),
Y M
the relationship would be: DRN =1+ ^ , which can be written under the general
form of the modified Schild equation (Williams et al., 1988):
log(DRN - 1) = M.logXB -logKB (A7).
N is the number of agonist molecules bound to the receptor, and M the number of
antagonist molecules bound to the receptor; Kb is the dissociation constant of RBm;
and Kd is the dissociation constant of RAn.
HI Two-state model
The receptor-channel can exist in two states: open or closed. It is assumed that if the
receptor is not occupied by the agonist, or is occupied by the antagonist, the channel is
closed, and that if the receptor is occupied by the agonist, the channel may be open or
closed:
Kd B ^ *
RB~c— R ^ RA
a (M4),
where RA is the receptor occupied by one molecule of agonist, but is not activated and
the channel is closed; RA*, is the receptor occupied by one molecule of agonist and
activated, the channel is therefore open; a is the channel closing rate, (3 is the channel
opening rate constant.
In the absence of antagonist, Po becomes:









and the dose-ratio, DR, can still be expressed in function of Xg and Kg: DR = 1+^- ,K-B
see the Schild equation (A4).
The addition of a closed state did not modify the relationship between the dose-ratio and




In the case of cooperative interaction, intermediate complex can be formed, RA and
RB may exist:
RB.v 'A RB r vKp'^ RA .. KpA. RA, — RA*
P (MS),
where Kdi is the dissociation constant for RA; Kd2 is the dissociation constant for
RA2*", Kgi is the dissociation constant of RB; Kg2 is the dissociation constant of RB2;
other symbols as before.
In the absence of antagonist, Po is:
Pi XA Xa2 J
In the presence of antagonist, Po is:
Po = 7 \ r (A12).
.a Kp2 Kpi .KD2.Xg2 Kpi .KD2.Xg Kpi .Kp2
P'l XA' Kgi.Kg2.XA'2 Kgi.XA'2 XA'2 J
The relationship between the dose-ratio and Xg becomes:
A.XA'.DR.(DR-l)+B.(DR2-l) = (C.Xg+D).Xg (A13),




In this caseDR is also dependent on the agonist concentration, Xa', and by
definition this means that the agonist dose-response curves, in the presence or absence
of the antagonist, are not parallel any more. If (RA) is very small compared to (RA2),
Kpi is very large compared to Kp2-
i v
If (A 13) is divided by Kqi,
KB1Kd2IXA-DR-(DR"1)+Kd2-Kbi-Kb2-(Dr2"1MKd2-Kbi-Xb+Kd2'Kb2)-Xb (a14),
Kbi'Rb2'Xa tends towards 0, so that (A14) can be simplified to,
Kd2-Kb1-Kb2.(DR2-1) = (Kd2.KBI.XB+Kd2-KB2).XB (A15).
If the intermediate complex (RB) is very small, Kbi must be very large. When (A15) is
divided by Kbi, simplification can be made since tends towards 0, and:
Kb2-(DR2-1) = XB2, which can be written in the form of the modified Schild equation
(A6),
log(DR2-l) = 2.1ogXB - logKB2 •
Reciprocally, if (RB) predominates and (RB2) is very small, Kb2 must be very
large and the expression can be simplified and written in the form (A5),
log(DR2-l) = logXB - logKBl .
V Intermediate complex can exist in two states
Further complexity arises if the intermediate complex, RA opens, RA*:
KT





where oq is the channel closing rate constant and Pi, the channel opening rate constant
of RA*; a.2 is the channel closing rate constant and P2 the channel opening rate constant
of RA2*.











The dose-ratio can be expressed as:
A.Xa'.DR.(DR-1)+B.XA'.DR.(1-DR)+C.(DR2-1)+^-;.(DR-1) = (E.XB2+F.XB).(G+^L;) (A18)AA AA
H






D = Kd 1 -KD22-KB 1 -KB2-a2-P 1
G = ai-p2
H=a2-Pi-KD2
If [RA*] very small, ai must be very large, and the expression simplifies to:
A'.Xa'.DR.(DR-1)+C'.(DR^-1) = (E.Xb2+F.Xb).G' (A19),
where A' = Kbi-Kb2-Kd2-P2
C = KD1.KD2-KB1.KB2-P2
G' = P2
E and F as before. (A19) can be divided by (32. and the expression is the same as
(A13). Further simplifications can be made, see (A13), (A14) and (A15).
CONCLUSION
Using the general model (M6), and by applying the law of mass action, the dose-
ratio is shown not to be a linear function of the antagonist concentration; moreover DR
is also dependent on the agonist concentration. These results differ from those obtained
when a Monod-Wyman-Changeux allosteric model is used, where even in the general
case, the dose-ratio will still be a linear function of the antagonist concentration (see
Colqhoun, 1973). The purpose of this appendix is not to decide which one of the
occupancy model or the allosteric model, is valid, but to illustrate the basis for the
analytical approach used in this thesis, although still a simplification. There are certainly
some uncertainties on whether the law of mass action can apply to drug-receptor
interaction, but the allosteric alternative is not fully satisfactory either. Both are
probably wrong in the fact that they are still oversimplifications. The results presented
in this thesis were analysed on the basis of an occupancy model. The reasons are that
occupancy models are still widely used, and here, it provided a good description of the
data even if some complications had to be introduced in the analysis of the antagonism.
Waud (1987) has prviously commented on using a simplified approach:
".../ do not blush when caught using a competitive kinetic ananlysis
heuristically when the underlying model may in fact be more along
allosteric lines..."
and,
"...A value for a Km can be useful even if the mechanism is not
really thatformulated by Michaelis-Menten. Similarly ifyou tell me the
KB ofa new antagonist, I know a lot about the drug..."
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EFFECTS OF THE ARYLAMINOPYRIDAZINE-GABA DERIVATIVES,
SR95103 AND SR95531 ON THE ASCARJS MUSCLE GABA RECEPTOR:
THE RELARIVE POTENCY OF THE ANTAGONISTS IN ASCARIS,
IS DIFFERENT TO THAT AT VERTEBRATE GABA-A RECEPTORS.
A.H.Duittoz & R.I.Martin
Department of Preclinical Veterinary Sciences, R.(D).S.V.S, University of Edinburgh,
Summerhall, EH1 9QH Edinburgh.
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SUMMARY
1. GABA-induced changes in input
conductance in the bag region of
Ascaris suum muscle were monitored
using a two-microelectrode current-
clamp technique.
2. Effects of the arylaminopyridazine
GABA derivatives SR95103 and
SR95531 on GABA conductance
responses were observed. SR95103
was more potent than SR95531 as an
antagonist; this potency order contrasts
with vertebrate GABA-A receptors.
3. The anatgonism of SR95103 was
associated with a parallel shift to the
right in the GABA dose-response
relationship. A modified Schild plot
was used to describe the action of
SR95103: the data was concistent with
two molecules of GABA but one
molecule of antagonist interacting with
the receptor. The Kg for SR95103 was
64±13|lM (mean+SE, n=14).
INTRODUCTION
A variety of antinemartodal drugs,
including piperazine and ivermectin
may interact with the parasite g-
aminobutyric acid (GABA) receptors,
(Martin, 1987), so it is of interest to
compare the pharmacology of [arasite
and host receptors in an attempt to
identify and exploit differences for
therapeutic purposes.
In mammals, GABA receptors have
been divided into two main classes:
GABA-A receptors and GABA-B
receptors (Bowery et al., 1983).
Isoguvacine and piperidine-4-sulphoftic
acid (P4S) are selective GABA-A
agonists and bicuculline is a selective
GABA-A antagonist (Bowery et al.,
1983); baclofen is a specific GABA-B
angonist and phaclofen is a selective
GABA-B antagonist (Kerr et al.,
1987). The GABA-A receptor is
directly linked to a CI channel; the
GABA-B receptor acts via a second
messenger on a K or Ca conductance
(Dunlap, 1981; Desarmenien et al.,
1982; Dutar and Nicoll, 1988). This
classification is useful although a
simplification, since both classes appear
to be heterogeneous (Krogsgaard-
Larsen, 1988; Levitan et al., 1988;
Pritchett et al., 1989). Bicuculline and
baclofen insensitive GABA receptors
have also been described (Ault and
Nadler, 1983; Johnston and Allan,
1984) and tentativelly named GABA-C
receptors (Johnston, 1986).
A nematode GABA receptor, amenable
to electrophysiological study is found
on the extrasynaptic region of large
muscle cells of Ascaris suum (Martin,
1980); this receptor is linked to a CI
channel (Martin, 1980, 1985). Prvious
pharmacological studies indicate that
most GABA-A agonists, except the
sulphonic acid derivatives 3APS and
P4S are active at the Ascaris receptor;
but the GABA-A antagonists
picrotoxin, bicuculline, pitrazepin,
securinine and TBPS are inactive
(Holden-Dye et al., 1988, 1989).
The actions of arylaminopyridazine
derivatives have been investigated in the
mammalian central nervous system,
where they are potent and selective
competitive antagonists of GABA-A
receptors (Chambon et al., 1985);
SR95531 is the most potent of the
series. However, the action of this
series of compounds remains to be fully
explored in Ascaris and more generally
in invertebrates. In these two papers,
we examine and describe the actions of
SR95103 and SR95531 (Figure 1) on
the Ascaris GABA receptor: the first
paper describes effects on GABA
conductance dose-response
relationships and shows that in Ascaris
SR95103 is more potent than SR95531;
the second paper describes effects of
SR95103 at the single-channel level.
The action of these antagonists suggests
that a knowledge of the pharmacology
of arylaminopyridazine-GABA
derivatives in Ascaris may be useful for
the design of new antiparasitic agents.
A preliminary account of this work has
appeared (Duittoz and Martin, 1989).
MATERIAL AND METHODS
- The preparation
Specimens of Ascaris suum were
collected from the local slaughter house
and maintained in Locke's solution t
37aC for up to four days. A two cm
flap preparation (Martin, 1980) was
mounted in the experimental chamber
which had a volume of 2.5ml. The
preparation was bathed in high-CL,
low-Ca solution containing (mM): NaCl
135; KC1 3; MgCl2 15.7; glucose 3;
TRIS 5; pH adjusted to 7.6 with maleic
acid.
- Current-clamp technique
Two glass microelectrodes (K acetate
2M filled) were introduced into the bag
region of a muscle cell; one pipette
(resistance 10-20MQ) was used to
inject hyperpolarizing current pulses
(40nA, 2s, 0.2Hz), the other pipette
(resistance 20-30MQ) was used to
record membrane potential. Signals
were recorded with a laboratory made
amplifier (Martin, 1982) in the current-
clamp mode and monitored on a
Tectronix 2210 oscilloscope and a
Lectromed two-channel chart-recorder.
- Voltage-clamp technique
The voltage-sensitivity of the action of
SR95103 was examined by applying
GABA iontophoretically to the bag
membrane with a third microelectrode;
the two intracellular micropopettes,
prviously placed for current-clamp,
were used for voltage-clamp under the
control of an Axoclamp 2A (set in the
voltage-clamp mode). Details of this
technique have been described
previously (Martin, 19820. The
holding-ppotentiai was 0 or -lOmV and
80mV voltage-steps to -80mV or -
90mV were made for 500ms at 1Hz.
GABA was applied iontophoretically as
a cation from a fine micropipette
(20M£2) using a standard charge of
150nC to obtain each response. GABA
2M at pH 2.5 filled the iontophoretic
pipette.
- Data analysis
The input conductance of the bag was
calculated directly from the amplitude of
the plateau of the voltage-reaponse to
the injected current pulse; the I/V plot of
the bag is linear during the injection of
hyperpolarizing current and input
conductance is unaltered by
hyperpolarization over the range of
membrane potentials observed during
these experiments (Martin, 1980). The
effects of GABA was then determined
by measuring the change in input
conductance. The bag region of the
muscle cell was approximated to a
sphere, consequently, the input
conductance was directly related to the
change in membrane conductance.
Dose-response relationships were
described by the modified Hill equation
(Nistri and Constanti, 1979):
Ag= Agmax6 1+(EC50/XA)n
where Ag is the change in input
conductance, Agmax is the maximum
response, EC50 is the concentration of
GABA producing 50% of the maximum
response, XA is the agonist
concentration and N is the Hill
coefficient. A non-linear regression
programme (patterensearch Colquhoun,
1971) was used to obtain the least-
square estimates for Agmax, EC50, and
N. Dose-response curves were
considered parallel if the Hill coefficient
and Agmax for the control GABA dose-
response curve and the response in the
presence of antagonsit were not
significantly different Dose-ratios were
measured for the effect of SR95103 on
GABA dose-response curves and
initially examined using a Schild plot
(Arunlakshana and Schild, (1959).
Since the slope of this plot was
significantly less than unity, the dose-
ratios were further examined using a
modified Schild plot (Williams et al.,
1988) which has the advantage of
taking account of the observed
cooperativity seen at the GABA
receptor. It is pointed out that the
relationship, between receptor
occupancy and fractionnal resposne, is
in general not known and that
physically plausible models for the
interaction of agonist and antagonist do
not predict simple or integral values for
these plots. However it is considered
that the plots provide a useful empirical
approach for describing agonist and
antagonist action.
- Bath-application ofdrugs
Initially, GABA was bath-applied using
a non-cumulative dose method with
washing of the preparation between
applications. GABA produced, as
reported previously (Martin, 1980;
Holden-Dye et al., 1988) a dose
dependent hyperpolarization and an
increase in input conductance.
However, one limitation of this
technique was that the recovery of the
resting input conductance was often
incomplete after application of high
concentrations of GABA; this may have
been due to slight movement of the
muscle flap preparation producing a
decrease in the leak resistance around
the micropopettes. It was found that the
recovery after application of high
GABA was more often complete if
cumulative bath-application of GABA,
without intermediate washing were
used, Figure 2. The method involved
gentle draining of the bath (volume
2.5ml), and then flushing the bath with
5ml of the next drug solution. This
method of application has the advantage
of a more certain drug concentration
over the cell surface than the "local
perfusion" technique using a
micropipette. The bath was not
perfused continuously because of the
limited quantities of antagonist
available. When the dose-response
relationships, obtained by non-
cumulative and by cumulative
application of GABA, were described
by the modified Hill equation, it was
found that the EC50s and Hill
coefficients were not significantly
different, Tablel. In contrast Agmax
was on average smaller when GABA
was applied cumulatively. One possible
explanation for the reduced maximum
response seen with cumulative
application is desensitization. Despite
this, Agmax was remarkably constant
for the smae cell, varying only between
cells. Cumulative dose-response
relationships were therefore used to
examine the effects of SR95103 on
EC50, N and Agmax.
- Statistical tests
Means and standard errors (SE) were
calculated for EC50, N and Agmax
values for GABA alone and in the
presence of different concentrations of
antagonist. Statistical significance was
assessed using a two-tailed independent
t-test.
- Drugs






chloride), Figure 1, were obtained as
gifts from SANOFI (France).
RESULTS
The results reported here are based on
an analysis of experiments conducted
on 18 muscle cells from 13
preparations. Cells selected for
recording and analysis had resting
membrane potentials greater than -
20mV and resting input conductances
between 1.9-4.0M-S (2.5±0.1|lS,
mean+SE, n=18). The recordings were
also rejected if resting input
conductances failed to return to at least
80% of the control after washing
GABA from the preparation.
- SR95531 and SR95103 as GABA
antagonists
In mammalian preparations, SR95531
is the most potent arylaminopyridazine
GABA-A antagonist and will
antagonize electrophysiologucal
responses to GABA (Chambon et al.,
1985; Desarmenien et al., 1987;
Michaud et al., 1986; Hamann et al.,
1988). In Ascaris, the application of
ImM SR95531 had a small effect on
3
conductance changes produced by
30pM GABA, Figure 3B. SR95103 is
less potent than SR93531 at the GABA-
A receptor in rat brain membranes
(Heaulme et al„ 1986a, 1986b). This
contrasts with effects seen in Ascaris,
Figure 3A, where ImM SR95103,
unlike SR95531, produces nearly
complete antagonism. The antagonism
reverses after washing.
The percentage of antagonism of the
response to 30pM GABA produced by
ImM concentrations of SR95103 and
SR95531 was measured in a series of
experiments; it was found that
SR95103 reduced the response by
92.3±3.2% (mean+SE, n=5) and that
SR95531 reduced the response by
46.2±6.7% (mean±SE, n=5). These
observations illustrate the contrast
between the pharmacology of a GABA-
A receptor and the Ascaris GABA
receptor.
- Dose-dependent nature of the
SR95103 antagonism
The dose-dependent nature of the
antagonism was tested by examining
the effect of 100, 300 and lOOOpM
SR95103 on cumulative GABA dose-
response curves. Figure 4 shows, from
a single cell, the typical effects of
100|lM antagonist where there is a
parallel shift to the right with no
reduction in the maximum response.
Table 2 shows pooled results with the
mean and SE values for the parameters
of the modified Hill equation used to
describe the dose-response curves. It
can be seen that SR95103 produces
increases in the EC50s without a
significant change in the Hill coefficient
or Agmax.
- Schild plots
Dose-ratios were determined from the
change in EC50 values and a classical
Schild plot obtained. This was
characterized by an apparently linear
relationship between log(DR-l) and
logXg and an intersect on the abcissa
giving a pA2 of 4.0. However this plot
was characterized by a slope
(0.45±0.15, mean±SE, n=14)
significantly less than one (p<0.05, t-
test). Thus the dose-ratios were smaller
at higher antagonist concentrations,
than predicted by the Schild equation.
One interpretation of this result is that
SR95103 might not be acting on a
single receptor in a competitive manner.
However, the classical Schild analysis
does not account for some cooperative
models of agonist action involving two
agonist binding sites (see for example
Rang, 1971; Williams et ah, 1988). We
therefore carried out a modified Schild
analysis, where it was assumed that
two agonist molecules were required to
bind to activate the receptor and the
slope of the plot is the number of
antagonist molecules required to inhibit
the receptor.
Figure 5 shows the modified Schild
plot of log(DR2-l) against logXg. The
slope was 0.62±0.17 (mean±SE,
n=14) which is not significandy less
than one (p<0.05, t-test). These results
then, are consistent with a model which
involves activation of the receptor by
two agonist molecules but only one
antagonist molecule is required.
Although these results do not
exclusively establish such a mode of
action for SR95103 it does permit the
estimation of an apparent dissociation
constant. The arithmetic mean of the
dissociation constant Kb as calculated
from the modified Schild equation
using N=2 and M=l, i.e.:
Kg was 64±13pM (mean±SE, n=14).
- Voltage-sensitivity of the antagonism
The two-micoelectrode voltage-clamp
technique with the iontophoretic
application of GABA (Martin, 1982)
was used to examine the voltage-
sensitivity of the antagonism produced
by bath-application of 0.1-lmM
SR95103. A holding potential of 0 or -
lOmV was used and voltage steps to -
80mV or -90mV were made for 500ms
at 1Hz. A standard charge of 150nC
was used to eject the GABA as a cation
from the iontophoretic pipette in the
absence and then in the presence of the
antagonist. The peak responses at the
holding potential and at the step
potential were measured from the
envelope of the current trace. The
voltage-sensitivity (Vs) of the
antagonism was expressed as:
Vs=l-\f(%antagomsm at 0 or -lOmV,
% antagonism at -80 or -90mV)
4
If SR95103 were acting predominently
as an anion to produce a channel block,
then it would be expected that the
degree of channel block would decrease
at more negative potentials. However




The main finding of this paper was that
SR95103 but not SR95531 acts as a
moderatly potent antagonist in Ascaris
with an apparent KB of 64pM; the
study also shows that the potency of
arylaminopyridazine GABA analogues
can vary at the Ascaris GABA receptor.
In a previous study with SR95531,
(Holden-Dye et al., 1989), it was found
that SR95531 was not a potent
antagonist in Ascaris. However, it was
suggested that this class of compounds
does not recognise the Ascaris GABA
receptor, although no other
arylaminopyridazine GABA analogues
were examined.
It has already been pointed out that
GABA-A receptors may be
heterogeneous (Levitan et ah, 1988;
Pritchett et ah, 1989; for a review see
Krogsgaard-Larsen, 1988), but that it is
still useful to compare the Ascaris
receptor to a typical GABA-A receptor.
The greater relative potency of
SR95103 compared to SR95531 in
Ascaris contrasts with the relative
potency at mammalian GABA-A
receptors: SR95531 displaces
[3H]GABA from rat brain membranes
with aglobal Ki=0.15|i.M, (Heaulme et
ah, 1986a) and SR95103 has a Ki of
2.2pM (Chambon et ah, 1985);
SR95103 has a pA2 of 5 and SR95531
has a pA2 of 7 in electrophysiological
experiments on rat dorsal root ganglion
cells (pA2 values calculated from data
presented by Chambon et al., 1985 and
Hamann et ah, 1988).
SR95531 is similar in structure to
SR95103 (Figure 1) but has a methoxy
group on the 6-phenyl substituent of the
pyridazine ring and no substituent on
the 4-position; SR95103 has no
substituent on the fi-phenyl ring but has
a methyl group in the 4-position on the
pyridazine ring. This difference, and
the greater relative potency of SR95103
on the Ascaris GABA receptor,
indicates that its structural requirements
for antagonists are different to a typical
GABA-A receptor. The lack of effect of
bicuculline on Ascaris, (Wann, 1987;
Holden-Dye et ah, 1988), also supports
this view. However, the agonist
profiles of GABA-A and Ascaris
receptors show a similar stereo¬
selectivity (Holden-Dye et al., 1989) so
that the structure-activity relationships
of agonists are apparendy correlated for
the two receptor types.
Aniens et al., (1979), have argued that
hydrophobic regions of a competitive
antagonist molecule binding to
"accessory" sites on the receptor, are
responsible for the molecule behaving
as a competitive antagonist; and that the
structure of the moiety binding to the
agonist-recognition site is less critical
than for the agonists. The mode of
action and structure-activity
relationships of arylaminopyridazine-
GABA antagonists at the vertebrate
GABA-A receptor has also been
explained in terms of Aniens theory
(Wermuth et ah, 1987). The fact that
potencies of vertebrate GABA-A
agonists correlate with the potencies of
agonists in Ascaris, but the potencies of
antagonists do not, suggests that there
are differences between the "accessory"
sites of the GABA-A receptor and the
Ascaris GABA receptor. The
differences in accessory binding sites
revealed by the actions of
arylaminopyridazine-GABA
antagonists, suggests that further
exploration of the pharmacology of
these compounds on the Ascaris GABA
receptor may be useful for the design of
new anthelminthic agents.
The examination of the antagonism
shown by SR95103 was not described
by a classical Schild plot with a slope of
one. However, this observation cannot
be used to exclude a competitive mode
of action, since even simple plausible
models of agonist and antagonist action
predict that the classical Schild plot will
not have a slope of unity (Williams et
al., 1988). We used a modified Schild
plot to describe the data and obtained
evidence, which was consistent with
two molecules of agonist but one
molecule of antagonist interacting with
the receptor. Intuititively, this is
reasonible, if binding of two molecules
of GABA to different sites are required
to open the channel and binding of a
single molecule of antagonist at either
site would be sufficient to prevent
opening.
In the subsequent paper the actions of
SR95103 were further explored at the
single-channel level.
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Figure 1: Chemical structure of SR95103 and SR95531
SR95103: Ri=-CH3 R2=-H
SR95531: Rj=-H R2=-OCH3
Figure 2: GABA cumulative dose-response relationship
The upper trace illustrates the change in input conductance during cumulative
application of GABA. The width of the trace represents the change in membrane
potential during the injection of hyperpolarizing current pulses (see methods). In this
experiment, the resting input conductance was 3.0|iS; in the presence of GABA 10}lM
Ag=0.2qS; in GABA 30|rM Ag=1.4qS; in GABA lOOpM Ag=3.1|iS; in GABA
300|iM Ag=3.1|iS. the conductance returned to the resting level after washing. The
chart speed was altered at the marked intervals during the experiment. The lower
diagram shows the dose-response relationship. The experimental values are represented
by filled circles ( ); the solid line represents the fitted modified Hill equation
(Agmax=3.5flS; EC50=32.6|iM; N=2.6).
Figure 3: SR95103 is a more potent GABA antagonist than SR95531.
A: SR95103. The resting input conductance is 2.2pS. In the presence of GABA 30pM
Ag=4.4(iS. SR95103 ImM antagonized 86% of the GABA resposne. The antagonism
was reversed when the preparation was washed in 30|lM GABA.
B: SR95531. SR95531 was tested in the same cell. The resting input conductance was
2.2|iS. In the presence of 3qM GABA Ag=4.4|iS. SR95531 lmM antagonized only
36% of the GABA response. The antagonism was completely reversed when the
preparation was washed in 30p.M GABA.
Figure 4: Effect of SR95103 on the cumulative GABA dose-response relationship.
( ): control GABA response and modified Hill fit; Agmax=5.8q.S; EC50=24.4|iM;
N=1.7.
( ): GABA response in the presence of SR95103 100|iM; Agmax=5.8|iS;
EC50=66.2|iM; N=1.5. Ordinate: change in input conductance. Abscissa: GABA
concentration.
Figure 5: Modified Schild plot: agonist: GABA, antagonist: SR95103.
The plot of log(DR2-l) against logXB appears linear with a slope of 0.62+0.17
(mean±SE, n=14). The linear regression had a F value of 0.0041, indicating a better























Table \(f. SR95103: Effects on GABA dose-response curve parameters
Parameters for the modified Hill equation used to describe cumulative GABA dose-
response curves in the presence of SR95103. ** indicates p20.05, T-test
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ABSTRACT
1. An outside-out patch-clamp
technique was used to examine the
actions of SR95103 (30|iM to 2mM) on
GABA-activated single-channel
currents recorded from the bag region
of somatic muscle of Ascaris suum.
2. Effects of SR95103 on open-
probability and the distribution of open-
, closed- and burst durations were
examine quantitatively.
3. The mode of action of SR95103 is
discussed; it is suggested that most of
the antagonism is competitive and
produced by a single molecule of
SR95103 combining with the GABA-
receptor-channel complex; there is an
additional small non-competitive
component, possibly a channel-
blocking action.
INTRODUCTION
In the previous paper, we have
described the action of SR95103 on the
GABA receptor of Ascaris suum
muscle under current-clamp. We have
shown that SR95103 produces a
parallel shift to the right in conductance
dose-response curves, but that the
classical Schild plot (Arunlakshana and
Schild, 1959) had a slope less than one.
This obsevation however, did not
exclude competitive antagonism since it
was possible to use a modified Schild
plot (Williams et al., 1988) to describe
the observations and which suggested
that only one molecule of antagonist
interacts with the receptor.
In order to investigate further the action
of SR95103 on the Ascaris GABA
receptor, a patch-clamp study was
carried out to look at effects at the
single-channel level. The paper
describes the results of those
experiments. It shows that most of the
antagonism appears to be competitive
but evidence for a small non¬
competitive component is seen at high
antagonist concentrations.
MATERIALS AND METHODS
The preparation was maintained in a
solution containing (mM): NaCl 35; Na
acetate 105; KC1 2; HEPES 10; glucose
3; ascorbic acid 2; pH 7.2 with NaOH.
Electrodes were filled with a solution
containing (mM); CsCl 145; MgC12 3;
CaC12 1; EGTA 11; HEPES 10; pH 7.2
with CsOH.
- Recording technique
Standard patch-clamp techniques were
used to obtain outside-out patches
(Hamill et al., 1981). Patch electrodes
were made from micro-haematocrit
capillary tubes (Garner glass 7052) and
had a resistance of 1-5MD. Sylgard™
was used to coat electrodes, to improve
the frequency responses (typically
greater than 2kHz). Currents were
recorded with a List EPC-7 and a
modified Sony Betamax video system.
An agar-plug electrode made with Agar
150mM KC1 set in a polythene tube,
was used to minimize junction
potentials. Records on tape were played
back into a CED 1401 interface,
connected to a DCS 286 PC computer




Records on tape were played back into
a CED 1401 interface, connected to a
DCS 286 PC computer and under the
control of PAT software (Dr
J.Dempster, Strathclyde university).
Records were filtered by a laboratory
made 8-pole Bessel filter, -3dB at
1kHz, and sampled at an interval of
lOOpis. The PAT software was used to
obtain current amplitude histograms
which were used to measure
proportions of the time when
1,2,3,...N channels were open.
Records with less than 5% of all
openings appearing as simultaneous
openings were selected and used to
measure channel open- and closed-
times; the double openings were edited
and not used for analysis. The
threshold for detection was set at 50%
of the unit channel current. This method
of detecting the transition between
open- and closed- times is different to
that described previously on the same
preparation (Martin, 1985). The
"effective mean open times" described
previously (Martin, 1985) approximates
to the mean "long" bursts in this study.
The PAT software produced files of
open and closed durations, which were
transferred to a mainframe computer for
further analysis.
- Exponential curve fitting
In these experiments, individual
channel activations were interrupted by
short closed-times. Bursts of openings
were therefore defined as groups of
openings separated by closed times
shorter than a specified time, Tcrit. Tcrjt
was chosen to make the proportion of
long closing misclassified (as short)
equal to the proportion of short
intervals misclassified (as long), by
solving numerically the equation:
|_e(Tcrit/Ts) = e(-Tcrit/Tm)
(Colquhoun and Sakmann, 1985),
where Ts and Tm are short and
intermediate time constants in the
distribution of all closed times. An
interval of l-2ms was used so that only
brief closings were classified as gaps in
bursts. After Tcrit had been determined,
the files of open and closed times were
rearranged to give files of burst
durations.
The next stage in the analysis was the
fitting of exponentials to the
distributions of closed and burst
durations. Only events greater than
0.5ms (twice the dead time) were used
to fit 1,2,3 or 4 exponentials to each
data file to see which was the best fit. A
maximum likelihood procedure was
used to estimate the parameters of the
probability density function (p.d.f.)
which best describes the distributions:
p.d.f. = ^ Ti.eC-tiTi)
i=l
where a; represents the area of the ilh
component (£a=l), T; is the fitted time
constant, t is the time in milliseconds
and k is the number of exponentials
fitted. A decrease of three log units with
each additional component fitted was
taken as a significant improvement in
the fit.
- Correction for missed events
After the exponentials had been fitted to
the burst and closed times, it was
possible to correct for missing events,
using the method described below
(Colquhoun and Sakmann, 1985). It
was assumed that very short closings
and openings will be missed in the
usual analysis of open and closed times
because of the limited resolution of the
recording technique. The number of
short events was estimated by
extrapolation from the data which had
been recorded.
Firstly, the total number of closed-times
and burst-times was estimated from the
observed number of events; this was
done separatly for the closed-times and
burst-times. Secondly, the total time
spent in gaps within bursts i.e., gaps
shorter than Tcrit, including those
which are undetected, was calculated.
Thirdly, the corrected total open-time
was calculated. The corrected mean
open-time estimated in this way is
shorter than the mean open-time
estimated in another way because it
allows for missed short events and
reduces the mean value. The corrected
mean lenght of an individual opening in
a "long" burst was then calculated
assuming that there were few gaps in
the "short" bursts.
- Stationarity
It was possible to examine open-times
and closed-times in sequence and, to
test for changes in their properties with
time. Desensitization for example, may
2
produce after a delay, an increase in the
mean closed-time and a reduction in the
probability of the channel being open.
CUSUM plots (see Glasbey and
Martin, 1986) were used to examine for
this and test for time-dependent changes
in channel durations (non-stationarity).
An example of these plots is shown in
Figure 1; it can be seen that there is no
evidence of change in channel
properties throughout the record. This
and similar observations on other
patches, showed no evidence of
changes in channel properties
throughout the records.
- Binomial distribution
If channels in a patch have the same
probability of being open and are
independent, then the distribution of the
proportion of time, Pr, that 0,1,2,...N,
channels are open will be described by
the binomial distribution:
p ™r r! (N-r)!pr(l-p)N~r
where p is the probability that an
individual channel is open and N is the
number of channels present. The
probability (p) of an individual channel
being open was calculated from the
areas under the amplitude histograms.
If the proportions of total recording
time spent with 1,2,....N, channels
open were Ti,T2,...Tn then:
Ti+2T2+...+NTN
P - N
The fraction of time which r channels
and only r channels were open was
calculated from the T values. The
binomial distribution was the used with
the value of p to predict the proportion
of time with only 0,1,2,...N channels
open.
- Percent antagonism
In order to compare the level of
antagonism produced by different
concentrations of SR95103, we defined
the percentage of antagonism as:
percent antagonism=100x(l-^p)
where psr was the probability of an
individual channel being open in the
presence of SR95103 and pc is the
control probability in the absence of
antagonist. The relationship between
percent antagonism and SR95103
concentration was described by the
modified Hill equation and a least
squares estimate of the parameters made
as described in the preceeding paper.
- t-test
The mean and standard errors for these
observations were calculated and
examined with a two-tailed unpaired t-
test, to determine if effects reached
statistical significance.
RESULTS
The following report is based on the
analysis of experiments on 11 outside-




across the patch (41mM outside,
153mM inside) were used throughout
this series of experiments to increase
the amplitude of the single channel
currents (at -50mV) and to further test
the identity of the ions flowing through
the channels. Figure 2 shows a
representative IN plot of the main
(most frequent) conductance state seen
in a particular patch. The plot shows
inward rectification and a reversal
potential of +27mV; the rectification
and a reversal potential close to this is
predicted by the Goldman constant field
equation (Hille, 1984) for a CI ion-
channel under these conditions. Figure
2 also shows (solid line) the IN
relationship predicted by the constant
field equation for a CI channel with a
permeability of 6.3 lO'^cm-V1.
- Main-stale conductance
GABA channels in Ascaris are
characterized by the presence of more
than one conductance state (Martin,
1985). The main state at -50mV had an
amplitude of 1.7pA, which corresponds
to a chord conductance of 22pS, if a
driving force of 77mV is assumed. The
two subconductance states had
amplitude of 1.0 and 0.5pA at -50mV
(conductances of respectively 13 and
6.5pS). In the following analysis, the
main state conductance was used
because it occurred most frequently; the
channel current spent only a very small
proportion of the open-time at the
subconductance levels. The inclusion of
subconductance states in the analysis
3
was further minimized by threshold
setting and editing record manually.
- Channels have the same P0pen and
operate independently
The application of 3|iM GABA to
outside-out patches produced the
simultaneous opening of up to three
channels. If GABA channels in a patch
have the same probability of being open
and are independent, then the
distribution of the proportion of time,
Pr, that 0,1,2,...N, channels are open
will be described by the binomial
distribution. Figure 3 shows predicted
and observed values of Pr from a
typical patch record with three channels
present, and p=0.082. It can be seen
that observed and predicted values are
close; this supports the hypothesis that
the channels behave independendy and
have the same open probability. Similar
results were obtained from all the
patches.
As a consequence of these
observations, the GABA channels were
assumed to be homogenous; effects of
SR95103 were not subsequently
explained by a selective action on a
group of GABA channels which have
long open-times and a different open
probability.
- SR95103 reduces GABA channel
opening frequency but not amplitude
Figure 4 shows the inhibitory effect of
SR95103 on the opening frequency of
GABA-activated channels at -50mV.
Figure 4A shows the effect of 3pM
GABA alone, where channel opening is
seen, at this time scale, as clusters of
inward currents spikes. When 30|lM
SR95103 was added, the frequency of
opening reduced from 0.7s"1 to 0.35s"
1. Figure 4B. The rate of channel
opening was further reduced to less
than 0.05s*1, when SR95103 was
increased to 100)J.M, Figure 4C. When
the antagonist was washed from the
preparation, the opening frequency
returned to 0.5s"1, Figure 4D.
The lack of effect of SR95103 on the
amplitude of GABA single-channel
currents is illustrated in Figure 5 which
shows the current-amplitude histograms
for the traces shown in Figure 4. The
current-amplitude histograms were
fitted and described by Gaussian
distributions. The control amplitude
(Figure 5A) was -1.74±0.02pA
(mean±SE); inthe presence of 30|iM
antagonist (Figure 5B) it was -
1.67±0.04pA (mean±SE); in the
presence of 100|iM antagonist (Figure
5C) it was -1.72+0.03pA (mean±I%c).
Similar results were obtained from all
the other experiments; it was concluded
that SR95103 does not affect single-
channel conductance.
- Modified Hill equation and percent
inhibition
The relative area under the open-
channel-current histogram allows
estimation of the proportion (p) of time
an individual channel is open in the
patch (see above). In Figure 5A for
example, the control p was 0.036; in
5B it was 0.025; in 5C it was 0.001.
Figure 6 shows the dose-response
relationship for the percent antagonism
and the fitted modified Hill equation.
With 3pM GABA as the agonist, the
Hill coefficient was 0.98, suggesting
that only one molecule of SR95103
combines with the GABA receptor, the
concentration producing half saturation
(IC50) was 24pM and the estimated
percent inhibition at saturating
concentrations of antagonist was 97%.
The fact that the maximum antagonism
is near 100% suggests that most, but
perhaps not all of the antagonism is
produced by an action at a single
binding site.
- Effects of SR95103 on burst-
distributions
Figure 7 illustrates representative
channel currents at a high time-
resolution and shows the effect of
SR95103 on these currents: Figure 7A
shows example of currents in the
absence of antagonist; Figure 7B shows
bursts in the presence of lOOpM
SR95103; Figure 7C shows the shorter
bursts seen in the presence of 100p.M
SR95103; Figure 7D shows the channel
bursts after washing. The main
apparent effect was a reduction in the
mean burst length at the 100|J.M
concentration of antagonist. The effect
reversed after SR95103 was washed
off.
The effects of SR95103 on burst-times
were further explored by examining the
burst-time distributions. Figure 8
4
shows burst-time frequency
histograms, from a representative
experiment where the effect of 30p.M,
then 100|lM SR95103, on the
distribution of channel bursts produced
by GABA 3|iM was examined.
Inspection of these histograms shows
that the effect of SR95103 is to produce
an incrase in the proportion of "brief"
bursts. This effect was described
quantitatively by fitting exponential
distributions.The control distribution
(Figure 8A) was best described by the
sum of two exponentials:
where pdfburst's burst probability
density function and t is time in
milliseconds. Thus 57% of the bursts
were of the "short" type with a mean
duration of 3.1 ,s; the "long" type of
burst had a mean duration of 33.2ms.
The short bursts appeared to be mostly
single short openings, whereas the long
burstsa were mostly multiple openings.
The effect of SR95103 30pM on this
distribution was small (Figure 8B), in
contrast to the effect of SR95103
100|iM (Figure 8C), where the burst
distribution was best fitted by the
equation:
pdfburst -
0.82 (-1/3.I) 0T8 (-1/41.9)
3.1 e + 4l9e>
The main effect was to increase the
proportion of short bursts, in this
experiment from 57 to 82%. Similar
results were obtained in other
experiments and are summarized in
Table 1. The The table shows that there
is a statistically significant increase in
the proportion of short bursts with
100pM but not 30pM SR95103, and
that there is no significant effect on the
mean duration of the short or long
bursts at either concentrations. It is
evident that the increase in the
proportion of short bursts in presence
of lOOpM SR95103, is responsible for
the reduction in mean burst duration.
It has been shown (above), that a high
concentration of SR95103 increase the
proportion of short bursts; it was of
interest to determine if an increase in
agonist concentration could reverse this
effect. In one patch 60pM SR95103
was used to produce an increase in the
proportion of short bursts from 25% to
83%; an increase in GABA
concentration from 3 to 6pM then,
partially reversed the effect of the
antagonist and decreased the proportion
of short bursts from 83 to 60%. Further
details of these results are shown in
Table 2.
- Effects of SR95103 on closed-time
distributions
Inspections of Figure 4 shows that the
antagonism of SR95103 was associated
with an increase in long closed-times.
The effects of SR95103 on closed-
times distributions were examined by
fitting exponentials to describe the
p.d.f. Control GABA 3|iM closed-time
distributions were best described by
three exponentials. In one
representative patch the result was:
Ddf , ,_02» (-1/0.7) M6(-p.a.i.ciosed ~"07 60
t/6.0) , 0.55 f-t/63)+
63 e
where p.d.f.dosed is the closed time
probability density function and t the
time in ms. This result is comparable to
that reported previously (Martin, 1985),
and shows that there are at least three
closed states giving rise to the "brief
(mean duration 0.7ms), "intermediate"
(mean duration 6.0ms) and "long"
(mean duration 63ms) types of
closings, the effect of 30 and 100|J.M
SR95103 on the distribution of closed
times of this patch was to increase the
duration of the intermediate and long
closings. The closed time distribution
for the same patch with 30(iM
SR95103 was best described by:





The mean closed time increased from
35.8ms to 77.7ms; the mean duration
of the intermediate closings increased
from 6 to 15.4ms and the mean
duration of the long closings increased
from 63 to 133ms. At lOOpM, the
mean closed time increased to 99.6ms;
the mean intermediate closed time to
21.8ms and the mean long closed time
to 215ms. The closed time distribution
was best described by:
Ddf , . _ 0^34 (-t/0.7) 022p.u.i.closed — 0 7 21.8
t/21.8) . 0-44 .(-1/215)
+
215 6
p.d.f.dosed — i -7 e'
t/15.4)
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No increase in the number of
components was required to describe
the closed times distributions in this or
other patches; therefore no increase in
the number of closed states in presence
of the antagonist was detected. The
effects of 30(iM and 100(tM SR95103
on closed-time distributions, from the
other patches, was qualitatively similar,
and was characterized by an increas in
the duration of intermediate and/or long
closings. However, there was a large
variation in mean estimates for the
intermediate closings and long closings,
possibly due to the variation in the
number of channel present in the patch.
In contrast, SR95103 had no consistent
effect on the duration of the brief
closings; Table 1 shows mean values
for the brief closings seen in the
different patches.
- Effects of SR95103 on corrected
mean open-times
One difficulty in measuring open times
directly is that unresolved brief closings
lead to bursts appearing as long single
openings (see Colquhoun and Hawkes,
1982). This artefact increases the
observed open times. However it is
possible to compensate for these
unresolved closings by estimating the
true number of closings by
extrapolating from the closed time
distributions. The estimated total open
time is divided by the true number of
closings to obtain the mean open time
(see methods). The control mean open
time with GABA 3|iM for one typical
patch was 11.9ms; this was unchanged
in presence of SR95103 30p.M :
12.0ms; and reduced to 5.8ms in
presence of SR95103 100|iM. Table 1
shows the mean±SE values obtained
from the different patches and shows
that there is a significant decrease in the
corrected mean open time in presence of
lOOpM antagonist but not at 30|iM.
DISCUSSION
This patch-clamp study of SR95103
was carried out to further investigate the
mode of antagonism. The percent
inhibition dose-response curve was
described by the modified Hill equation
with a coefficient close to one. A lower
antagonist concentration (30(iM),
reduced the probability of the channel
being open without significantly
affecting the burst distribution,
corrected mean open-time or channel
conductance; only the mean duration of
the two slower closed-time components
was increased. A higher (100pM)
antagonist concentration, further
decreased the probability of channel
opening, but significantly increased the
proportion of short bursts. In the
subsequent discussion, it is suggested
that SR95103 acts mosdy as a simple
competitive antagonist; but at higher
concentrations there is an additional
small non-competitive action, possibly
channel block.
- A possible kinetic scheme for the
antagonism
A variety of patch-clamp studies in
different preparations have been carried
out on GABA-activated channels where
the open-time distributions were
described by two exponentials and the
closed-times distributions described by
three exponentials (Ascaris, Martin
1985; mouse spinal neurones, Jackson
et al. 1982, Sackmann et al. 1983,
Mathers 1985; chick cerebral neurones,
Weiss and Magleby 1989; and bovine
chromaffin cells, Bormann and
Clapham 1985). More recently,
however, MacDonald et al. (1989) have
described an additional open-time
component, which suggests a greater
complexity. Molecular biology studies
on the GABA channel structure
(Schofield et al., 1987) have shown
that the receptor-channel complex is
formed by two a and two (3 protein
transmembrane subunits. The }3
subunits were shown to bind GABA
(Barnard et al., 1986) so it was
concluded that two agonist molecules
combine with the receptor-channel
complex to bring about opening.
However, in contrast to GABA the
results of the current-clamp experiments
presented in the previous paper, and the
percent inhibition dose-response curve
presented here, suggest that one
molecule of SR95103 is responsible for
most of the antagonism.
Figure 9 shows a minimal kinetic
scheme which may explain these
observations. It predicts (Colquhoun
and Hawkes, 1977; 1982) in the
absence of antagonist, three
components to the closed-time
distribution and two components to the
open- and burst-time distributions.
However in the presence of the
antagonist, an extra closed state should
give rise to an extra component in the
closed-time distribution. Our
experiments did not reveal an increase
in the number of components in the
closed-time distributions. But the long
duration of many closed-times, seen in
the presence of the antagonist, reduced
the number of events available for
analysis and the ability to separate
components. There was also the further
complication of different numbers of
channels present in each patch; this
complication gave rise to considerable
variation in estimates of the mean
duration of "intermediate" and "long"
closed-times. Both of these factors
would make the detection of any extra
long closed-states in the presence of the
antagonist difficult.
- Low but not high concentrations of
SR95103 appear to be competitive
Simple competitive antagonism predicts
no change in the channel mean open-
time or burst distribution. In our
experiments there was no significant
effect of 30|iM SR95103 on corrected
mean open-times or on the burst
distribution, so it is argued that this
concentration of antagonist behaves like
a competitive antagonist. The effects of
100(lM however, were not compatible
with just simple competitive
antagonism, because they were
associated with reductions in corrected
mean open-times and a significant
increase in the proportion of short
bursts.
- Possible mode of action for SR95103
A variety of experimental preparations
have been used in to look at the action
of arylaminopyridazine GABA
derivatives on the vertebrate GABA-A
receptor. Binding studies (Chambon et
al., 1985; Heaulme et al., 1986a;
1986b) and electrophysiological studies
(Chambon et al., 1985; Michaud et al.,
1986; Desarmenien et al., 1987) have
indicated that arylaminopyridazine
derivatives of GABA can act as simple
competitive antagonists.
SR95531 (a close derivative of
SR95103) has been examined at the
single-channel level, in bovine
chromaffin cells (Hamann et al., 1988);
SR95531 reduced the open propbability
of GABA channels without affecting
open and burst kinetics, an effect
compatible with competitive
mechanism. However, it was suggested
that an additional channel-block might
occur at higher concentrations, but the
potent competitive action of the
analogue did not allow further analysis.
A small inhibitory effect of SR95103
on the glycine receptors, as well as the
GABA receptors, of rat cortical
neurones has been described by
Michaud et al. (1986), but not for other
pyridazinyl GABA derivatives. The
GABA- and glycine-activated channels
both conduct CI so that the pore of the
channel might be a common site of
action. These two reports raise the
question of a channel-block mechanism
in addition to competitive antagonism
for SR95103.
- Does SR95103 act as a channel-
blocker?
A simple channel-block mechanism (see
Colquhoun and Hqwkes, 1983)
predicts, at the current-clamp level, a
reduction in the maximum response and
a reduction in the slope of dose-
response curves at higher antagonist
concentrations; we did not observe such
an effect with up to ImM SR95103
(previous paper). At the single-channel
level, the effect of channel-block on the
burst duration depends on the duration
of the blocked state. If the blocked state
is brief (less than Tcrjt), then the burst
duration and the number of gaps per
burst would increase; we did not
observe these effects. However, if the
blocked state weer longer than Tcrjt,
then the observed mean long burst
duration would get shorter and the
mean open-time in the long bursts
would decrease. Although the observed
reduction in the mean duration of long
bursts did not reach statistical
significance, Table 1, there was a
significant reduction in the corrected
mean open-times in the long bursts.
We assumed that all brief closings
occur in the long bursts and then
calculated the mean duration of
openings in the long bursts (see
7
methods). . Figure 10 shows the
observed linear relationship between the
reciprocal of this duration and the
concentration of SR95103. The
reciprocal of this duration will be equal
to the sum of the rate constants leading
from the long open state Figure 9. The
slope of the plot in Figure 10, is then an
estimate of the channel blocking rate
constant; it was 1.44M"^s_1.
Although SR95103 may act in part as a
channel-blocker, this cannot play a big
role in the antagonism of GABA
conductance responses because high
concentrations of SR95103 did not
significantly depress the maximum
response seen in current-clamp
experiments. Thus, for example, if the
mean blocked state lasted 10ms and the
blocking rate, k+BL was 1.44M"6s"'
(see above) then with 3qM GABA and
lOOpM SR95103, we have estimated
that the proportion of time the channel
spends in the blocked state is only near
1%. The inclusion of a blocked state
would produce a reduction of less than
2% in Popen when compared to a
similar model without blocking. This
estimate was based on an anlysis of
kinetic schemes with plausible rate
constants. The illustration shows that
such a channel-block would not be
detectable at the current-clamp level.
It is concluded that SR95103 acts like a
competitive antagonist at low
concentrations, but at higher
concentrations, there is an additional
non-competitive element; this has some
properties of channel-block.
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Figure 1: CUSUM plots of closed and open times.
j
The CUSUM (for closed times), Sj = ZXj-Xmean > for j=i„..n; where X; is the rank
i=l
order of the ith closed time, Xmean is the mean rank. A random fluctuation about zero
is expected for channels which show stationary behaviour. The significance of the
deviation may be tested (Glasbey and Martin, 1986) by determining Da, the maximum





This is also repeated for the open-times. A: closed times; ordinate, CUSUM; abscissa,
observation number. The p values were 0.17; 0.95; and 0.13; the closed times were
considered to be in random order. B; open times; ordinate, CUSUM; abscissa,
observation number. The p values were 0.12; 0.89; and 0.39; the open times were
considered to be in random order.
Figure 2: Main state GABA channel I/V relationship. A: Channel openings to the main
state at four transpatch potentials from +50 to -50mV. B: Plot of main state channel
currents at different potentials. The reversal potential was near +27mV the Nerst CI
potential. The solid line shows a plot of the I/V relationship predicted by the Goldman-
Hodgkin-Katz constant field equation with a single permeability of 6.3xl0"14cm3s_1.
Note the inward rectification.
Figure 3: Observed and binomial distribution of the proportion of time channels were,
or predicted to be, open in a patch.
The horizontal bars are the observed values of the % time spent with 0,1,2, and 3
channels open. The arrows indicate the values predicted by the binomial distribution
with n=3, the total number of channels present in the patch, and p=0.082, the
probability of channel opening.
Figure 4: Inhibitory effect of SR95103 on opening frequency of GABA channels.
A: Control GABA 3|iM; Popen=0.036. B: GABA 3(lM + SR95103 30p.M;
Popen=0.007. C: GABA 3pM + SR95103 100p.M; Popen=0.001. D: wash; GABA
3|UM alone. SR95103 reduces the opening frequency of GABA channels.
Figure 5: GABA channel current-amplitude histograms and the lack of effect of
SR95103.
A; Control GABA 3pM; I=-1.74±0.02pA (mean±SE). B: GABA 3|uM +SR95103
30pM; I=-1.64±0.04pA (mean±SE). C: GABA 3)tM + SR95103 lOOpM; I=-
1.72±0.03pA (mean±SE).
Figure 6: Percent inhibition dose-response curve.
Ordinate: percent inhibition (see methods) in the presence of 3|aM GABA. Abscissa:
SR95103 concentration. The line fitted was a least-squares estimate of parameters for
the modified Hill equation: maximum percent inhibition, 97%; IC50, 24pM; N, 0.98.
Figure 7: Effects of SR95103 on channel currents seen at high time resolution.
A: Control; GABA 3pM. B: GABA 3)lM + SR95103 30)tM. C; GABA 3)iM +
SR95103 100)iM. D; wash; GABA 3p.M alone. Note the short bursts in C.
Figure 8: Frequency histograms showing the effect of SR95103 on channel burst
distribution.
10
A: Control GABA 3(lM; p.d.f. aj=0.56, Ti=3.1ms,a2=0.44, T2=33.2ms; mean burst
duration=16.1ms. B: GABA 3pM + SR95103 30p.M; p.d.f. ai=0.30, Ti=1.6ms,
a2=0.70, T2=26.7ms; mean burst duration=19.4ms. C: GABA 3|i.M +SR95103
100|iM; p.d.f. ai=0.82, Ti = 1.6ms, 32=0.18, T2=41.9ms; mean burst
duration=10.2ms.
Figure 9: Minimal kinetic scheme for agonist and antagonist action.
The receptor-channel complex (R) has two sites to which the agonist (A), but one site
to which the antagonist (B) combines. Open states (*) may occur only after
isomerization of the single-bound or double-bound agonist receptor-channel complex.
The dissociation constant for the first agonist molecule to combine (Kdi) is much larger
than for the second agonist molecule (Kd2); the dose-response relationship would then
be approximated by the modified Hill equation with N=2. The channel closing rates are
al and a2. al is larger than a2 so that RA2* is the long open state, the channel
opening rates are (31 and [32. The antagonist dissociation constant is Kbi- The putative
blocked channel state (RA2BL) is also shown in brackets.
Figure 10: Effects of SR95103 on mean open-times in long bursts.
Ordinate: Reciprocal of mean open times in long bursts. Abscissa: Concentration pf
SR95103. The slope (obtained by least squares regression) was 1.44M"6s_1 and could
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Table 1jr. Summary of GABA-activated channel properties in the absence and presence
of SR95103. Each observation is the mean from experiments on at least four patches.
* p<0.05 T-test.
Control GABA 3(lM + GABA 3|lM+









































Tabled: Effects of SR95103 on GABA channel burst distributions and the partial
reversal by increasing GABA concentration
GABA 3|lM GABA 3|iM GABA 3|uM GABA10|lM
control SR95103 30)tM SR95103 60|lM SR95103 60pM
Corrected
mean burst 23.8 20.2 2.3 8.7
duration (ms)
pdfburst
abf 0.246 0.241 0.829 0.591
Tbf (ms) 0.5 0.7 0.4 1.0
abs 0.754 0.759 0.171 0.409
Tbs (ms) 31.4 26.4 11.7 19.8
